EHF INVITED SPEAKERS
S1 Intracranial Hyper-and Hypotension
Jan Hoffmann
S2 Emerging non CGRP drug targets
Messoud Ashina
S3 Emergency headaches
Luigi Titomanlio
S4 Hypothalamic Regulation in Headache
Arne May (a.may@uke.de)
University Clinic of Hamburg, Dept. of Systems Neuroscience
S5 CGRP CNS models in headache
U. Reuter
Charité Universitätsmedizin Berlin, Department of Neurology, Charitéplatz 1, 10117 Berlin, Germany
S6 The classification of headache disorders has improved over the years
Henrik Schytz
S7 CGRP PNS models in headache
A. Maassen van den Brink
Div. of Pharmacology, Dept. of Internal Medicine, Erasmus MC Rotterdam, The Netherlands
S8 Understanding the non-pain phases of migraine: premonitory and postdromal
Peter J Goadsby
NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, UK
S9 The Eurolight Project 2017
Christian Lampl
Headache Medical Center, Seilerstätte, Ordensklinikum Linz Barmherzige Schwestern, Austria
S10 Multidisciplinary approach to head pain
Rigmor Hoejland Jensen
Danish Headache Center, Rigshospitalet-Glostrup, University of Copenhagen, Denmark
S11 GWAS studies in migraine
Arn M.J.M. van den Maagdenberg
Departments of Human Genetics & Neurology, Leiden University Medical Center, Leiden, The Netherlands
S12 Diagnostic tests for assessing patients with neuropathic pain
A Truini
Department of Neurology and Psychiatry, University Sapienza, Rome, Italy
S13 Neuromodulation and Headache. Future perspectives
Massimo Leone (Massimo.Leone@istituto-besta.it)
Neuroalgology Department, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, 20133, Italy
S14 What we should in the future
T.J. Nurmikko
The Walton Centre NHS Foundation trust
S15 Posttraumatic headache in children and adolescents
Ishaq Abu-Arafeh
Consultant in paediatric Neurology, Royal Hospital for Children, Glasgow, UK
S16 Contraception in Women with Seizure Disorder
György Bártfai
Department of Gynaecology and Obstetrics, University of Szeged
S17 CSD evolution in 2017
H. Bolay
S18 Trigeminal Neuralgia and other facial pains
R. Benoliel
S19 The concept of trigeminal neuralgia
Giorgio Cruccu
S20 The HUNT Studies
Mattias Linde
S21 CSD in primary and secondary headaches
Cenk Ayata
S22 Headache in the Emergency Room
Anne Ducros
University of Montpellier, and Headache Centre, Neurology department, Montpellier University Hospital, France
S23 Progestin-only contraception and beneficial effects on migraine
Gabriele S. Merki-Feld
S24 Current Consensus on Classification of the Trigeminal Neuralgia
Zaza Katsarava
Unna/Essen, Germany
S25 Traumas and headache
Mark Braschinsky (mark.braschinsky@kliinikum.ee)
Department of Neurology, Tartu University Clinics, Tartu 51014, Estonia
S26 Within person variation in headache days in persons with migraine
Richard Lipton
S27 Migraine and the Glymphatic System
Rami Burstein and Aaron Schain
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston MA 02115 and Harvard Medical School, Boston, MA 02215, USA
S28 Photophobia and Hypothalamus
Rami Burstein, Rodrigo Noseda
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston MA 02115 and Harvard Medical School, Boston, MA 02215, USA
S29 The Gymphatic System
Maiken Nedergaard
S30 A population based survey for headaches in greece
Dimos D. Mitsikostas1, Chrisanthy Arvanity2, Theodoros Constantinidis3, Manolis Dermitzakis4, Nikolaos Fakas5, Jobst Rudolf6, Michail Vikelis7, on behalf of the Hellenic Headache Society
1First Neurology Department, Aeginition Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece; 2Second Neurology Department, Attikon Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece; 3Private Headache Clinic, Korinthos, Greece; 4Department of Neurology, “Geniki Kliniki” Euromedica, Thessaloniki, Greece; 5401 Army General Hospital of Athens, Neurology Department, Athens, Greece; 6Neurology Department, Papageorgiou Hospital, Thessaloniki, Greece; 7Headache Clinic, Mediterraneo Hospital, Glyfada, Greece
S31 The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system
Karl Messlinger
Institute of Physiology and Pathophysiology, Friedrich-Alexander-University of Erlangen-Nürnberg, 91054 Erlangen, Germany
S32 EHF-LTB Aids to management of headache disorders in primary care (2nd edition)
TJ Steiner1,2, R Jensen3, Z Katsarava4,5, M Linde1,6, EA MacGregor7, P Martelletti8,9, V Osipova10,11 and K Paemeleire12, on behalf of Lifting The Burden: The Global Campaign against Headache and the European Headache Federation
1Department of Neuroscience, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; 2Division of Brain Sciences, Imperial College London, London, UK; 3Danish Headache Centre, Department of Neurology, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark; 4Department of Neurology, Evangelical Hospital Unna, Unna, Germany; 5Medical Faculty, University of Duisburg-Essen, Essen, Germany; 6Norwegian Advisory Unit on Headache, St Olavs Hospital, Trondheim, Norway; 7Centre for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK; 8Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy; 9Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy; 10Research Department of Neurology, First “I. Sechenov” Moscow State Medical University, Moscow, Russian Federation; 11 Research Center for Neuropsychiatry, Moscow, Russian Federation; 12 Department of Neurology, Ghent University Hospital, Ghent, Belgium
Correspondence: P Martelletti (paolo.martelletti@uniroma1.it)
S33 Combined hormonal contraception and migraine, WHO and EHF/ESCRH criteria and balancing risks and benefit
Simona Sacco (simona.sacco@univaq.it)
Neurology section, Department of Applied Clinical Science and Biotechnology, University of L’Aquila, L’Aquila, Italy
S34 Neuropathic pain: basic concepts
Rolf-Detlef Treede
Department of Neurophysiology, Center for Biomedicine and Medical Technology Mannheim, Heidelberg University, Germany
S35 Migraine and cerebellum
Koppen Hille
S36 Neurophysiology of Headaches
Gianluca Coppola
G.B. Bietti Foundation-IRCCS, Research Unit of Neurophysiology of Vision and Neurophthalmology, Rome, Italy
S37 Mechanisms of Photophobia
Andrew Russo
S38 Classical trigeminal neuralgia – clinical and MRI findings
Stine Maarbjerg
Department of Neurology, Helse Fonna, Haugesund, Norway
S39 PACAP in migraine
László Vécsei1,2, Délia Szok1, János Tajti1
1Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center University of Szeged, H-6725 Szeged, Semmelweis u. 6, Hungary; 2MTA-SZTE Neuroscience Research Group, University of Szeged, H-6725 Szeged, Semmelweis u. 6, Hungary
Correspondence: László Vécsei (vecsei.laszlo@med.u-szeged.hu)
S40 Comorbidity Grounds
Noemi Faedda1, Vincenzo Guidetti2, Giulia Natalucci2
1PhD program in Behavioural Neuroscience, Department of Paediatrics and Child and Adolescent Neuropsychiatry, Sapienza University of Rome; 2Department of Paediatrics and Child and Adolescent Neuropsychiatry, Sapienza University of Rome
Correspondence: Vincenzo Guidetti (vincenzo.guidetti@uniroma1.it)
SISC INVITED SPEAKERS
S41 Application of “very low-calorie ketogenic diet” in migraine treatment
Cherubino Di Lorenzo1, Roberta Ienca2, Simona Sodano2, Gianluca Coppola3, Francesco Pierelli4,5
1Don Carlo Gnocchi Onlus Foundation, Milan, Italy; 2Department of Experimental Medicine-Medical Physiopathology, Food Science and Endocrinology Section, Sapienza University, Rome, Italy; 3G.B. Bietti Foundation – IRCCS, Department of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 4Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy; 5IRCCS – Neuromed, Pozzilli (IS), Italy
Correspondence: Cherubino Di Lorenzo (cherub@inwind.it)
S42 Real Clinical Practice: Physiotherapy Evaluation of Disorders cranial-cervical-mandibular headaches in ebm
Riccardo Rosa (clinicadelmalditesta@gmail.com)
1La Sapienza University of Roma, Italy; 2CLINICADELMALDITESTA, via campania 37, Roma, 00161, Italy
S43 Pediatric Hedache
Massimiliano Valeriani (m.valeriani@tiscali.it)
Centro per lo Studio e la Cura delle Cefalee in Età Evolutiva, UO Neurologia, Ospedale Pediatrico Bambino Gesù, Rome, Italy; Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark
S44 Overuse of Headache Medications: from Neurochemistry to Pathophysiology. Clinical and Preclinical Clues
Alberto Chiarugi
Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, and Headache Center University Hospital, Italy
S45 The very low calorie ketogenic diet in the clinical practice
Roberta Ienca, Simona Sodano
1Department of Experimental Medicine, Medical Pathophysiology, food science and endocrinology section, Sapienza University, Rome, 00100, Italy
Correspondence: Roberta Ienca (roberta.ienca@libero.it)
Daily dose | RDA | |
---|---|---|
Vit A | 800 mcg | 100% RDA |
Vit B1 | 1.4 mg | 100% RDA |
Vit B2 | 1.6 mg | 100% RDA |
Vit B3 | 18 mg | 100% RDA |
Vit B5 | 6 mg | 100% RDA |
Vit B6 | 2 mg | 100% RDA |
Vit B8 | 150 mcg | 100% RDA |
Vit B9 | 200 mcg | 100% RDA |
Vit B12 | 1 mcg | 100% RDA |
Vit C | 60 mg | 100% RDA |
Vit D | 5 mcg | 100% RDA |
Vit E | 10 mg | 100% RDA |
Ca | 800 mg | 100% RDA |
Cr | 7.5 mcg | 15% RDA |
Cu | 0.6 mg | 50% RDA |
Mg | 90 mg | 30% RDA |
Mn | 1.75 mg | RDA 1-10 mg |
Zn | 7.5 mg | 50% RDA |
S46 Headache and temporomandibular disorders: association or causality? The bio-psychosocial model applied to the clinical reasoning
Marco Testa
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova – Campus of Savona, 17100 Savona - Italy
S47 Tension-Type Headache and Central Sensitization: the Role of Physical Therapy According to EBM
Matteo Castaldo1,2,3 (matteo.castaldo@poliambulatoriofisiocenter.com)
1Department of Health Science and Technology. Aalborg University, Aalborg, Denmark; 2Siena University, Siena, Italy; 3Poliambulatorio Fisiocenter, private practice, Parma, Italy
S48 The use of nutraceuticals in migraine
Cherubino Di Lorenzo (cherub@inwind.it)
Don Carlo Gnocchi Onlus Foundation, Milan, Italy
S49 Headaches and Algology (Pain Therapy)
M. Evangelista (maurizio.evangelista@unicatt.it)
Istituto di Anestesiologia, Rianimazione e Terapia del Dolore, Università Cattolica del Sacro Cuore, Roma, Italia
S50 Neuroimaging and headaches
Paola Sarchielli, Laura Bernetti
Headache Center, Neurologic Clinic, Ospedale Santa Maria della Misericordia, University of Perugia Perugia Italy
S51 Risk factors for chronic migraine
Cristina Tassorelli1,2, Grazia Sances1, Sara Bottiroli1, Michele Viana1, Natascia Ghiotto1, Marta Allena1, Giorgio Sandrini1,2, Giuseppe Nappi1
1Headache Science Center (HSC), C. Mondino National Institute of Neurology Foundation, Pavia, Italy; 2Dept of Brain and Behavioural Sciences, University of Pavia, Italy
Correspondence: Cristina Tassorelli (cristina.tassorelli@unipv.it)
S52 Comorbidities in primary headaches
Antonio Carolei1,2, Cindy Tiseo1, Diana Degan1
1 Institute of Neurology, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, via Vetoio, 67100 L’Aquila, Italy; 2 Department of Neurology and Stroke Unit, Avezzano Hospital, 67051, Avezzano, Italy
Correspondence: Antonio Carolei (antonio.carolei@univaq.it)
S53 Headeache in the Emergency Department
Vittorio Di Piero (vittorio.dipiero@uniroma1.it)
Department of Neurology and Psychiatry, “Sapienza” - University of Rome, Rome, Italy
S54 Migraine without aura, arthrogenic and myofascial cervical afferents: role of EBM physiotherapy
Firas Mourad1,2,3(firas.mourad@me.com)
1“Tor Vergata” Roma University, Roma, Italy; 2Alumno de Doctorado, Escuela Internacional de Doctorado, Universidad Rey Juan Carlos, Alcorcon, Madrid, Spain; 3PHYSIOPOWER, viale Duca degli Abruzzi 107, Brescia, 25124, Italy
S55 OnabotulinumtoxinA for migraine treatment
Andrea Negro1,2 (andrea.negro@uniroma1.it)
1Regional Referral Headache Centre, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00191; 2Department of Clinical and Molecular Medicine, Sapienza University of Rome, Italy
S56 Trigeminal autonomic cephalalgias (TACs)
Ferdinando Maggioni (ferdinando.maggioni@unipd.it)
Headache Centre, Department of Neurosciences, University of Padua, Italy
S57 Chronic Headaches Cefalee Croniche
Grazia Sances1, Sara Bottiroli1, Michele Viana1, Natascia Ghiotto1, Elena Guaschino1, Marta Allena1, Cristina Tassorelli1-2
1Headache Science Center (HSC), C. Mondino National Institute of Neurology Foundation, Pavia, Italy; 2Dept of Brain and Behavioural Sciences, University of Pavia, Italy
Correspondence: Grazia Sances (grazia.sances@mondino.it)
S58 Headache in the elderly
Carlo Lisotto
Headache Centre, Department of Neurology, Azienda Sanitaria Friuli Occidentale, Pordenone, Italy
EHF POSTER PRESENTATIONS
P1 Anti-CGRP monoclonal antibodies for the treatment of chronic migraine: an overview of available results and comparison with the currently used prophylactics
Fenne Vandervorst, Laura Van Deun, Jacques De Keyser, Jan Versijpt
Department of Neurology, University Hospital Brussels, Brussels, Belgium
Correspondence: Fenne Vandervorst
P2 Biomarkers of inflammation in patients with Chronic Migraine after withdrawal from Medication Overuse: longitudinal changes and comparison with healthy subjects
Licia Grazzi1, Emanuela Sansone1, Alberto Raggi2, Matilde Leonardi2, Emilio Ciusani3, Elena Corsini3, Giovanni D’Andrea4, Andrea Bolner4, Francisco Salgado-García5, Frank Andrasik5, Domenico D’Amico1
1Headache and Neuroalgology Unit; Neurological Institute “C. Besta” IRCCS Foundation; Milan; 20133; Italy; 2Neurology, Public Health and Disability Unit; Neurological Institute “C. Besta” IRCCS Foundation; Milan; 20133; Italy; 3Laboratory of Clinical Pathology and Medical Genetic; Neurological Institute “C. Besta” IRCCS Foundation; Milan; 20133; Italy; 4Research & Innovation (R&I); Padua; 35121; Italy; 5Department of Psychology; University of Memphis; Memphis, TN; 38152; USA
Correspondence: Domenico D’Amico
WBC | Neutrophils | Lymphocytes | CD3 | CD4 | CD8 | CD19 | |
---|---|---|---|---|---|---|---|
Healthy Controls | 5732 [5299-6165] | 3674 [3233-4010] | 1836 [1703-1971] | 1366 [1259-1473] | 766 [703-829] | 559 [486-632] | 196 [171-222] |
Patients-T0 | 7322 [6489-8156] | 4801 [4120-5482] | 2019 [1773-2265] | 1577 [1364-1790] | 1027 [869-1185] | 568 [491-645] | 219 [186-253] |
P-value | .003 | .006 | .611 | .362 | .014 | .949 | .627 |
Patients-3M | 6185 [5681-6690] | 3639 [3263-4016] | 1899 [1730-2267] | 1475 [1332-1617] | 933 [841-1026] | 550 [481-619] | 196 [166-226] |
P-value | .197 | .950 | .677 | .253 | .009 | .827 | .663 |
Patients-6M | 6226 [5544-6908] | 3762 [3226-4297] | 1829 [1659-1998] | 1399 [1263-1535] | 890 [779-1001] | 525 [475-576] | 190 [156-224] |
P-value | .517 | .885 | .820 | .969 | .112 | .748 | .264 |
Patients-12M | 6182 [5601-6763] | 3758 [3266-4250] | 1802 [1639-1965] | 1367 [1230-1504] | 875 [781-969] | 515 [461-570] | 186 [157-214] |
P-value | .373 | .890 | .598 | .729 | .101 | .480 | .278 |
P3 Outcome of microvascular decompression in trigeminal neuralgia is highly dependent on sex and degree of neurovascular contact – A prospective systematic study using independent assessors
Tone B. Heinskou1, Per Rochat2, Stine Maarbjerg1, Frauke Wolfram3, Jannick Brennum2, Jes Olesen1, Lars Bendtsen1
1Danish Headache Center, Department of Neurology, Rigshospitalet. Faculty of Health and Medical Sciences, University of Copenhagen., Glostrup; 2Department of Neurosurgery, Rigshospitalet. Faculty of Health and Medical Sciences, University of Copenhagen., Copenhagen; 3Department of Diagnostics, Rigshospitalet. Faculty of Health and Medical Sciences, University of Copenhagen., Glostrup, Denmark
Correspondence: Tone B. Heinskou
P4 Headache Clinical Refractoriness
Christian Lampl
Headache Medical Center, Seilerstätte, Ordensklinikum Linz Barmherzige Schwestern, Austria
P5 Sphenopalatine ganglion block using Tx360 device. First results in refractory chronic migraine in Spain
Jose M Sanchez, Maria Rico, Elena Ameijide, Maria Castanon
Hospital Universitario Central de Asturias, Neurology, Oviedo, Spain
Correspondence: Jose M Sanchez (jmsancheza@gmail.com)
P6 Efficacy of erenumab (AMG 334) in chronic migraine patients with prior prophylactic treatment failure: Subgroup analysis of the phase 2, randomised, double-blind, placebo-controlled study
Messoud Ashina1, Stewart J Tepper2, Jan Lewis Brandes3, Uwe Reuter4, Guy P Boudreau5, David Dolezil6, Sunfa Cheng7, Dean Leonardi7, Robert A Lenz7, Jan Klatt8, Daniel D Mikol7
1Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Medical and Health Sciences, University of Copenhagen, Copenhagen, Denmark; 2Geisel School of Medicine at Dartmouth, Hanover, NH; 3Nashville Neuroscience Group and Vanderbilt University School of Neurology, Nashville, TN; 4Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 5Headache unit Neurology department University Hospital Center of Montreal Qc. Canada; 6DADO MEDICAL s.r.o., Prague Headache Center, Czech Republic; 7Amgen Inc., Thousand Oaks, CA; 8Novartis Pharma AG, Basel, Switzerland
Correspondence: Messoud Ashina (ashina@dadlnet.dk)
P7 Sequential presentation of ipsilateral supraorbital and lacrimal neuralgias in a patient
Chavarría Miranda, A.; Talavera De la Esperanza, B.; Martínez Pías, E.; Trigo López, J.; Gómez López de San Román, C.; Ruiz Piñero, M.; Pedraza Hueso, M.I.; Guerrero Peral, Á.L.; García Azorín, D
P8 Cognitive impairment in episodic and chronic migraineurs and tension-type headache suffers
A. Bianchi, R. Monastero, M. Davì, F. Brighina, C. Camarda
Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Italy
Correspondence: A. Bianchi (alessia.bianchi@unipa.it)
Study population n: 307 | ||
---|---|---|
Number: | Percent | |
Sex | ||
Male | 61 | 19,9% |
Female | 246 | 80,1% |
Age group (year-old) | ||
<21 | 5 | 1,6 |
21 – 30 | 20 | 6,5 |
31 – 40 | 38 | 12,4 |
41 – 50 | 94 | 30,6 |
51 – 60 | 86 | 28,0 |
61 – 70 | 48 | 15,6 |
≥71 | 16 | 5,2 |
Headache type | ||
Migraine without aura | 138 | 45 |
Chronic Migrain | 43 | 14,0 |
Tension type headache | 84 | 27,7 |
Chronic tension type headache | 42 | 13,7 |
Education (years of school | ||
0 | 3 | 1,0 |
1– 5 | 85 | 27,7 |
6– 8 | 104 | 33,9 |
9– 13 | 79 | 25,7 |
>13 | 36 | 11,7 |
Marital status | ||
Unmarried | 44 | 14,3 |
Married | 234 | 76,2 |
Divorced | 29 | 9,4 |
Mean ± DS | ||
MMSE | 28,2 ± 1,6 | |
HAD_A | 9,4 ± 4,6 | |
HAD_D | 7,2 ± 4,0 |
Prevalence of cognitive deficit n = 61 | ||||||
---|---|---|---|---|---|---|
Prevalence of attentive deficit | Prevalence of esecutive deficit | Prevalence of language deficit | Prevalence of memory deficit | Prevalence of praxis deficit | Prevalence of cognitive deficit in ≥1 domain | |
Migraine without aura | 11 (8%) | 8 (5,8%) | 2 (1.4%) | 18 (13%) | 0 (0,0%) | 29 (21.0%) |
Chronic Migrain | 4 (9,3%) | 2 (4,7%) | 0 (0,0%) | 4 (9,3%) | 1 (2,3%) | 6 (14.0%) |
Tension type headache | 7 (8,3%) | 4 (8%) | 2 (2,4%) | 7 (8,3%) | 0 (0,0%) | 14 (16.7%) |
Chronic tension type headache | 5 (11,9%) | 6 (14,3%) | 2 (4.8%) | 6 (14,3%) | 0 (0,0%) | 12 (28.6%) |
P9 A multicenter, prospective, randomized, open-label study to compare the efficacy, safety, and tolerability of onabotulinumtoxinA and topiramate for headache prophylaxis in adults with chronic migraine: the FORWARD study
John F. Rothrock1, Aubrey Manack Adams2, Esther Jo3, Xiang Zhao4, Andrew M. Blumenfeld5
1George Washington School of Medicine, Washington, DC, 20037, USA; 2Global Medical Affairs, Allergan plc, Irvine, CA, 92623-9534, USA; 3Bioststistics, Allergan plc, Irvine, CA, 92623-9534, USA; 4Statistics, Pharmaceutical Product Development, LLC, Austin TX, 78744, USA; 5Headache Center of Southern California, The Neurology Center, Carlsbad, CA, 92024, USA
Correspondence: John F. Rothrock (jrothrock@mfa.gwu.edu)
Patients with Adverse Event (AE), % (n) | OnabotulinumtoxinA (n=220) | Topiramate (n=142) | Total (N=282) | Switched to OnabotulinumtoxinA (n=80) |
---|---|---|---|---|
Any AE | 45.5 (100) | 76.8 (109) | 62.4 (176) | 41.3 (33) |
Cognitive disorder | 0.5 (1) | 12.7 (18) | 6.4 (18) | 1.3 (1) |
Disturbance in attention | 0 | 7.7 (11) | 3.9 (11) | 0 |
Dizziness | 2.7 (6) | 12.7 (18) | 8.2 (23) | 1.3 (1) |
Migraine | 2.7 (6) | 2.1 (3) | 2.5 (7) | 5.0 (4) |
Paraesthesia | 0.5 (1) | 31.0 (44) | 16.0 (45) | 0 |
Sinusitis | 5.5 (12) | 6.3 (9) | 5.7 (16) | 6.3 (5) |
Nausea | 0.5 (1) | 13.4 (19) | 7.1 (20) | 0 |
Neck pain | 4.5 (10) | 2.1 (3) | 4.3 (12) | 6.3 (5) |
Fatigue | 0.5 (1) | 13.4 (19) | 7.1 (20) | 0 |
Depression | 1.8 (4) | 5.6 (8) | 3.5 (10) | 2.5 (2) |
Vision blurred | 2.7 (6) | 7.0 (10) | 5.0 (14) | 3.8 (3) |
Decreased appetite | 0 | 10.6 (15) | 5.3 (15) | 0 |
P10 Chronic migraine treatment with erenumab: Responder rates
Hans-Christoph Diener1, Jan Brandes2, David Dolezil3, Marshall C Freeman4, Peter J McAllister5, Paul Winner6, Sunfa Cheng7, Dean K Leonardi7, Robert A Lenz7, Daniel D Mikol7
1University Duisburg-Essen, Essen, Germany; 2Nashville Neuroscience Group, Nashville, TN, USA; 3Prague Headache Center, DADO MEDICAL s.r.o., Prague, Czech Republic; 4Headache Wellness Center, Greensboro, NC, USA; 5New England Institute for Neurology and Headache, Stamford, CT, USA; 6Palm Beach Headache Center, West Palm Beach, FL, USA; 7Amgen Inc., Thousand Oaks, CA, USA
Correspondence: Hans-Christoph Diener (Hans.Diener@uk-essen.de)
P11 Systematic Cochrane review of botulinum toxins for the prevention of migraine in adults
Alexandra Sinclair1, Clare P Herd2, Claire L Tomlinson3, Caroline Rick3, WJ Scotton1, Julie Edwards4, Natalie Ives3, Carl E Clarke2
1Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK; 2Institute of Applied Health Research, University of Birmingham, Birmingham, UK; 3Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK; 5Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK
P12 Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial
Louise N Carlsen, Signe B Munksgaard, Rigmor H Jensen, Lars Bendtsen
Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, Lars Bendtsen; Ndr. Ringvej 69, 2600 Glostrup, Denmark
Correspondence: Lars Bendtsen (lars.bendtsen@regionh.dk)
P13 Sphenopalatine ganglion block using Tx360 device. First results in refractory chronic cluster headache in Spain
Jose M Sanchez, Maria Rico, Maria Castanon, Elena Ameijide
Hospital Universitario Central de Asturias, Neurology, Oviedo, Spain
Correspondence: Jose M Sanchez (jmsancheza@gmail.com)
P14 Are there gender differences related to cost of disease in patients with Medication Overuse Headache receiving structured withdrawal?
Grazzi Licia1, D’Amico Domenico1, Emanuela Sansone1, Matilde Leonardi2, Raggi Alberto2
1Headache and Neuroalgology Unit; Neurological Institute “C. Besta” IRCCS Foundation; Milan; 20133; Italy; 2Neurology, Public Health and Disability Unit; Neurological Institute “C. Besta” IRCCS Foundation; Milan; 20133; Italy
Correspondence: Grazzi Licia
P15 Optimal response to onabotulinumtoxina in chronic migraine: evaluation in a series of 124 patients
D García-Azorín, M Ruiz, Mi Pedraza, Al Guerrero
P16 N=1 statistical approaches to examine within-individual risk factor profiles of ICHD-3beta classified migraines versus non-migraine headaches
Ty Ridenour1, Francesc Peris2, Gabriel Boucher2, Alec Mian2, Stephen Donoghue2, Andrew Hershey3
1Behavioral and Urban Health, RTI International, Research Triangle Park, NC, 27709, USA; 2Curelator, Inc., Cambridge, MA, 02142, USA; 3Cincinnati Children’s Hospital Medical Center, Cincinnati, 45229, USA
P17 N=1 statistical approaches to examine risk factor profiles of ICHD-3beta classified migraines within individuals
Ty Ridenour1, Francesc Peris2, Gabriel Boucher2, Alec Mian2, Stephen Donoghue2, Andrew Hershey3
1Behavioral and Urban Health, RTI International, Research Triangle Park, NC, 27709, USA; 2Curelator, Inc., Cambridge, MA, 02142, USA; 3Cincinnati Children’s Hospital Medical Center, Cincinnati, 45229, USA
P18 Reliability and validity of a questionnaire for detecting cluster headache among headache patients
Pil-Wook Chung1, Soo-Jin Cho2, Kwang-Yeol Park3, Mi-Ji Lee4, Chin-Sang Chung4, Byung-Su Kim5, and Korean Cluster Headache Registry Group
1Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul; 2Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong; 3Department of Neurology, Chung-Ang University Hospital, Chung-Ang University, Seoul; 4Department of Neurology, Neuroscience Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 5Department of Neurology, Bundang Jesaeng Hospital, Seoul, Republic of Korea
Correspondence: Pil-Wook Chung
P19 Postdural Puncture Headache after Cervical Medial Branch Block
Young In Lee1, Donggyu Han2, Yoo Jung Rark2, Eung Don Kim1
1Department of Anesthesiology and Pain Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea ; 2Department of Anesthesiology and Pain Medicine, Saint Vincent’s Hospital, College of Medicine, The Catholic University of Korea
Correspondence: Young In Lee (ehs99@catholic.ac.kr)
P20 Cervical Medial Branch Block using Botulinum Toxin Type A in Patient with Cervicogenic Headache
Young In Lee1, Donggyu Han2, Eung Don Kim1, Yoo Jung Rark2
1Department of Anesthesiology and Pain Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea; 2Department of Anesthesiology and Pain Medicine, Saint Vincent’s Hospital, College of Medicine, The Catholic University of Korea
Correspondence: Young In Lee (genial7@naver.com); Yoo Jung Rark (genial7@naver.com)
P21 Chronic Migraine Treatment and Work Productivity
Valeria Canzonetta1, Valerio De Angelis2, Elena Rogante1, Eleonora Sabatelli2, Salvatore Sarubbi1, Alice Sparagna1, Denise Erbuto1, Marco Innamorati1, Maurizio Pompili1, Paolo Martelletti2
1Department NESMOS, Sapienza Univeristy of Rome, Italy; 2Department of Clincal and Molecular Medicine, Sapienza University of Rome, Italy
Correspondence: Valeria Canzonetta
P22 A systematic literature review and meta-analysis of prevalence estimates in migraine
Akaterini Bilitou1, Pamela Vo2, Sandra Lopez-Leon3, Sneha Kelkar4, Claudia Cheung4, Emily Gao5, Keith A. Betts6, Zhou Zhou5
1 Novartis Global Services Centre, Patient Access Services, Dublin; 2 Novartis Pharma AG, Basel, Switzerland; 3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 4 Analysis Group, New York/USA; 5 Analysis Group, Boston/USA; 6 Analysis Group, Los Angeles/USA
Correspondence:Akaterini Bilitou (katerina.bilitou@novartis.com)
P23 Anxiety and Depression in Patients with Cluster Headache
Kwang-Yeol Park1; Soo-Jin Cho2; Byung-Kun Kim3; Pil-Wook Chung4; and Korean Cluster Headache Registry Group
1Department of Neurolgy, Chung-Ang University, Seoul, Korea; 2Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University, Hwaseong, Korea; 3Department of Neurolgy, Seoul Eulji Hospital, Eulji University, Seoul, Korea; 4Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea
P24 Benefit-Risk Assessment of Migraine Prophylaxis Treatments Using Likelihood of Being Helped or Harmed (LHH)
Pamela Vo1, Shihua Wen1, Marie-Josee Martel2, Dimos Mitsikostas3, Uwe Reuter4, Jan Klatt1
1Novartis Pharma AG, Switzerland; 2Xcenda, UK; 31st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, Greece; 4Department of Neurology, Charité Universitätsmedizin Berlin, Germany
Correspondence: Pamela Vo (pamela.vo@novartis.com)
Chronic migraine (CM) | Episodic migraine (EM) | ||||||
---|---|---|---|---|---|---|---|
Erenumab 140 mg | Topiramate 100 mg | Onabotulinum-toxin A | Erenumab 140 mg | Topiramate 100 mg | Propranolol 160 mg | ||
Data source : | NCT 02066415 | Silberstein et al 2007 & 2009 | Diener et al 2007 | Dodick et al 2010 | NCT 02456740 | Bussone et al 2005 | Diener et al 2004 |
NNT ≥50% RR (95%CI) | 6 (4,12) | 13 (NE, NE) | 4 (3, 10) | 9 (6, 15) | 6 (4, 9) | 5 (4, 6) | 5 (4, 10) |
NNH % d/c due to AEs (95%CI) | 250 (NE, NE) | 21 (NE, NE) | 13 (NE, NE) | 39 (23, 100) | 1000a (NE, NE) | 8 (6, 13) | 11 (6, 72) |
LHH NNH/NNT (95%CI) | 41.7 (5.3, 301.8) | 1.6 (0.0, 112.8) | 3.3 (0.7, 364.9) | 4.3 (1.9, 11.4) | 166.7 (9.0, 299.3) | 1.6 (1.1, 3.1) | 2.2 (0.8, 14.5) |
P25 Healthcare resource utilization among migraine sufferers in the EU5 from the patient perspective
Pamela Vo1, Aikaterini Bilitou2, Juanzhi Fang3, Annik Laflamme1, Shaloo Gupta4
1Novartis Pharma AG, Switzerland; 2Novartis Global Services Centre, Ireland; 3Novartis Pharma, USA; 4Kantar Health, USA
Correspondence: Pamela Vo (pamela.vo@novartis.com)
Non-migraine controls (N=218) | Migraine (N=218) | p-value | |
---|---|---|---|
Number of HCP visits in the past 6 months (mean, SD) | 5.13 (6.86) | 8.48 (10.89) | <0.001a
|
Number of ED visits in the past 6 months (mean, SD) | 0.21 (0.79) | 0.46 (1.20) | 0.011a
|
Number of hospitalizations in the past 6 months (mean, SD) | 0.11 (0.53) | 0.18 (0.54) | 0.056a
|
Visited General Practitioner/Family Practitioner in the past 6 months (n, %) | 147 (67.4%) | 168 (77.1%) | 0.025b
|
Visited Neurologist in past 6 months (n, %) | 8 (3.7%) | 30 (13.8%) | < 0.001b
|
Visited Psychiatrist in past 6 months (n, %) | 7 (3.2%) | 29 (13.3%) | < 0.001b
|
Visited ED in the past 6 months (n, %) | 27 (12.4%) | 45 (20.6%) | 0.020b
|
Hospitalized in the past 6 months (n, %) | 16 (7.3%) | 28 (12.8%) | 0.056b
|
P26 Burden of migraine in the 5EU from the patient perspective: A cross-sectional analysis of National Health and Wellness Survey (NHWS) data
Pamela Vo1, Juanzhi Fang2, Aikaterini Bilitou3, Annik K. Laflamme1, Shaloo Gupta4
1Novartis Pharma AG, Basel/Switzerland; 2Novartis Pharmaceuticals Corporation, NJ/USA; 3Novartis Global Services Centre, Patient Access Services, Dublin/Ireland; 4Kantarhealth, Princeton NJ/USA
Correspondence: Pamela Vo (pamela.vo@novartis.com)
P27 Understanding the impact of migraine on work productivity using self-reported migraine diary data using the Migraine Buddy application in Europe
Nicolas Paris1, Pamela Vo2, Tomas Valena3, Aikaterini Bilitou4, Frederic de Reydet de Vulpillieres2, Juanzhi Fang5, Christel Naujoks2, Francois Everhard2, Francois Cadiou1
1Healint Pte. Ltd, Singapore 118520; 2Novartis Pharma AG, Switzerland; 3Novartis s.r.o., Czech Republic; 4Novartis Global Services Center Dublin, Ireland; 5 Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA
Correspondence: Aikaterini Bilitou (katerina.bilitou@novartis.com)
Symptoms | CM (n=730) | 8-14EM (n=1237) | 4-7EM (n=1139) | Total (n=3106) |
---|---|---|---|---|
Pain/Body | 684 (94%) | 1145 (93%) | 1024 (90%) | 2853 (92%) |
Mood and cognition | 661 (91%) | 1114 (90%) | 972 (85%) | 2747 (88%) |
Environmental handicap | 643 (88%) | 1073 (87%) | 944 (83%) | 2660 (86%) |
Depression | 436 (60%) | 590 (48%) | 435 (38%) | 1461 (47%) |
Sleep alterations | 296 (41%) | 435 (35%) | 256 (22%) | 987 (32%) |
Others | 271 (37%) | 296 (24%) | 213 (19%) | 780 (25%) |
No symptoms | 126 (17%) | 274 (22%) | 161 (14%) | 561 (18%) |
P28 A descriptive analysis of the burden of migraine based on self-reported migraine diary data using the Migraine Buddy application in Europe
Nicolas Paris1, Pamela Vo2, Tomas Valena3, Aikaterini Bilitou4, Frederic de Reydet de Vulpillieres2, Juanzhi Fang5, Christel Naujoks2, Francois Everhard2, Francois Cadiou1
1Healint Pte. Ltd, Singapore 118520; 2Novartis Pharma AG, Switzerland; 3Novartis s.r.o., Czech Republic; 4Novartis Global Services Center Dublin, Ireland; 5Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA
Correspondence: Aikaterini Bilitou (katerina.bilitou@novartis.com)
Type of activity affected | CM (n=900) | 8-14 EM (n=1500) | 4-7 EM (n=1500) | Total (n=3900) |
---|---|---|---|---|
Home activities | 520 (58%) | 985 (66%) | 933 (62%) | 2438 (63%) |
Productivity | 590 (66%) | 993 (66%) | 841 (56%) | 2424 (62%) |
Social activities | 553 (61%) | 882 (59%) | 736 (49%) | 2171 (56%) |
Sleep | 470 (52%) | 827 (55%) | 676 (45%) | 1973 (51%) |
Others | 268 (30%) | 298 (20%) | 204 (14%) | 770 (20%) |
Any activity | 855 (95%) | 1447 (96%) | 1430 (95%) | 3732 (96%) |
P29 Evaluating clinically meaningful within-subject change in functioning associated with migraine prevention using the Migraine Physical Function Impact Diary (MPFID)
Ariane K Kawata1, Asha Hareendran2, Jiat-Ling Poon1, Andrew Thach3, Pooja Desai3, Yumi Kubo3, Daniel D Mikol3, David W Dodick4, Richard B Lipton5, Stewart J Tepper6
1Evidera, Bethesda, MD, USA; 2Evidera London, UK; 3Amgen Inc., Thousand Oaks, CA, USA; 4Department of Neurology, Mayo Clinic Arizona, Phoenix, AZ, USA; 5Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; 6Geisel School of Medicine at Dartmouth, Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
Correspondence: Ariane K Kawata (ariane.kawata@evidera.com)
P30 The Trigger Avoidance Model of Headaches and Learning to Cope with Triggers: An update
Paul R Martin (paul.martin@griffith.edu.au)
School of Applied Psychology and Menzies Health Institute Queensland, Griffith University, Mount Gravatt, Queensland, Australia, 4122
P31 The intermediary relationship between analgesic/abortive medication use, sleep quality, and headache frequency: A potential new partial mechanism contributing to medication overuse headache
Daniel P Sullivan, Paul R Martin
School of Applied Psychology and Menzies Health Institute Queensland, Griffith University, Mount Gravatt, Queensland, Australia, 4122
Correspondence: Daniel P Sullivan (daniel.sullivan5@griffithuni.edu.au)
P32 State and Trait anger and its expression in migraine and cluster headache
Marialuisa Rausa1,3, Sabina Cevoli2, Giulia Giannini1, Valentina Favoni1, Sara A Contin3,Donatella Ballardini3, Pietro Cortelli1,2, Giulia Pierangeli1,2,3
1Department of Biomedical and Neuromotor Sciences DIBINEM, University of Bologna, Bologna,40100, Italy; 2IRCCS Istituto delle Scienze Neurologiche di Bologna, 40100, Italy; 3Centro Gruber. Service for the Diagnosis and Treatment of Eating Disorders. Service for the Diagnosis and Treatment of Anxiety and Psychosomatic Disorders, Bologna,40100, Italy
Correspondence: Marialuisa Rausa (m.rausa@gmail.com)
STAXI-2 | Migraine patients (n=134) | Cluster headache patients (n=105) | p |
---|---|---|---|
State Anger | 17,51 | 20,11 | P<0.05 |
Trait Anger | 5,42 | 6,15 | ns |
Anger Expression index | 46,27 | 47,29 | ns |
Anger Expression in | 20,25 | 19,76 | ns |
Anger Expression out | 16,99 | 18,32 | P<0.05 |
Anger Control in | 18,48 | 18,79 | ns |
Anger Control out | 20,48 | 20,00 | ns |
P33 A Phase 1 Study to Assess the Pharmacokinetics, Safety, Tolerability and immunogenicity of Fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian Healthy Subjects
Orit Cohen-Barak1, Xiaojun Hu1, Michele Rasamoelisolo1, Nicola Faulhaber1, Paul Yeung1, Esther Yoon2, Mohit Gandhi 3, Ernesto Aycardi1
1Global Research and Development, Teva Pharmaceutical Industries, Netanya, Israel; 2PAREXEL International, Los Angeles; 3PRA Health Sciences, Lenexa, United States
Correspondence: Orit Cohen-Barak
P34 Fremanezumab increases the maximum number of consecutive headache free days for patients with high frequency episodic migraine
Robert Noble, Ernesto Aycardi, Marcelo Bigal, Mirna McDonald, Pippa Loupe, Investigators of the EM study
1Statistics, Teva Global Medical Affairs, Hamilton; 2Global Clinical Development; 3Clinical Development, Teva Global Research and Development, Frazer; 4Academic Affairs and Network, Teva Global Research and Development, Overland Park , United States
P35 A Phase 1 Study to Assess the Pharmacokinetics, Safety, Tolerability and immunogenicity of Fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian Healthy Subjects
Orit Cohen-Barak, Xiaojun Hu, Michele Rasamoelisolo, Nicola Faulhaber, Paul Yeung, Esther Yoon, Mohith Gandhi and Ernesto Aycardi
P36 Analysis of injection site reactions across four placebo controlled trials of erenumab for migraine prevention
Julio Pascual1, David Doležil2, Brendan Davies3, Hernan Picard4, Frank Hong5, Feng Zhang4, Fei Xue4, Dan Mikol4, Jan Klatt5
1Service of Neurology, University Hospital Marqués de Valdecilla and IDIVAL, Santander, Spain; 2DADO MEDICAL sro, Prague Headache Center, Prague, Czech Republic; 3Department of Neurology, Royal Stoke University Hospital, Stoke-on-Trent, UK; 4Amgen Inc., Thousand Oaks, CA, USA; 5Novartis Pharma AG, Basel, Switzerland
Correspondence: Julio Pascual (juliopascual@telefonica.net)
Erenumab, mg | |||
---|---|---|---|
Placebo (N=1043) | 70 (N=893) | 140 (N=507) | |
Any ISR-AE | 33 (3.2) | 50 (5.6) | 23 (4.5) |
ISR-AEs with >0.5% frequency in any group | |||
Injection site pain | 18 (1.7) | 33 (3.7) | 8 (1.6) |
Injection site erythema | 2 (0.2) | 9 (1.0) | 10 (2.0) |
Injection site pruritus | 3 (0.3) | 4 (0.4) | 4 (0.8) |
Erenumab, mg | ||
---|---|---|
70 (N=2128)a
| 140 (N=1198)a
| |
Subjects who experienced an ISR-AE, n (%) | 130 (6.1) | 50 (4.2) |
Total time at risk summed across subjects, years | 1738 | 649 |
Exposure-adjusted subject incidence rate per 100 subject-years | 7.5 | 7.7 |
P37 Ipoglycemia a trigger factor for migraine chronification in migraineurs: diagnosis with glycemic load
Claudio Mostardini
Headache Center, Ospedale G.B. Grassi, ASL Roma 3
P38 Peripheral Vagal Nerve Stimulation attenuates migraine aura: a case report
Grazia Sances1, Vito Bitetto1, Eric J Liebler2, Roberto De Icco1, Michele Viana1, Cristina Tassorelli1,3
1Headache Science Center (HSC), C. Mondino National Institute of Neurology Foundation, Pavia, 27100, Italy; 2Electrocore LLC, Basking Ridge, NJ, 07920, USA; 3 Dept of Brain and Behavioural Sciences, University of Pavia, 27100, Italy
Correspondence: Grazia Sances (grazia.sances@mondino.it)
P39 Cortical laminar necrosis in a 14-year old patient with status migrainosus
L. M. Messina, C. Gallo, V. Raieli, E. Correnti, F. Vanadia
P40 Visual snow in a patient with occipital stroke: do we have to rethink migrainous infarction pathophysiology?
Teresa Catarci (teresa.catarci@aslroma2.it)
Headache Centre, Azienda Sanitaria Locale Roma 1-2, Rome, Italy
P41 Treatment patterns and medication use among migraine patients in Finland
Timo Purmonen, Hanna Wahlman, Minna Korolainen
Novartis Finland Oy, Espoo, 02130, Finland
Correspondence: Timo Purmonen
P42 The impact of fremanezumab on headache-related disability in patients with chronic migraine using the Headache Impact Test
Paul K Winner1, Timothy Fitzgerald2, Sanjay K Gandhi2, Paul P Yeung2, Joshua M Cohen2, Yuju Ma2, Ernesto Aycardi2
1Palm Beach Neurology, West Palm Beach, Florida, 33407, USA; 2Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA
Correspondence: Paul K Winner
P43 Development of the Italian version of the “identify chronic migraine” (IT-ID-CM)
Simona Sacco1, Silvia Benemei2, Sabina Cevoli3, Gianluca Coppola4, Pietro Cortelli3, Francesco De Cesaris2, Cristiano De Marco5, Cherubino Di Lorenzo4, Luana Evangelista1, Pierangelo Geppetti2, Andrea Negro5, Giulia Pierangeli3, Francesco Pierelli4, Luigi Alberto Pini6, Francesca Pistoia1, Antonio Russo8, Cristina Tassorelli7, Gioacchino Tedeschi8, Paolo Martelletti5
1Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L’Aquila, L’Aquila, Italy; 2 Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy; 3 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; 4 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University Polo Pontino, Latina, Italy; 5 Department of Clinical and Molecular Medicine, Regional Referral Headache Centre, Sant'Andrea Hospital, Sapienza University, Rome, Italy; 6 Headache and Drug Abuse Research Centre, Policlinico Hospital, University of Modena e Reggio Emilia, Modena, Italy; 7 Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy Dept. of Brain and Behavioral Sciences, University of Pavia, Italy; 8 Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Naples, Italy
P44 Importance of Anatomical Diagnostic Approach for Migraine and Tension type headache using Acupuncture and Meridian of Korean Hand Therapy
SoonWon Park1, Kyuhyun Park2, Taewoo Yoo3
1Dept. of Neurology, Bongseng Memorial Hospital, Busan, Korea; 2Emeritus Prof. Pusan National University, Busan, Korea; Dept. of Neurology, Jungang Nara Hospital, Busan, Korea; 3Korean Hand Acupuncture Therapy Institute, Seoul, Korea
Correspondence: Kyuhyun Park (qhynbak@pusan.ac.kr)
P45 Use of nutraceutical Clevia, in Pure Menstrual Migraine
Claudio Mostardini
Headache Center, Ospedale G.B. Grassi, ASL Roma 3
P46 Maternal alexithymia and attachment style: which relationship with their children's headache features and psychological profile?
Samuela Tarantino1, Laura Papetti1, Cristiana De Ranieri2, Angela Rocco2, Valeria Valeriano2, Francesca Boldrini2, Barbara Battan1, Maria Francesca Paniccia2, Federico Vigevano1, Simonetta Gentile2, Massimiliano Valeriani1,3
1Headache Center, Division of Neurology; 2Unit of Clinical Psychology, Ospedale Pediatrico Bambino Gesù, IRCCS, Piazza Sant’Onofrio 4, Rome, Italy; 3Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark
Correspondence: Samuela Tarantino
P47 Post accidental dural puncture headache: 3 years of obstetric experience using conservative treatment
Paolo Diamanti1, Laura Toscani1, Luigi Farina1, Maurizio Evangelista2
1Cristo Re Hospital, U.O.C Anestesia e Rianimazione,Via delle Calasanziane 25, 00167 Rome, Italy; 2Università Cattolica del Sacro Cuore, Istituto di Anestesiologia, Rianimazione e Terapia del Dolore,Largo Francesco Vito, 1, 00168 Rome, Italy
Correspondence: Paolo Diamanti (diamantipaolo1@tin.it)
Age | Weight | Height | BMI |
---|---|---|---|
33.7 | 73.6 | 164.8 | 27.09 |
P48 Pediatric use of Tanacetum Parthenium, Griffonia Simplicifolia an Magnesium in the prophylaxis and symptomatic treatment of headache attacks
Anna Rita Bellomo1, Federica Di Ruscio2, Lorenzo Toni3 (tonilor@tin.it)
1G.B.Grassi Hospital,Rome,Italy,00122; 2Medical and Surgery School Campus Bio-medico University, Rome Italy,00128; 3Department of Mental Health ASL RM/3, Rome,Italy,00125
Correspondence: Anna Rita Bellomo1 (annaritabellomo62@gmail.com); Federica Di Ruscio (federica.diruscio@gmail.com)
P49 The impact of fremanezumab on migraine-specific health-related quality of life and overall health status in chronic migraine
Richard B Lipton1, Sanjay K Gandhi2, Timothy Fitzgerald2, Paul P Yeung2, Joshua M Cohen2, Yuju Ma2, Ernesto Aycardi2
1Albert Einstein College of Medicine, Bronx, New York, 10461, USA; 2Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA
Correspondence: Richard B Lipton
P50 Clinical presentation and diagnostic evaluation of idiopathic intracranial hypertension in children and adolescents
Barbara Battan, Laura Papetti, Irene Salfa, Federico Vigevano, Massimiliano Valeriani
1Headache Center, Child Neurology Unit, Bambino Gesu’ Children’s Hospital, Rome, Italy
Correspondence: Barbara Battan (barbara.battan@opbg.net)
P51 Onabotulinumtoxin A in a patient with ileointestinal bypass and chronic migraine: a case report
Ottavio Di Marco, Stefania Di Mauro, Fernando Ferrauti
ASL Frosinone
P52 The impact of headache free days on headache-related disability and productivity among people with migraine with ≥4 headache days in the past month
Lulu Lee1, Jvawnna Bell2, Timothy Fitzgerald2, Joshua M. Cohen2
1Kantar Health, 1810 Gateway Drive, Suite 120, San Mateo, CA, 94404, USA; 2Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA
Correspondence: Lulu Lee
P53 Early Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine
Paul Yeung1, Ernesto Aycardi1, Marcelo Bigal1, Tricia Blankenbiller1, Melissa Grozinski-Wolff1, Ronghua Yang1, Yuju Ma1, Jan Brandes2
1Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA; 2Nashville Neuroscience Group, Nashville, TN 37203, USA
Correspondence: Paul Yeung
-
At Week 1, (-1.1 days; p<0.0001) versus placebo (-0.5 days)
-
At Week 2, (-1.2 days; p<0.0001) versus placebo (-0.5 days)
-
At Week 3, (-1.2 days; p<0.0001) versus placebo (-0.6 days)
-
At Week 4, (-1.1 days; p=0.0006) versus placebo (-0.7 days)
P54 Burden of illness among treated migraine patients with ≥4 headache days in the past month
Jvawnna Bell1, Lulu Lee 2,Timothy Fitzgerald1, Joshua M. Cohen1
1Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA; 2 Kantar Health, 1810 Gateway Drive, Suite 120, San Mateo, CA, USA 94404
Correspondence: Jvawnna Bell
P55 Efficacy and Safety of Motilitone in Migraine Patients with Gastrointestinal Symptoms
Dong Wook Kim1 and Kwang Ki Kim2
1Department of Neurology, Konkuk University School of medicine, Seoul, Korea; 2Department of Neurology, Dongguk University Ilsan Hospital, Ilsan, Korea
P56 Topiramate is more effective than acetazolamide at lowering intracranial pressure in healthy rodents
Hannah Botfield1,2†, William J Scotton1,2,3†, Maria Uldall4, Connar Westgate1,2, James Mitchell1,2,3, Rigmor Jensen4, Alex Sinclair1,2,3
1Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, B15 2TT, UK; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, B15 2TH, UK; 3Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, B15 2TH, UK; 4Danish Headache Center, Clinic of Neurology, Rigshospitalet-Glostrup, University of Copenhagen, Nordre Ringvej 69, 2600 Glostrup, Denmark
Correspondence: Alex Sinclair (a.b.sinclair@bham.ac.uk)
P57 National awareness campaign to prevent medication-overuse headache in Denmark
Louise Ninett Carlsen1, Maria Lurenda Westergaard1, Mette Bisgaard1, Julie Brogaard Schytz2, Rigmor Højland Jensen1
1Danish Headache Center, Neurology Department, Rigshospitalet, Ndr. Ringvej 69, 2600 Glostrup, Copenhagen, Denmark; 2Association of Danish Pharmacies, Copenhagen, Denmark
Correspondence: Rigmor Højland Jensen (rigmor.jensen@regionh.dk, +45 38 63 30 59)
P58 Alcohol as a risk factor for migraine attacks: an exploration
Pablo Prieto1, Gabriel Boucher1, Stephen Donoghue1, Alec Mian1, Noah Rosen2
1Curelator Inc., Cambridge; 2Northwell Health, New York, United States
Correspondence: Pablo Prieto
Total | Did not consume alcohol | Consumed Alcohol | Adequate data for analysis | Potential trigger | Potential protector | No Association | |
---|---|---|---|---|---|---|---|
Suspected | 304 (57.3%) | 23 (8%) | 281 (92%) | 198 (72%) | 16 (8%) | 14 (7%) | 168 (75%) |
Not suspected | 227 (42.7%) | 110 (48%) | 117 (52%) | 74 (64%) | 4 (5.5%) | 4 (5.5%) | 66 (89%) |
Totals | 531 | 133 (25%) | 398 (75%) | 272 (68.3%) | 20 (7%) | 18 (7%) | 234 (86%) |
Total | Potential trigger | Potential protector | No Association | |
---|---|---|---|---|
Mildly suspected | 75 | 4 (8%) | 11 (21%) | 35 (71%) |
Moderately suspected | 99 | 8 (11%) | 10 (14%) | 76 (75%) |
Highly suspected | 154 | 5 (5%) | 16 (18%) | 57 (77%) |
Lagged analysis (previous day) | Same-day analysis | |||||
---|---|---|---|---|---|---|
Potential trigger | Potential protector | No Association | Potential trigger | Potential protector | No Association | |
Suspected | 34 (16.1%) | 1 (0.5%) | 176 (83.4%) | 16 (8%) | 14 (7%) | 168 (75%) |
Not suspected | 15 (20.6%) | 2 (2.7%) | 56 (76.7%) | 4 (6%) | 4 (4%) | 66 (89%) |
Totals | 49 (17%) | 3 (1%) | 232 (82%) | 20 (7%) | 18 (7%) | 234 (86%) |
P59 Medication use and overuse patterns in a cohort of US and UK individuals with migraine using a digital platform
Pablo Prieto1, Gabriel Boucher1, Stephen Donoghue1, Stephen D. Silberstein2
1Curelator Inc., Cambridge, United States; 2Jefferson Headache Center, Thomas Jefferson University, Philadelphia, United States
Correspondence: Pablo Prieto
Variable / Cohort | US | UK | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
CM | EM | CM+MO | CM+nMO | EM+MO | EM+nMO | CM | EM | CM+MO | CM+nMO | EM+MO | EM+nMO | |
Average medication classes per user | 2.45 | 2.19 | 2.80 | 1.89 | 2.53 | 2.10 | 2.82 | 2.45 | 3.11 | 2.53 | 2.48 | 2.45 |
Average medications per user | 3.55 | 2.81 | 4.13 | 2.63 | 3.33 | 2.67 | 3.58 | 2.91 | 4.26 | 2.89 | 2.95 | 2.90 |
Average medications classes per headache | 0.81 | 0.94 | 1.16 | 0.24 | 1.19 | 0.83 | 0.72 | 1.01 | 1.04 | 0.37 | 1.25 | 0.96 |
Average medications per headache | 0.86 | 0.97 | 1.23 | 0.24 | 1.22 | 0.84 | 0.74 | 1.02 | 1.07 | 0.38 | 1.28 | 0.97 |
P60 Individual self-prediction of migraine attacks: longitudinal analysis of cohort of migraine patients using a digital platform
Pablo Prieto1, Gabriel Boucher1, Alec Mian1, Noah Rosen2
1Curelator Inc., Cambridge; 2Northwell Health, New York, United States
Correspondence: Pablo Prieto
Good predictors (≥75% accuracy) | Rest | Bad predictors (≤25% accuracy) | |
---|---|---|---|
Migraine prediction | 9% | 64% | 27% |
Migraine free prediction | 71% | 28.3% | 0.7% |
Both | 5% | 95% | 0% |
P61
P62 A rapidly progressive cerebral hematoma secondary to cerebral venous sinus thrombosis (CVST) - A Case Report
Andrea Giorgetti (andrea.giorgetti@asst-ovestmi.it), Elena P. Verrengia, Patrizia Perrone
Department of Neuroscience, Neurology and Stroke Unit, Legnano Hospital, Italy
P63 Benign intracranial hypertension in children can be due to hypoparathyroidism: a case-report
Giorgia Sforza1,3, Annalisa Deodati2, Laura Papetti1, Barbara Battan1, Paolo Curatolo3, Federico Vigevano1, Massimiliano Valeriani1
1Headache Center, Child Neurology Unit, Bambino Gesu’ Children’s Hospital, Rome, Italy; 2Child Endocrinology Unit, Bambino Gesu’ Children’s Hospital, Rome, Italy; 3Child Neurology and Psychiatry Unit, Tor Vergata University of Rome, Italy
Correspondence: Giorgia Sforza (sforzagiorgia@gmail.com)
P64 Headache following head injury: A population-based longitudinal cohort study (HUNT)
Lena Hoem Nordhaug1; Knut Hagen1, 2; Anne Vik1, 3; Lars Jacob Stovner1, 2; Turid Follestad4, Torunn Pedersen5; Gøril Bruvik Gravdahl2, Mattias Linde1, 2
1Department of Neuromedicine and Movement Science (INB), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; 2Norwegian Advisory Unit on Headaches, St. Olavs University Hospital, Trondheim, Norway; 3Department of Neurosurgery, St. Olavs University Hospital, Trondheim, Norway; 4Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; 5Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
Correspondence: Lena Hoem Nordhaug (lena.h.nordhaug@ntnu.no)
P65 Pediatric headache clinics: toward in-pediatric emergency department models
Laurence Geffroy1, Silvana De Lucia1, Luigi Titomanlio1,2
1APHP-Hospital Robert Debré, Department of Pediatric Emergency Care, APHP-Hospital Robert Debré, Paris, France; 2APHP-Hospital Robert Debré, Pediatric Migraine and Neurovascular Diseases Unit, Paris, France
Correspondence: Laurence Geffroy
2011 | 2012 | 2013 | 2014 | 2015 | 2016 |
p
| |
---|---|---|---|---|---|---|---|
PED consultants for headache (% on total) | 647 (0.8%) | 829 (1%) | 824 (1%) | 955 (1.1%) | 933 (1.1%) | 997 (1.1%) | - |
Male gender | 360 (55.6%) | 453 (54.6%) | 440 (53.4%) | 490 (52.1%) | 498 (53.4%) | 527 (52.9%) | - |
Age (mean, years) | 8.9 | 9 | 9.2 | 9.3 | 9.3 | 9.8 | <.001 |
Arrival during night shift | 273 (42.1%) | 298 (35.9%) | 266 (32.3%) | 318 (33.2%) | 312 (33.4%) | 318 (31.8%) | - |
Arrival during weekend shift | 153 (23.6%) | 210 (25.3%) | 219 (26.5%) | 248 (25.9%) | 233 (25%) | 244 (24.5%) | - |
Triage severity
| - | ||||||
Low | 309 (47.8%) | 404 (48.8%) | 394 (47.8%) | 430 (45%) | 404 (43.3%) | 429 (43.1%) | |
Intermediate | 272 (42 %) | 326 (39.3%) | 322 (39%) | 385 (40.3%) | 383 (41.1%) | 397 (39.8%) | |
Urgent | 66 (10.2%) | 99 (11.9%) | 108 (13.2%) | 40 (14.7%) | 146 (15.6%) | 171 (17.1%) | <.05 |
Context of head trauma | 122 (18.9%) | 198 (23.9%) | 193 (23.4%) | 224 (23.5%) | 184 (19.7%) | 193 (19.7%) | |
Dismissed without investigations | 392 (60.6%) | 411 (49.6%) | 400 (48.6%) | 387 (40.5%) | 417 (44.7%) | 382 (38.3%) | <.05 |
Head CT scans at PED (% on all headaches) | 29 (4.5%) | 14 (1.7%) | 25 (3%) | 23 (2.4%) | 16 (1.7%) | 39 (3.9%) | |
Admission following PED (% on all headaches) | 40 (6.2%) | 48 (5.8%) | 52 (6.3%) | 58 (6.1%) | 91 (9.8%) | 100 (10%) | <.05 |
Length of stay at the PED (mean, min) | 197 | 193 | 205 | 203.5 | 211.4 | 230.2 | <.0001 |
P66 Individual identification of factors associated with reduced risk of migraine attacks: potential ‘protectors’
Stephen Donoghue1, Francesc Peris1, Gabriel Boucher1, Alec Mian1, Christian Wöber2
1Curelator Inc, suite 4503, 5th floor, 195 Binney, Cambridge, MA, USA 02142; 2Headache Group, Department of Neurology, Medical University of Vienna, Vienna Austria
Correspondence: Stephen Donoghue
All | EM | CM | |
---|---|---|---|
Total number in population | 557 | 473 | 84 |
Mean Age (years) (SD) | 42.9 (13.4) | 43.5 (13.2) | 39.4 (14.2) |
Age range (years) | 11 - 75 | 11 -75 | 15 - 69 |
No. Females (%) | 488 (87.6%) | 409 (86.5%) | 79 (94%) |
Female - menstrual cycles (%) | 292 (52.4%) | 240 (50.7%) | 52 (61.9%) |
Female - menopausal (%) | 90 (16.2%) | 80 (16.9%) | 10 (11.9%) |
Female - non-menstrual or menopausal (%) | 106 (19.0%) | 89 (18.8%) | 17 (20.2%) |
P67 Self-reported triggers vs prospectively statistically determined factors associated with attacks in individuals with episodic and chronic migraine
Stephen Donoghue1, Gabriel Boucher1, Francesc Peris1, Alec Mian1 and Paul R. Martinl2
1Curelator Inc., Cambridge, MA, USA; 2School of Applied Psychology, Griffith University, Queensland, Australia
Correspondence: Stephen Donoghue
All | EM | CM | |
---|---|---|---|
Total number in sample | 488 | 391 | 97 |
Mean Age (years) (SD) | 43.0 (13.4) | 43.7 (13.2) | 40.3 (14.0) |
Age range (years) | 11 - 75 | 11 -75 | 15 - 69 |
No. Females (%) | 440 (90.2%) | 348 (89.0%) | 92 (94.8%) |
Female - menstrual cycles (%) | 275 (56.4%) | 215 (55.0%) | 60 (61.9%) |
Female - menopausal (%) | 87 (17.8%) | 72 (18.4%) | 15 (15.5%) |
Female - non-menstrual or menopausal (%) | 78 (16.0%) | 61 (15.6%) | 22 (22.7%) |
All (N = 488) | EM (N = 391) | CM (N = 97) | |
---|---|---|---|
Mean no. suspected per individual (95% CI) (range) | 23.2 (1.1) (3 - 44) | 22.9 (1.2) (3 - 44) | 24.3 (2.4) (5 - 43) |
% of total suspected triggers identified statistically | 11.5 | 12.2 | 8.9 |
Mean no. of previously suspected
triggers statistically identified (95% CI) (range) | 2.7 (0.21) (0 - 12) | 2.8 (0.24) (0 -12) | 2.2 (0.39) (0 - 8 ) |
Mean no. of previously suspected
triggers with no association with attacks (95% CI) (range) | 14.2 (0.74) (0 - 33) | 13.8 (0.81) (0 - 33) | 15.5 (0.74) (1 - 33) |
Mean no. previously suspected
triggers with insufficient data to determine statistical association (95% CI) (range) | 5.1 (0.37) (0 - 23) | 5.0 (0.42) (0 - 23) | 5.4 (0.74) (0 - 18) |
Mean no. of unsuspected triggers statistically identified (95% CI) (range) | 1.3 (0.15) (0 -9) | 1.4 (0.17) (0 - 9) | 1.1 (0.30) (0 - 9) |
P68 Vertigo and Migraine
Elena Filatova, Tatiana Ivanova
Institute of Professional Education, Chair of Neurology. I.M. Sechenov First Moscow State Medical University 8-2 Trubetskaya st., Moscow 119991, Russia
Correspondence: Tatiana Ivanova (itamail@mail.ru)
P69 Characterising the effect of lumbar puncture on headache in idiopathic intracranial hypertension
Andreas Yiangou1,2, James Mitchell1,3, Keira Annie Markey1,2, William Scotton1,2, Peter Nightingale5, Ryan Ottridge6, Susan Mollan1,4, Alexandra Sinclair1,3
1Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, B15 2TT, UK; 2Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, B15 2TH, UK; 3Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, B15 2TH, Birmingham, UK; 4Birmingham Neuro-Ophthalmology Unit, Ophthalmology Department, University Hospitals Birmingham NHS Foundation Trust, B15 2TH, Birmingham, UK; 5Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital, Birmingham, UK; 6Birmingham Clinical Trials Unit, School of Cancer Sciences, Robert Aitken Institute, University of Birmingham, Birmingham, UK
Correspondence: Andreas Yiangou (a.yiangou@bham.ac.uk)
P70 Effectiveness of a digital platform for headache training of specialists
Edvige Correnti1, Filippo Brighina2, Antonino Sandullo3, Marcello Romano4, Francesca Marchese1, Carmela Loiacono1, Luca Messina11, Vincenzo Raieli5
1Child Neuropsychiatry School – University of Palermo –Italy 90100; 2Department of Experimental Biomedicine and Clinical Neurosciences - University of Palermo-Italy 90100; 3Primary Care Dept. –ASP 1 Agrigento- Italy 92100; 4Neurology Dept.- Cervello-Villa Sofia Ospedali Riuniti –Palermo –Italy 90100; 5UO NPI- P.O. Cristina - ARNAS Civico Palermo –Italy 90100
Corrispondence: Vincenzo Raieli (v.raieli@alice.it)
Academic groups | members | Members with no actions performed | Login | Downloaded files | Uploaded files | Clinical cases submitted | Contribution on clinical cases |
---|---|---|---|---|---|---|---|
Sisc (Italian society for the study of headache) members | 18 | 5 | 112 | 146 | 68 | 4 | 20 |
SINPIA (Italian society of neuropsychiatry for childhood and adolescence) members | 11 | 6 | 28 | 139 | 3 | 1 | 2 |
Other specialists | 8 | 4 | 7 | 31 | 3 | 0 | 0 |
Total | 37 | 15 | 147 | 316 | 74 | 5 | 22 |
P71 Tanacethum Parthenium , 5 - hydroxy tryptophan and magnesium (Aurastop©) efficacy in episodic migraine prevention. A multicentric observational study
Federico Mainardi1, Paola Merlo2, Ferdinando Maggioni3, Giorgio Zanchin3, Giorgio Dalla Volta4
1Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice; 2Headache Centre of Neurological Division of Gavazzeni Hospital, Bergamo; 3Headache Centre, Department of Neurosciences, Padua University, Padua; 4Headache Center of Neurological Unit of Istituto Clinico Citta’ di Brescia, Brescia
Correspondence: Giorgio Dalla Volta (dalla@numerica.it)
P72 Association of Tanacethum Parthenium, 5-Hydroxytryptophan and Magnesium (Aurastop®) in the treatment of migraine aura: an observational study
F. Antonaci1-3, V.Rebecchi4, G. Sances1, P.Merlo5, A.Giorgetti6, F. Di Palma7, E. Matta8, C.Dall’ Occhio9, C.Tassorelli1-3, G.Dalla Volta10, On behalf of Società Italiana per lo Studio delle Cefalee (SISC–Lombardia) - Italia
1Headache Science Centre, Istituto Neurologico Nazionale Mondino, Pavia; 2 UC Neurologia Speciale d'Urgenza, Istituto Neurologico Nazionale, Pavia; 3 Dipartimento di Scienze del Sistema Nervoso e del Comportamento Università di Pavia; 4 Centro Cefalee UOC Neurologia -Varese- ASST Settelaghi – Univ. Insubria; 5 U.O.Neurologia- Centro Cefalee, Humanitas Gavazzeni, Bergamo; 6 Centro Cefalee, Dipartimento di Neuroscienze H di Legnano ASST Ovest milanese; 7 Centro Cefalee UOC Neurologia della ASST Lariana-Ospedale S. Anna di Como; 8 Centro Cefalee UOC neurologia ASST Bergamo ovest; 9 UO Neurologia, ASST Pavia. Ospedale Civile, Voghera; 10 Centro Cefalee U.O Neurologia - Istituto Clinico Citta’ di Brescia - Brescia
Correspondence: G.Dalla Volta (dalla@numerica.it)
P73 Medical (respiratory, sleep, cardiovascular and gastrointestinal) comorbidities of migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study
Richard B. Lipton1, Vincent T. Martin2, Michael L. Reed3, Kristina M. Fanning3, Aubrey Manack Adams4, Dawn C. Buse5
1The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; 2University of Cincinnati Headache and Facial Pain Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA; 3Vedanta Research, Chapel Hill, NC, USA; 4Global Medical Affairs, Allergan plc, Irvine, CA, USA; 5Montefiore Headache Center, Bronx, NY, USA
Correspondence: Richard B. Lipton (Richard.Lipton@einstein.yu.edu)
P74 Development of a claims-based algorithm for use in patients with migraine to identify potentially undiagnosed chronic migraine patients
Jelena M. Pavlovic1, Justin S. Yu2, Stephen D. Silberstein3, Michael L. Reed4, Steve H. Kawahara5, Robert P. Cowan6, Firas Dabbous7, Karen L. Campbell2, Anand S. Shewale2, Riya Pulicharam5, Jonathan W. Kowalski2, Hema N. Viswanathan2, Richard B. Lipton1
1Montefiore Medical Center, Bronx, NY, USA; 2Health Economics and Outcomes Research, Allergan plc, Irvine, CA, 92612, USA; 3Jefferson Medical Center, Philadelphia, PA, USA; 4Vedanta Research, Chapel Hill, NC, USA; 5DaVita Medical Group, El Segundo, CA, USA; 6Stanford University School of Medicine, Stanford, CA, USA; 7Independent Consultant, La Jolla, CA, USA
Correspondence: Justin S. Yu (Justin.Yu@Allergan.com)
P75 The relationship between pain, psychiatric, and endocrine/neurological comorbidities of migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study
Richard B. Lipton1, Vincent T. Martin2, Michael L. Reed3, Kristina M. Fanning3, Aubrey Manack Adams4, Dawn C. Buse1
1The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; 2University of Cincinnati Headache and Facial Pain Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA; 3Vedanta Research, Chapel Hill, NC, USA; 4Global Medical Affairs, Allergan plc, Irvine, CA, USA
Correspondence: Richard B. Lipton (Richard.Lipton@einstein.yu.edu)
P76 Are there sex differences among self-report pain features in patients with migraine? A pilot study
Lidiane L. Florencio1, Gabriela F. Carvalho1, Carina F. Pinheiro1, Marcela B. Mendes1, Mariana T. Benato1, Samuel S. Lodovichi1, Fabiola Dach2, Débora. Bevilaqua-Grossi1
1 Department of Biomechanics, Medicine and Locomotor Apparatus Rehabilitation –Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto-SP, Brazil; 2 Department of Neurosciences and Behavioral Sciences – Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto-SP, Brazil
Correspondence: Lidiane L. Florencio
Men with migraine (n=12) | Women with migraine (n=12) | |
---|---|---|
Age (years) | 34.2 (8.1) | 34.3 (10.6) |
ASC-12 | 4.2 (3.3)*
| 9.1(4.5) |
Migraine | ||
Frequency (days/moth) | 16.3 (9.8) | 15.4 (8.5) |
Intensity (0-10) | 8.3 (1.4) | 7.9 (2.3) |
Onset (years) | 15.2 (13.0) | 19.6 (18.7) |
MIDAS | 19.3 (14.1) | 34.1 (32.5) |
Neck pain | ||
Intensity (0-10) | 2.7 (3.7)*
| 5.7 (3.0) |
Onset (years) | 2.8 (6.0) | 6.6 (5.8) |
NDI | 6.7 (6.5)*
| 12.6 (5.6) |
P77 Analysis of endurance capacity of cervical extensors and flexors muscles in individuals with migraine and controls: a pilot study
Iuri V De Oliveira1, Samuel S Lodovichi1, Lidiane L Florencio1, Carina Pinheiro1, Fabiola Dach1, Debora Bevilaqua Grossi1
1 Department of Biomechanics, Medicine and Rehabilitation of Locomotor Apparatus, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, 14049-900, Brazil
Correspondence: Iuri V De Oliveira (iurivaloti@gmail.com)
Control (n=15) | Migraine (n=15) | |
---|---|---|
Age (y) | 25,06(4,07) | 29,93 (7,17) |
Weight(kg) | 64,38(11,35) | 68,4 (11,28) |
Height (cm) | 164(8) | 165 (7) |
Endurance | Control (n=15) | Migraine (n=15)) |
p
|
---|---|---|---|
Flexion (s)
| 81,33(51,06) | 46,73(31,34) | 0,03 |
Extension (s)
| 351(138,42) | 242,20(169,24) | 0,07 |
P78 Light-induced discomfort changes semi-static posture control of migraine patients
Carina F Pinheiro1, Renato Moraes2, Lais Sestari1, Gabriela F Carvalho1, Anamaria S Oliveira1, Fabiola Dach1, Débora B Grossi1
1Department of Biomechanics, Medicine and Rehabilitation of Locomotor Apparatus, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, 14049-900, Brazil; 2School of Physical Education and Sports of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, 14049-900, Brazil
Correspondence: Carina F Pinheiro (carinafp@hotmail.com)
Visual threshold | Visual discomfort | Control | |
---|---|---|---|
CoP area (cm2) | 3.54 (0.87 to 6.20)a
| 5.03 (1.82 to 8.25) | 1.52 (0.99 to 2.06)a
|
CoP speed (cm/sec2) | 1.74 (1.35 to 2.14) | 1.78 (1.45 to 2.10) | 1.49 (1.39 to 1.59) |
P79 Poor sleep quality in probable migraine: a population-based study
Tae-Jin Song1, Soo-Jin Cho2, Won-Joo Kim3, Kwang Ik Yang4, Chang-Ho Yun5, Min Kyung Chu6
1Department of Neurology, Ewha Womans University School of Medicine, Seoul, Korea; 2Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea; 3Department of Neurology, Gangnam Severance Hospital, Yonsei University, College of Medicine, Seoul, Korea; 4Department of Neurology, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan, Korea; 5Clinical Neuroscience Center, Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea; 6Department of Neurology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
Correspondence: Min Kyung Chu (chumk@hallym.ac.kr)
Survey participants N (%) | Total population N (%) | p | Migraine N, % (95% CI) | PM N, % (95% CI) | Poor sleep quality N, % (95% CI) (PSQI> 5) | |
---|---|---|---|---|---|---|
Sex | ||||||
Men | 1,345 (49.3) | 17,584,365 (50.6) | 0.854a
| 36, 2.7 (1.8-3.5) | 136, 10.1 (8.5-11.8) | 334, 24.8 (22.5-27.1) |
Women | 1,350 (50.7) | 17,198,350 (49.4) | 107, 7.9 (6.5-9.4) | 243, 17.9 (15.8-19.9) | 381, 28.2 (25.8-30.6) | |
Age | ||||||
19–29 | 542 (20.5) | 7,717,947 (22.2) | 0.917a
| 25, 4.5 (2.7-6.2) | 69, 12.6 (9.8-15.4) | 153, 28.3 (24.4-32.0) |
30–39 | 604 (21.9) | 8,349,487 (24.0) | 42, 7.0 (4.9-9.1) | 102, 16.8 (13.7-19.8) | 136, 22.5 (19.2-25.9) | |
40–49 | 611 (23.1) | 8,613,110 (24.8) | 39, 6.5 (4.5-8.4) | 102, 16.8 (13.9-19.8) | 167, 27.3 (23.8-30.9) | |
50–59 | 529 (18.9) | 6,167,505 (17.7) | 22, 4.1 (2.4-5.9) | 62, 11.6 (8.8-14.4) | 160, 30.2 (26.3-34.2) | |
60–69 | 409 (15.6) | 3,934,666 (11.3) | 15, 3.9 (2.0-5.7) | 44, 11.2 (8.1-14.2) | 99, 24.2 (20.0-28.4) | |
Size of residential area | ||||||
Large city | 1,248 (46.3) | 16,776,771 (48.2) | 0.921a
| 76, 6.1 (4.8-7.5) | 180, 14.4 (12.4-16.3) | 338, 27.1 (24.6-29.6) |
Medium-to-small city | 1186 (44.0) | 15,164,345 (43.6) | 48, 4.0 (2.9-5.2) | 174, 14.7 (12.7-16.7) | 303, 25.5 (23.1-28.0) | |
Rural area | 261 (9.7) | 2,841,599 (8.2) | 19, 7.4 (4.2-10.6) | 25, 9.7 (6.1-13.3) | 74, 28.4 (22.8-33.9) | |
Education level | ||||||
Middle school or less | 393 (14.9) | 6,608,716 (19.0) | 0.752a
| 22, 5.5 (4.2-7.7) | 44, 11.5 (8.4-14.7) | 110, 28.0 (23.5-32.4) |
High school | 1,208 (44.5) | 15,234,829 (43.8) | 60, 5.0 (3.8-6.3) | 178, 14.7 (12.7-16.7) | 317, 26.2 (23.8-28.7) | |
College or more | 1,068 (39.6) | 12,939,170 (37.2) | 60, 5.6 (4.3-7.0) | 155, 14.4 (12.3-16.5) | 281, 26.3 (23.7-29.0) | |
Not responded | 26 (9.6) | 1, 3.8 (0.0-11.8) | 2, 7.7 (0.0-18.7) | 7, 26.9 (8.7-45.2) | ||
Total | 2695 (100.0) | 34,782,715 (100.0) | 143, 5.3 (4.5-6.2) | 379, 14.1 (12.7-15.4) | 715, 26.5 (24.9-28.2) |
Non-headache individuals N = 1,422 (52.8%) | PM N = 379 (14.1%) | Migraine individuals N = 143 (5.3%) | p value | |
---|---|---|---|---|
Subjective sleep quality | 2.0 (2.0-2.0) | 2 (2.0-2.0) | 2.0 (2.0-2.0) | 0.879 |
Sleep latency | 1.0 (0.0-1.0) | 1.0 (0.0-2.0)a
| 1.0 (0.0-2.0)a
| <0.001 |
Sleep duration | 0.0 (0.0-1.0) | 0.0 (0.0-1.0)a
| 0.0 (0.0-1.0) | <0.001 |
Habitual sleep efficacy | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.244 |
Sleep disturbance | 1.0 (0.0-1.0) | 1.0 (1.0-1.0)ab
| 1.0 (1.0-2.0)a
| <0.001 |
Use of sleeping medication | 0.0 (0.0-0.0) | 0.00 (0.0-0.0)a
| 1.0 (0.0-1.0)a
| <0.001 |
Daytime functioning | 0.0 (0.0-1.0) | 1.0 (0.0-1.0)a
| 1.0 (0.0-1.0)a
| <0.001 |
Total | 4.0 (3.0-5.0) | 5.0 (4.0-6.0)a
| 5.0 (4.0-7.0)a
| <0.001 |
P80 Correlation and differences between kinesiophobia, fear of falling and disability among women and men with migraine
Gabriela Ferreira Carvalho1; Lidiane L Florêncio1, Carina Ferreira Pinheiro1, Marcela B. Mendes1, Mariana T. Benato1, Samuel S. Lodovichi1, Fabiola Dach2, Débora Bevilaqua-Grossi1
1Department of Biomechanics, Medicine and Locomotor Apparatus Rehabilitation – Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto-SP, Brazil. 2Department of Neurosciences and Behavioral Sciences – Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto-SP, Brazil
Correspondence: Gabriela Ferreira Carvalho
Men with migraine (n=17) | Women with migraine (n=38) | |
---|---|---|
Age (years) | 33.8 (7.3) | 34.2 (11.3) |
BMI | 27.2 (4.7) | 27.2 (5.8) |
Migraine | ||
Frequency (days/month) | 17.0 (9.0) | 17.3 (10.7) |
Intensity (0-10) | 8.5 (1.4) | 7.9 (2.2) |
Onset (years) | 14.0 (12.6) | 14.1 (10.0) |
Level of physical activity*
| ||
Inactive | 11% | 12% |
Minimally active | 27% | 47% |
Active | 51% | 29% |
Hepa active | 11% | 12% |
MIDAS | 17.3 (13.7)*
| 32.0 (37.7) |
FES | 22.2 (11.9) | 24.8 (8.7) |
Tampa | 39.2 (8.1) | 35.3 (8.7) |
Dizziness | ||
Self-report | 24%*
| 63% |
DHI | 34.5 (16.1)*
| 47.4 (20.5) |
P81 Handl syndrome in pediatric age
Irene Salfa, Laura Papetti, Barbara Battan, Romina Moavero, Massimiliano Valeriani
Pediatric Headache Center, Children Hospital Bambino Gesù of Rome, Italy
P82 Usage of Quetiapine in Profilactic Treatment of Chronic Migraine
Tetiana Maikova, Sergiy Lukashov, Ekaterina Dzevitskaya, Mariya Kuts
Headache Center, Kyiv, Ukraine, 04070
Correspondence: Tetiana Maikova (maykova@headache.com.ua)
P83 Ice cream headache and rock and roll
Federico Mainardi1, Giorgio Zanchin2, Ferdinando Maggioni2
1Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice, Italy; 2Headache Centre, Department of Neurosciences, Padua University, Padua, Italy
Correspondence: Federico Mainardi (fmainardi@iol.it)
P84 Implementation of improved working practices in a chronic migraine Botox® clinic has increased treatment capacity by up to 60% with the same resources
Rebecca Stuckey, 1 April Bostock, 1 Stuart Weatherby, 1 Gemma Taylor, 1 Donna Clewer, 1 Paul Button, 2 Julie Button2
1Neurology Department, Plymouth Hospitals NHS Trust, UK; 2ProcEx Solutions Ltd., Wales, UK
Clinics | Clinic Times | Frequency | Current Annual Capacity | New Annual Capacity |
---|---|---|---|---|
Tuesday AM | 09:00-12:30 | Weekly | 336 | 546 |
Wednesday AM | 09:00-12:30 | Monthly | 96 | 156 |
Wednesday PM | 13:30-16:30 | Monthly | 84 | 132 |
Thursday PM | 13:30-16:30 | Monthly | 84 | 132 |
Friday PM | 13:30-16:30 | Fortnightly | 168 | 264 |
768 | 1230 | |||
% Increase | 60% |
P85 Zonisamide for headache prophylaxis in dementia
Yunju Choi1, Seung H. Lee2, Myeong K. Kim2, Kyung W. Kang2
1Department of neurology, Presbyterian Medical Center, Jeonju, Republic of Korea, 54987; 2Department of neurology, Chonnam National University Hospital, Gwangju, Republic of Korea, 61469
Correspondence: Yunju Choi (neurologist16@gmail.com)
P86 Postural headache and spontaneous intracranial hypotension: clinical features, neuroimaging and quality of life improvements in patients treated with blind epidural blood patch: a case series
Marco Mercieri1, Riccardo Chierichini1, Barbara Silvestri2, Roberto Arcioni1
1 Department of Medical and Surgical Science and Translational Medicine, Sapienza University of Rome and Pain Therapy Unit, Sant'Andrea Hospital, Rome, IT; 2 Unit of Anaesthesia, Intensive Care and Pain Management, Campus Bio-Medico University, Rome, Italy
Correspondence: Marco Mercieri (marco.mercieri@uniroma1.it)
Case n. | Sex | Age | Spine NMR | Cisternography | Leakage | Blood administered (ml) | n° of Blood Patches |
---|---|---|---|---|---|---|---|
1 | F | 35 | + | T2-T3 | 20 | 1 | |
2 | M | 57 | - | + | L2-L3 | 20 | 1 |
3 | M | 43 | + | C7-T1 | 20 | 1 | |
4 | F | 45 | + | T12-L1 | 20 | 2 | |
5 | F | 27 | - | / | 20 | 1 |
P87 Retinal migraine: three case reports
Vlasta Vukovic Cvetkovic, Lars Bendtsen, Jes Olesen
Danish Headache Center, Rigshospitalet-Glostrup, Copenhagen, Denmark
Correspondence: Vlasta Vukovic Cvetkovic (vlasta.vukovic@uclmail.net)
P88 Changes in grey matter volume and functional connectivity in cluster headache versus migraine
Silvia Benemei1, Antonio Giorgio2, Jian Zhang2, Chiara Lupi1, Marzia Mortilla3, Antonio Federico2, Pierangelo Geppetti1, Francesco De Cesaris1, Nicola De Stefano2
1Department of Health Sciences, University of Florence, Florence, Italy; 2Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy; 3Anna Meyer Children’s University Hospital, Florence, Italy
Correspondence: Silvia Benemei
P89 Intercepting migraine in its path towards chronicity
Angela Koverech, Paolo Martelletti1,2
1Department of Clinical and Molecular Medicine, Sapienza University, Rome Italy; 2Regional Referral Headache Centre, Sant’Andrea Hospital, Via di Grottarossa 1035, 00189 Rome, Italy
Correspondence: Paolo Martelletti (paolo.martelletti@uniroma1.it)
P90 Induction of migraine-like photophobia by PACAP-38: A potential target in migraine treatment
Adisa Kuburas1, Bianca N. Mason2, Maria-Christina M. Loomis4, Leon F. Garcia-Martinez4, Andrew F. Russo1,2,3
1Department of Molecular Physiology and Biophysics; 2Molecular and Cellular Biology Program, 3Veterans Affairs Medical Center; University of Iowa, Iowa City, Iowa 52242; 4Alder Biopharmaceuticals; Bothell, Washington 98011
Correspondence: Andrew F. Russo
P91 Burden and impact of migraine: a caregiver’s perspective
Elena Ruiz de la Torre1, Paolo Martelletti2,3, Audrey Craven1,4, Donna Walsh4, Simon Evans5, Paula Dumas6, Hans-Christoph Diener7, Michel Lanteri-Minet8, Todd J. Schwedt9, Jean-Pierre Malkowski10, Monisha Sodha11, Susann Walda11, Anne Aronsson11, Annik Laflamme10, Pamela Vo10
1European Headache Alliance, Brussels, Belgium; 2European Headache Federation, Rome, Italy; 3Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy; 4European Federation of Neurological Associations; 5Migraine Action, Leicester, LE1 6NB, UK; 6Migraine Again, USA; 7Department of Neurology and Headache Center, University of Duisburg-Essen, Essen, Germany; 8Département d’Evaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, Hôpital de Cimiez, 06300 Nice, France; 9Department of Neurology, Mayo Clinic, USA; 10Novartis Pharma AG, 4002 Basel, Switzerland; 11GfK Switzerland, 4058 Basel, Switzerland
Correspondence: Pamela Vo (pamela.vo@novartis.com)
P92
P93 Real-world patient perspective on the burden and impact of migraine
Elena Ruiz de la Torre1, Paolo Martelletti2,3, Audrey Craven1,4, Donna Walsh4, Simon Evans5, Paula Dumas6, Hans-Christoph Diener7, Michel Lanteri-Minet8, Todd J. Schwedt9, Jean-Pierre Malkowski10, Monisha Sodha11, Susann Walda11, Anne Aronsson11, Annik Laflamme10, Pamela Vo10
1 European Headache Alliance, Brussels, Belgium; 2 European Headache Federation, Rome, Italy; 3 Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy; 4 European Federation of Neurological Associations; 5 Migraine Action, Leicester, LE1 6NB, UK; 6 Migraine Again, USA; 7 Department of Neurology and Headache Center, University of Duisburg-Essen, Essen, Germany; 8 Département d’Evaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, Hôpital de Cimiez, 06300 Nice, France; 9 Department of Neurology, Mayo Clinic, USA; 10Novartis Pharma AG, 4002 Basel, Switzerland; 11 GfK Switzerland, 4058 Basel, Switzerland
Correspondence: Pamela Vo (pamela.vo@novartis.com)
3 Most Common per Category | |||
---|---|---|---|
Migraine attack triggers | Bright light | Loud/repetitive sounds | Stress |
97%(n=58) | 93%(n=56) | 93%(n=56) | |
Migraine symptoms | Pounding/throbbing | Photophobia | Sensitivity to sound and noise |
97%(n=58) | 97%(n=58) | 93%(n=56) | |
Coping mechanisms | Lying down in a darkened room | Avoidance of sounds/noise | Medication use |
97%(n=58) | 95%(n=57) | 77%(n=46) |
P94 Efficacy of Onabotulinumtoxin A and Physical Therapy combined treatment in chronic migraine
Antonio Granato1; Antonella Monticco2; Manuela Deodato2; Ugogiulio Sisto1; Mariana Ridolfi1; Roberto Marcovich2; Paolo Manganotti1
1Department of Medical, Technological and Translational Sciences, Headache Centre, University of Trieste, Italy; 2University of Trieste, Italy
P95 The antimigraine butterbur ingredient, isopetasin, desensitizes peptidergic nociceptors via the TRPA1 channel activation in vitro
De Logu F1, Benemei S1, Li Puma S1, Marone IM1, Coppi E1, Ugolini F1, Liedtke W2, Pollastro F3, Appendino G3, Geppetti P1, Materazzi S1 and Nassini R1
1Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy; 2Departments of Neurology, Anesthesiology and Neurobiology, Clinics for Headache, Head-Pain and Trigeminal Sensory Disorders, Duke University, Durham, NC 27710 USA; 3Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy
Correspondence: De Logu F
P96 Use of acute headache and migraine medications in patients with episodic migrainein the STRIVE Phase 3 trial of erenumab for migraine prevention
Uwe Reuter1, Jo Bonner2, Gregor Broessner3, Yngve Hallstrom4, Hernan Picard5, Sunfa Cheng5, Feng Zhang5, Dan Mikol5, Jan Klatt6
1Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 2Mercy Research, St Louis, MO, USA; 3Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria; 4Stockholm Neuro Center, Stockholm, Sweden; 5Amgen Inc., Thousand Oaks, CA, USA; 6Novartis Pharma AG, Basel, Switzerland
Correspondence: Uwe Reuter (uwe.reuter@charite.de)
P97 Ex-Migraine: Clinical and Neurophysiological Analysis
Vera Osipova1, Alexey Sergeev2, Elena Snopkova1, Ada Artemenko1, Guzial Tabeeva2, Zaza Katsarava3,4
1Research Department of Neurology, Sechenov University, Moscow, Russia; 2Department of Neurology and Neurosurgery, Sechenov University, Moscow, Russia; 3Department of Neurology, University of Duisberg-Essen, Essen, Germany; 4Department of Neurology, Evangelical Hospital Unna, Unna, Germany
P98 Reducing the impact of migraine on functioning: Results from the STRIVE trial, a phase 3, randomised, double-blind, placebo-controlled study of erenumab in patients with episodic migraine
Dawn C Buse1, Richard B Lipton1, Daniel D Mikol2, Andrew V Thach2, Pooja Desai2, Hernan Picard2, Yumi Kubo2, Asha Hareendran3, Ariane K Kawata4
1Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; 2Amgen Inc., Thousand Oaks, CA, USA; 3Evidera, London, UK; 4Evidera, Bethesda, MD, USA
Correspondence: Dawn C Buse (DBUSE@montefiore.org)
Least squares mean changes (95% confidence interval) | p-values (Erenumab vs Placebo) | ||||
---|---|---|---|---|---|
Erenumab 70 mg | Erenumab 140 mg | Placebo | Erenumab 70 mg | Erenumab 140 mg | |
Physical function | −13.7 (−15.5, −11.9) | −15.1 (−17.0, −13.3) | −9.4 (−11.3, −7.6) | <0.001 | <0.001 |
Usual activities | −12.3 (−13.9, −10.6) | −13.4 (−15.1, −11.8) | −8.3 (−10.0, −6.6) | <0.001 | <0.001 |
Social function | −13.2 (−14.9, −11.4) | −14.5 (−16.2, −12.8) | −9.5 (−11.3, −7.7) | 0.003 | <0.001 |
Emotional function | −16.4 (−18.4, −14.5) | −18.4 (−20.3, −16.5) | −11.2 (−13.1, −9.2) | <0.001 | <0.001 |
P99 Reducing impaired days: Results from the STRIVE trial, a phase 3, randomised, double-blind study of erenumab for episodic migraine
Asha Hareendran1, Dawn C Buse2, Richard B Lipton2, Martha S Bayliss3, Daniel D Mikol4, Dennis A Revicki5, Feng Zhang4, Pooja Desai4, Hernan Picard4, Ariane K Kawata5
1Evidera, London, UK; 2Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; 3Optum, Lincoln, RI, USA; Amgen Inc., Thousand Oaks, CA, USA; Evidera, Bethesda, MD, USA
Correspondence: Asha Hareendran (asha.hareendran@evidera.com)
P100 Patient-reported outcomes in patients with chronic migraine receiving placebo or erenumab (AMG 334) in a phase 2, randomised, double-blind study
Richard B Lipton1, Stewart J Tepper2, Uwe Reuter3, Stephen Silberstein4, Walter Stewart5, Dean Leonardi6, Pooja Desai6, Sunfa Cheng6, Daniel D Mikol6, Robert A Lenz6
1Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, NY, USA; 2Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 3Department of Neurology, Charité Universitätsmediz in Berlin, Berlin, Germany; 4Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA; 5Sutter Health, Walnut creek, CA, USA; 6Amgen Inc., Thousand Oaks, CA, USA
Correspondence: Richard B Lipton (Richard.Lipton@einstein.yu.edu)
P101 Treatment-Induced Improvement in Migraine Classification in the Fremanezumab HFEM Study
Robert Noble1, Ernesto Aycardi2, Marcelo Bigal3, Pippa Loupe4
1Statistics, Teva Global Medical Affairs, Hamilton; 2Global Clinical Development; 3Clinical Development, Teva Global Research and Development, Frazer; 4Academic Affairs and Network, Teva Global Research and Development, Overland Park , United States
Correspondence: Robert Noble
Table 1A. Overall shift in migraine categorya
| Placebo n = 104 | Fremanezumab 225 mg n = 95 | Fremanezumab 675 mg n = 96 |
Worsen | 7 (7%) | 2 (2%) | 3 (3%) |
Stable | 42 (40%) | 14 (15%) | 17 (18%) |
Improve | 51 (49%) | 69 (73%) | 68 (71%) |
Discontinued | 4 (4%) | 10 (11%) | 8 (8%) |
Table 1B: Migraine Categories Num (%) patients in 3rd month | Placebo (n = 98)b
| Fremanezumab 225 mg (n = 88) | Fremanezumab 675 mg (n = 91) |
CM | 7 (7%) | 2 (2%) | 2 (2%) |
HFEM | 41 (42%) | 14 (16%) | 17 (19%) |
MFEM | 28 (29%) | 22 (25%) | 21 (23%) |
LFEM | 20 (20%) | 40 (45%) | 47 (52%) |
P102 Analysis of blood pressure following short-term and long-term treatment with erenumab
Stewart J Tepper1, Julio Pascual2, Uwe Reuter3, Hernan Picard4, Frank Hong5, Marie-Louise Trotman4, Fei Xue4, Dan Mikol4, Jan Klatt5
1Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 2Service of Neurology, University Hospital Marqués de Valdecilla and IDIVAL, Santander, Spain; 3Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 4Amgen Inc., Thousand Oaks, CA, USA; 5Novartis Pharma AG, Basel, Switzerland
Correspondence: Stewart J Tepper
P103 The role of peripheral CGRP on the vasculature in a preclinical mouse model of migraine
Bianca Mason
P104 Peripheral vagal nerve stimulation modulates the nociceptive withdrawal reflex in healthy subjects: a cross-over sham-controlled study
Roberto De Icco1,2, Daniele Martinelli1,2, Eric Liebler3, Marta Allena2, Vito Bitetto1, Grazia Sances2, Giorgio Sandrini1,2, Giuseppe Nappi1,2, Cristina Tassorelli1,2
1Department of Brain and Behavioral Sciences, University of Pavia, 27100, Pavia, Italy; 2 Headache Science Center, C. Mondino National Neurological Institute, 27100, Pavia, Italy; 3 electroCore LLC, Basking Ridge, NJ, 07920, USA
Correspondence: Roberto De Icco (rob.deicco@gmail.com)
P105 Non-invasive vagal nerve stimulation reduces provoked cranial parasympathetic output in healthy volunteers
Celina F. Schroeder*, Maike Moeller*, Arne May
Department of Systems Neuroscience, University Medical Center Eppendorf, Hamburg, 20246, Germany
P106 Obesity is more prevalent in chronic migraine than in episodic migraine
Brad D Torphy1, Nicole Montes Buckley2
1Diamond Headache Clinic, Chicago, IL, 60642, USA; 2Adler University, Chicago, IL, 60602, USA
Correspondence: Brad D Torphy
P107 The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine
Richard B Lipton1; Sanjay K Gandhi2; Timothy Fitzgerald2; Paul P Yeung2; Joshua M Cohen2; Yuju Ma2; Ernesto Aycardi2
1Albert Einstein College of Medicine, Bronx, New York, 10461, USA; 2Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA
Correspondence: Richard B Lipton
P108 The Impact of Fremanezumab on Headache-related Disability in Patients With Episodic Migraine Using the Migraine Disability Assessment
Paul K Winner1; Timothy Fitzgerald2; Sanjay K Gandhi2; Paul P Yeung2; Joshua M Cohen2; Yuju Ma2; Ernesto Aycardi2
1Palm Beach Neurology, West Palm Beach, Florida, 33407, USA; 2Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA
Correspondence: Paul K Winner
P109 The positive impact of fremanezumab on work productivity and activity impairment in patients with chronic migraine
Richard B Lipton1; Sanjay K Gandhi2; Timothy Fitzgerald2; Paul P Yeung2; Joshua M Cohen2; Yuju Ma2; Ernesto Aycardi2
1Albert Einstein College of Medicine, Bronx, New York, 10461, USA; 2Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA
Correspondence: Richard B Lipton
P110 Surface electromyografy of masticatory and neck muscles in patient with temporomandibular disorders and headeache: a case report
Novi S1, SaviL2
1Gnathologist, freelance, Brunico –Italy; 2 Headeache Center- City of Healthe Science University Hospital-Torino- Italy Headeache Center LBS- Lugano-Switzerland
P111 Headache secondary to subarachnoid haemorrhage due to arteriovenous malformation can be presented as migraine in its clinical phenotype
Srdjan Ljubisavljevic (srljub@gmail.com)
Faculty of Medicine, University of Nis, Nis, Serbia, Clinic for Neurology, Clinical Center Nis, Nis, Serbia
P112 Decreased medial prefrontal cortex volume in migraine without aura: a multispectral MRI study
Sourena Soheili-Nezhad1, Alireza Sedghi2, Ferdinand Schweser3,4, Neda Jahanshad1, Paul Thompson1, Amir Eslami Shahr Babaki5, Aida Tabrizi6, Mansoure Togha6
1 Imaging Genetics Center, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Marina del Rey, CA 90292, United States of America; 2 Medical Informatics Laboratory, School of Computing, Queen’s University, Kingston, ON K7L2N8, Canada; 3 Department of Neurology, Buffalo Neuroimaging Analysis Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, United States of America; 4 Translational Imaging Center, Clinical and Translational Science Institute, University at Buffalo, Buffalo, NY 14203 United States of America; 5 Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; 6 Iranian Center of Neurological Research, Neuroscience Research Institute, Tehran University of Medical Sciences, Tehran, Iran
Correspondence: Mansoure Togha (toghae@sina.tums.ac.ir)
P113 Chronic paroxysmal hemicrania in paediatric age: report of four cases
Laura Papetti, Samuela Tarantino, Barbara Battan, Federico Vigevano, Massimiliano Valeriani
Headache Center, Department of Neuroscience, Bambino Gesù Children Hospital, Rome, Italy
Correspondence: Laura Papetti (laura.papetti@opbg.net)
P114 Early Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine
Paul Yeung1, Ernesto Aycardi1, Marcelo Bigal1, Tricia Blankenbiller1, Melissa Grozinski-Wolff1, Ronghua Yang1, Yuju Ma1, Jan Brandes2
1Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA; 2Nashville Neuroscience Group, Nashville, TN 37203, USA
Correspondence: Paul Yeung
-
At Week 1, (-0.9 days; p<0.0001) versus placebo (-0.3 days)
-
At Week 2, (-0.8 days; p<0.0001) versus placebo (-0.3 days)
-
At Week 3, (-0.9 days; p<0.0001) versus placebo (-0.4 days)
-
At Week 4, (-0.9 days; p=0.0123) versus placebo (-0.6 days)
-
At Week 1, (-0.8 days; p<0.0001) versus placebo (-0.3 days)
-
At Week 2, (-0.8 days; p<0.0001) versus placebo (-0.3 days)
-
At Week 3, (-0.8 days; p=0.0003) versus placebo (-0.4 days)
-
At Week 4, (-0.8 days; p=0.0403) versus placebo (-0.6 days)
P115 Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab (TEV-48125) Versus Placebo for the Preventive Treatment of Episodic Migraine
Ernesto Aycardi MD1, Marcelo Bigal MD1, PhD, Paul Yeung MD1, MPH, Tricia Blankenbiller1, Melissa Grozinski-Wolff1, Ronghua Yang PhD1, Yuju Ma MS, Stephen Silberstein MD2, Peter J. Goadsby MD PhD3, and David Dodick MD4
1Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA; 2Jefferson Headache Center, Philadelphia, Pennsylvania, 19107, USA; 3Mayo Clinic, Scottsdale, Arizona, 85259, USA; 4NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, UK
Correspondence: Ernesto Aycardi
P116 Efficacy and Safety of 2 Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine
Ernesto Aycardi MD1, Marcelo Bigal MD1, PhD, Paul Yeung MD1, MPH, Tricia Blankenbiller1, Melissa Grozinski-Wolff1, Ronghua Yang PhD1, Yuju Ma MS, Stephen Silberstein MD2, Peter J. Goadsby MD PhD3, and David Dodick MD4
1Teva Pharmaceutical Industries, Frazer, Pennsylvania, 19355, USA; 2Jefferson Headache Center, Philadelphia, Pennsylvania, 19107, USA; 3Mayo Clinic, Scottsdale, Arizona, 85259, USA; 4NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, UK
Correspondence: Ernesto Aycardi
P117 Influence of pre-treatment pain intensity on usage pattern, effectiveness and safety of Aspirin®: Subgroup analysis of six pharmacy-based surveys with 6.985 patients with headache or migraine
Marius Dörr, Uwe Gessner, Christoph Theurer
Scientific Affairs Consumer Health, Bayer Vital GmbH, Leverkusen, Germany
Correspondence: Marius Dörr
P118 Botox is a safe and efficient treatment for cervicogenic headache
Monica Drottning 1, Sebastian Drottning2, Steffen Grønneberg3, Per Skjelbred1
1Department of maxillary surgery, Oslo University Hospital, Ullevaal, University of Oslo, Oslo, 0407, Norway; 2Division of Paediatric and Adolecent Medicine, Oslo University Hospital, Rikshospitalet, Oslo 0424, Norway; 3BI Norwegian Business School, N-0442 Oslo, Norway
Correspondence: Monica Drottning
P119 Impaired cholinergic transmission during the migraine cycle: a short-latency afferent inhibition (SAI) study
Davide Di Lenola1, Gianluca Coppola2, Francesca Cortese2, Cherubino Di Lorenzo3, Francesco Pierelli3
1Sapienza University of Rome Polo Pontino, Department of medico-surgical sciences and biotechnologies, Latina, Italy; 2G.B. Bietti Foundation IRCCS, Department of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 3Don Gnocchi foundation-IRCCS, Milan, Italy
Correspondence: Davide Di Lenola
P120 BRAIN HERNIATION INTO TRANSVERSAL VENOUS SINUS: Case Report
Miodrag Vrcakovski1,2; Metodi Cepreganov1,2; Marija Milanovska1,2
1Polyclinic NEUROMEDICA, Skopje, Macedonia (FYR Macedonia); 2Department of neurology and neuroradiology
P121 Comparative study of mechanosensitivity and neural mobility in subjects with episodic tension type headache versus control group
Leandro H Caamaño1,2, Ricardo Ortega3, Fernando Galán3
1International PhD School. Health Sciences, King Juan Carlos University, Madrid, 28922, Spain; 2Department of Physical Therapy, Gimbernat University School, Cantabria, 39316, Spain; 3Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, King Juan Carlos University, Madrid, 28922, Spain
Correspondence: Leandro H Caamaño (leandro.caamano@eug.es)
P122 Physiotherapy and basic headache research: Why using a pre-post design?
Sarah Mingels1,2, Marita Granitzer1
1REVAL Rehabilitation Research Centre, Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, 3590-Belgium; 2Musculoskeletal Research Unit, Department of Rehabilitation Sciences, Faculty of Kinesiology and Rehabilitation Sciences, Leuven University, 3000-Belgium
Correspondence: Sarah Mingels (sarah.mingels@uhasselt.be)
P123 Real-life use of onabotulinumtoxinA for the symptomatic treatment of chronic migraine: The Repose Study
Fayyaz Ahmed,1 Charly Gaul,2 Paolo Martelletti,3 Juan Carlos Garcia-Monco,4 Aubrey Manack Adams5
1Spire Hesslewood Clinic, Hull York Medical School, Brough, Hull, UK; 2Department of Headache and Facial Pain, Migraine and Headache Clinic, Koenigstein, Germany; 3Department of Clinical and Molecular Medicine, Sapienza University, Regional Referral Headache Centre, Rome, Italy; 4Service of Neurology, Hospital de Galdakao, Vizcaya, Spain; 5Global Medical Affairs, Allergan plc, Irvine, CA, USA
Correspondence: Fayyaz Ahmed (fayyaz.ahmed@hey.nhs.uk)
P124 Simulated airplane headache: a proxy towards identification of underlying mechanisms
Torben Petersen
P125 Chronic Headache Education and Self-management Study (CHESS) – a feasibility study
Kimberley White, Rachel Potter, Martin Underwood, On behalf of the CHESS team
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry. CV4 7AL, UK
Correspondence: Kimberley White (Kimberley.white@warwick.ac.uk)
P126 Management of headache in the acute medical unit: what can we improve and how?
Hannah C. Johnson1, Sophie L. Main1, Oliver A.T. Seglah1, Johann R. Selvarajah1,2
1School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, G12 8QQ, United Kingdom; 2Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, G51 4TF, United Kingdom
Correspondence: Oliver A.T. Seglah (oliverseglah@doctors.org.uk)
P127 The relationship between sleep disorders and migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study
Dawn C. Buse, 1 Jeanetta C. Rains, 2 Jelena M. Pavlovic, 1 Kristina M. Fanning, 3 Michael L. Reed, 3 Aubrey Manack Adams, 4 Richard B. Lipton 1
1 Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; 2 Elliot Hospital, Center for Sleep Evaluation, Manchester, NH, USA; 3 Vedanta Research, Chapel Hill, NC, USA; 4 Global Medical Affairs, Allergan plc, Irvine, CA, USA
Correspondence:Dawn C. Buse (dbuse@montefiore.org)
EM (n=11,699) | CM (n=1,111) | Total (N=12,810) | Chi-square |
P-value | |
---|---|---|---|---|---|
“Have you ever had sleep apnea?”
a
| |||||
No | 10,563 (90.3) | 954 (85.9) | 11,517 (89.9) | 21.9 | <0.001 |
Yes | 1,136 (9.7) | 157 (14.1) | 1,293 (10.1) | ||
Total | 11,699 (100.0) | 1,111 (100.0) | 12,810 (100.0) | ||
Among those reporting ever having sleep apnea, “Has this condition been diagnosed or confirmed by a healthcare professional?”
| |||||
No | 287 (25.3) | 27 (17.2) | 314 (24.3) | 4.9 | <0.05 |
Yes | 849 (74.7) | 130 (82.8) | 979 (75.7) | ||
Total | 1,136 (100.0) | 157 (100.0) | 1,293 (100.0) |
P128 Are there many placebos? “Sugar pills” and stimulation of complex emotional networks -Pilot data
Maria Nicolodi, Vanessa Sandoval, Anna Torrini, Martina Irasa
Foundation Prevention and Therapy of Primary Pain and Headache, Florence, Italy
Correspondence:Maria Nicolodi
P129 Occipital Headaches in Children – Are They a Red Flag?
Jacob Genizi 1,2,3 Amal Khourieh-Matar 2 Nurit Assaf 2,3 Irena Chistyakov 2 Isaac Srugo 2,3
1 Pediatric Neurology Unit, Bnai Zion Medical Center, Haifa, Israel; 2 Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel; 3 Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel
P130
P131 Effect of non-invasive Vagus Nerve Stimulation on Laser Evoked Potentials in Migraine
Eleonora Vecchio 1 , Katia Ricci 1 , Anna Montemurro 1 , Lia Spitzer 2 , Eric J. Liebler 2 , Marina de Tommaso 1
1 Applied Neurophysiology and Pain Unit, SMBNOS Department, Bari Aldo Moro University (Italy); 2 electroCore LLC, Scientific, Medical and Clinical Affairs, Basking Ridge, NJ 07920 USA
Correspondence:Eleonora Vecchio (eleonora.vecchio@uniba.it)
P132 Adherence to prophylaxis pharmacotherapies in patients with Medication Overuse Headache: a 10-year experience in a single-centre
Lanfranco Pellesi 1 , Simona Guerzoni 1 , Carlo Baraldi 1 , Maria M Cainazzo 1 , Luigi A Pini 1
1 Medical Toxicology and Headache Centre, University of Modena and Reggio Emilia, Modena, 41124, Italy
Correspondence:Lanfranco Pellesi (lanfranco.pellesi@gmail.com)
P133 Cerebral hemodynamics in the anterior and posterior circulation in patients with migraine with aura, stroke and controls
Altamura Claudia 1 , Paolucci Matteo 2 , Brunelli Nicoletta 2 , Cascio Rizzo Angelo 2 , Vernieri Fabrizio 1
1 Neurology Department, Headache and Neurosonology Unit, Campus Bio-Medico University of Rome; 2 Neurology Department, Campus Bio-Medico University of Rome
P134 Development of a claims-based algorithm for use in patients with migraine to identify potentially undiagnosed chronic migraine patients
Jelena M. Pavlovic 1 , Justin S. Yu 2 , Stephen D. Silberstein 3 , Michael L. Reed 4 , Steve H. Kawahara 5 , Robert P. Cowan 6 , Firas Dabbous 7 , Karen L. Campbell 2 , Anand S. Shewale 2 , Riya Pulicharam 5 , Jonathan W. Kowalski 2 , Hema N. Viswanathan 2 , Richard B. Lipton 1
1 Montefiore Medical Center, Bronx, NY, USA; 2 Health Economics and Outcomes Research, Allergan plc, Irvine, CA, 92612, USA; 3 Jefferson Medical Center, Philadelphia, PA, USA; 4 Vedanta Research, Chapel Hill, NC, USA; 5 DaVita Medical Group, El Segundo, CA, USA; 6 Stanford University School of Medicine, Stanford, CA, USA; 7 Independent Consultant, La Jolla, CA, USA
Correspondence:Justin S. Yu (Justin.Yu@Allergan.com)
P135 Antibodies in patients with chronic tension type headache and chronic migraine: is there a link between headache and autoimmunity?
Anastasia Prishchepa, Alexey Danilov
Department of neurology, I.M. Sechenov First Moscow State Medical University, Moscow, 119435, Russia
Correspondence:Anastasia Prishchepa (prischepa@intermeda.ru)
Identified changes of autoantibodies level against: | Total number of patients | Chronic migraine | Chronic tension type headache |
---|---|---|---|
NF-200 | 11 (25%) | 9* (39,1%) | 2 (9,5%) |
Protein of intercurrent as trocytes’ filaments GFAP | 7 (15,9%) | 3 (13%) | 4 (19%) |
Protein S100 | 13 (29,5%) | 7 (30,4%) | 6 (28,6%) |
Myelin basic protein MBP | 11 (25%) | 5 (21,7%) | 6 (28,6%) |
Voltage-dependent Ca channels | 11 (25%) | 9* (39,1%) | 2 (9,5%) |
Acetylcholine Receptor | 7 (15,9%) | 4 (17,4%) | 3 (14,3%) |
Glutamat Receptor | 15 (34,1%) | 5 (21,7%) | 10 (47,6%) |
GABA-Receptor | 17 (38,7%) | 6 (26,1%) | 11 (52,4%) |
Dopamin Receptor | 12 (27,3%) | 4 (17,4%) | 8 (38,1%) |
5HT-Receptor | 8 (18,2%) | 2 (8,7%) | 6 (28,6%) |
μ-Opioid Receptor | 10 (22,7%) | 2 (8,7%) | 8* (38,1%) |
β -Endorphin | 21 (50%) | 3 (13%) | 18** (85,7%) |
dsDNA | 15 (34,1%) | 14** (60,9%) | 1 (4,8%) |
Beta2-glycoprotein I | 13 (29,5%) | 13** (56,5%) | 0 |
Fc-fragment of immunoglobulins IgG | 11 (25%) | 7 (30,4%) | 4 (19%) |
Collagen | 10 (22,7%) | 7 (30,4%) | 3 (14,3%) |
Membrane antigen of myocardial cells | 12 (27,3%) | 3 (13%) | 9* (42,9%) |
b-adrenoreceptors | 18 (40,9%) | 12 (52,2%) | 6 (28,6%) |
Membrane antigen of platelets | 8 (18,2%) | 5 (21,7%) | 3 (14,3%) |
Anionic antigen of endothelium | 6 (13,6%) | 3 (13%) | 3 (14,3%) |
Membrane antigen of kidney | 11 (25%) | 9* (39,1%) | 2 (9,5%) |
Membrane antigen of lungs | 14 (31,8%) | 5 (22,7%) | 9 (42,9%) |
Membrane antigen of stomach | 11 (25%) | 8 (34,8%) | 3 (14,3%) |
Membrane antigen of small intestine | 13 (29,5%) | 4 (17,4%) | 9 (42,9%) |
Membrane antigen of large intestine | 18 (40,9%) | 4 (17,4%) | 16** (76,2%) |
Cytoplasmic antigen of liver | 5 (11,3%) | 3 (13%) | 2 (9,5%) |
Antigen of liver mitochondria | 8 (18,2%) | 2 (8,7%) | 6 (28,6%) |
Insulin | 19 (43,2%) | 11 (47,8%) | 8 (38,1%) |
Insulin receptors | 5 (11,3%) | 5* (21,7%) | 0 |
Thyroglobulin | 13 (29,5%) | 13** (56,5%) | 0 |
Receptor of TSH | 9 (20,5%) | 8* (34,8%) | 1 (4,8%) |
Membrane antigen of adrenal gland AdrM-D/C | 15 (34,1%) | 13** (56,5%) | 2 (9,5%) |
Membranous antigen of pros tate/spermatozoids | 8 (18,2%) | 4 (17,4%) | 4 (19%) |
P136 Non-invasive vagus nerve stimulation for acute treatment of episodic and chronic cluster headache: pooled analysis of data from 2 randomised, double-blind, sham-controlled clinical trials
Ilse F de Coo 1 , Juana Marin 2 , Stephen D Silberstein 3 , Deborah I Friedman 4 , Charly Gaul 5 , Alok Tyagi 6 , Eric Liebler 7 , Stewart J Tepper 8 , Michel D Ferrari 1 , Peter J Goadsby 2
1 Leiden University Medical Centre, Leiden, the Netherlands; 2 NIHR-Wellcome Trust CRF, King’s College Hospital, London, UK; 3 Jefferson Headache Center, Philadelphia, PA, USA ; 4 UT Southwestern Headache and Facial Pain Program, Dallas, TX, USA; 5 Migraine and Headache Clinic, Königstein, Germany; 6 The Southern General Hospital, Glasgow, UK; 7 electroCore, LLC, Basking Ridge, New Jersey, USA; 8 Geisel School of Medicine at Dartmouth, Hanover, NH, USA
Correspondence:Michel D Ferrari (M.D.Ferrari@lumc.nl)
P137 The profile of super-responders to onabotulinumtoxin A for chronic migraine: data from an observational study
Luana Evangelista 1 , Simona Guezoni 2 , Lanfranco Pellesi 2 , Francesca Pistoia 1 , Cindy Tiseo 1 , Luigi Alberto Pini 2 , Simona Sacco 1
1 Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L’Aquila, L’Aquila, Italy; 2 Headache and Drug Abuse Research Centre, Policlinico Hospital, University of Modena e Reggio Emilia, Modena, Italy
Correspondence:Simona Sacco (simona.sacco@univaq.it)
Super responders (n=27) | Non-responders (n=40) | P value | OR | |
---|---|---|---|---|
Age, median (IQR) | 54.4 (53-56) | 47 (45-54) | 0.638 | - |
Female sex, n (%) | 21 (77.6) | 37 (92.5) | 0.083 | 0.52 (0.20-1.34) |
Migraine years, median (IQR) | 44.5 (38-51) | 27 (23-45) | 0.144 | - |
Chronic migraine duration (months), median (IQR) | 8.5 (5-12) | 120 (24-120) | 0.056 | - |
Monthly headache days, median (IQR) | 30 (23.5-30) | 30 (25-30) | 0.146 | - |
Medication overuse, n (%) | 17 (63.0) | 33 (84.6) | 0.044 | 1.84 (1.07-3.16) |
Allodynia, n (%) | 10 (41.7) | 16 (47.1) | 0.684 | 0.91 (0.59-1.41) |
Unilateral headache, n (%) | 12 (44.4) | 16 (41.0) | 0.782 | 1.06 (0.70-1.60) |
Throbbing headache, n (%) | 18 (66.7) | 21 (53.8) | 0.298 | 1.24 (0.84-1.84) |
Baseline MIDAS score, median (IQR) | 106.5 (81-132) | 92 (41-203) | 0.923 | - |
Baseline HIT-6 score, median (IQR) | 77 (72-82) | 71 (64-72) | 0.154 | - |
Baseline VAS score, median (IQR) | 9.5 (9-10) | 10 (8-10) | 0.301 | - |
Baseline BDI score, median (IQR) | 33.5 (30-37) | 9 (6-21) | 0.051 | - |
Baseline GAD-7 score, median (IQR) | 19 (14-24) | 4 (3-12) | 0.051 | - |
Super responders (n=27) | Others (n=82) | P value | OR | |
---|---|---|---|---|
Age, median (IQR) | 54.4 (53-56) | 51 (45-54) | 0.774 | - |
Female sex, n (%) | 21 (77.6) | 71 (86.6) | 0.274 | 0.83 (0.58-1.21) |
Migraine years, median (IQR) | 44.5 (38-51) | 30 (23-45) | 0.204 | - |
Chronic migraine duration (months), median (IQR) | 8.5 (5-12) | 60 (24-120) | 0.061 | - |
Monthly headache days, median (IQR) | 30 (23.5-30) | 30 (25-30) | 0.093 | - |
Medication overuse, n (%) | 17 (63.0) | 68 (87.2) | 0.010 | 0.63 (0.40-0.98) |
Allodynia, n (%) | 10 (41.7) | 24 (34.8) | 0.546 | 0.81 (0.40-1.61) |
Unilateral headache, n (%) | 12 (44.4) | 36 (45.4) | 0.960 | 1.02 (0.53-1.96) |
Throbbing headache, n (%) | 18 (66.7) | 52 (65.0) | 0.875 | 0.95 (0.47-1.89) |
Baseline MIDAS score, median (IQR) | 106.5 (81-132) | 92 (41-180) | 0.824 | - |
Baseline HIT-6 score, median (IQR) | 77 (72-82) | 66 (61-72) | 0.132 | - |
Baseline VAS score, median (IQR) | 9.5 (9-10) | 9 (8-10) | 0.134 | - |
Baseline BDI score, median (IQR) | 33.5 (30-37) | 9 (8-22) | 0.059 | - |
Baseline GAD-7 score, median (IQR) | 19 (14-24) | 5 (3-14) | 0.088 | - |
P138 Personalized Medicine, Drug-Drug Interactions (DDIs) and Adverse Events (AEs) in Migraine Treatment. Rational, Strategy and Targets
A. Negro 1,2 , L. Lionetto 3 , C. Cicione 3 , A. Koverech 1,2 , C.M. De Marco 2 , G. Gentile 4,5 , M. Borro 4,5 , M. Simmaco 4,5 , P. Martelletti 1,2
1 Department of Clinical and Molecular Medicine, Sapienza University of Rome, Italy; 2 Regional Referral Headache Center, Sant’Andrea Hospital, Rome, Italy; 3 Advanced Molecular Diagnostics Unit, IDI Istituto Dermopatico dell'Immacolata - IRCSS, Rome, Italy; 4 Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Italy; 5 Advanced Molecular Diagnostics Unit, Sant'Andrea Hospital, Sapienza University of Rome, Italy
Correspondence:A. Negro (andrea.negro@uniroma1.it)
P139 Withdrawn
P140 Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: findings from the randomised, double-blind, sham-controlled ACT2 study
Peter J Goadsby 1 , Ilse F de Coo 2 , Nicholas Silver 3 , Alok Tyagi 4 , Fayyaz Ahmed 5 , Charly Gaul 6 , Rigmor H Jensen 7 , Hans-Christoph Diener 8 , Andreas Straube 9 , Eric Liebler 10 , Juana Marin 1 , Michel D Ferrari 2
1 NIHR-Wellcome Trust CRF, King’s College Hospital, London, UK; 2 Leiden University Medical Centre, Leiden, the Netherlands; 3 Walton Centre for Neurology and Neurosurgery, Liverpool, UK; 4 The Southern General Hospital, Glasgow, UK; 5 Hull Royal Infirmary, Hull, UK; 6 Migraine and Headache Clinic, Königstein, Germany; 7 Glostrup Hospital, Glostrup, Denmark; 8 West German Headache Centre, Essen, Germany; 9 University of Munich, Munich, Germany; 10 electroCore, LLC, Basking Ridge, New Jersey, USA
Correspondence:Peter J Goadsby (peter.goadsby@kcl.ac.uk)
P141 IntegratingLearning to Cope with Triggersinto a cognitive behavioural therapy program for primary headaches: Can it enhance efficacy?
Paul R Martin 1 , John Reece 2 , Sharon Mackenzie 1 , Siavash Bandarian-Balooch 1 , Arissa Brunelli 1 , Peter J Goadsby 3
1 School of Applied Psychology and Menzies Health Institute Queensland, Griffith University, Mount Gravatt, Queensland, Australia, 4122; 2 School of Psychological Science, Australian College of Applied Psychology, Melbourne, Victoria, Australia, 3000; 3 King’s College London, Institute of Psychiatry, United Kingdom
Correspondence:Paul R Martin (paul.martin@griffith.edu.au)
P142 Sleep Disturbance in Children with primary headache
Ayse Kartal (kartalays@gmail.com)
Department of Child Neurology, Selçuk University Faculty of Medicine, Konya
Migraine n (%) | TTH n (%) | Total n (%) | P value | |
---|---|---|---|---|
Age years | 13.2±2.6 | 13.7±2.6 | 0.206a
| |
Gender | ||||
Female | 85 (74.6) | 49(64.5) | 134 (70.5) | 0.183b
|
Male | 29 (25.4) | 27 (35.5) | 56 (29.5) | |
Localisation | ||||
Unilateral | 46 (40.4) | 40 (52.6) | 86 (45.3) | |
bilaterally | 68 (59.6) | 36 (47.4) | 104 (54.7) | |
Nausea | 109 (95.6) | 5 (6.6) | 114 (60 | <0.001c
|
Vomiting | 42 (36.8) | 2 (2.6) | 44 (23.2) | <0.001c
|
photophobia | 108 (94.7) | 40 (52.6) | 148 (77.9) | <0.001c
|
phonophobia | 110 (96.5) | 53 (69.7) | 163 (85.8) | <0.001c
|
osmophobia | 60 (52.6) | 17 (22.4) | 77 (40.5) | <0.001c
|
allodynia | 77 (67.5) | 25 (32.9) | 102 (53.7 | <0.001c
|
Headache frequency mean (SD) | 8.6±7.8 | 6.3±5.8 | ||
1 per month | 11 (9.6) | 13 (17.1) | 24 (12.6) | 0.006d
|
1 per week | 19(16.7) | 22 (28.9) | 41 (21.6) | |
2-3 per week | 49 (43.0) | 27 (35.5) | 76 (40) | |
>3 per week | 26 (22.8) | 10 (13.2) | 36 (18.9) | |
Daily | 9 (7.9) | 4 (5.3) | 13. (6.8) | |
Headache duration (h) mean (SD) | 9.2±8.8 | 2.6±1.8 | ||
<1 h | 5 (4.4) | 39 (51.4) | 44 (25.2) | 0.006d
|
1-6 | 47 (41.2) | 28 (36.8) | 75 (39.5) | |
6-12 | 60 (52.6) | 8 (10.5) | 68 (25.8) | |
>12 | 2 (1.8) | 1 (1.3) | 3 (1.6) | |
Pain severity, 0-10 scale, mean (SD) | 6.2±5.8 | 3.4±2.1 | ||
Grade 1 | 2 (1.8) | 16 (21.1) | 18 | 0.001d
|
Grade II-III | 27 (23.6) | 56 (73.6) | 83 ( | |
Grade IV | 85 (74.6) | 4 (5.3) | 89 |
Migraine (n=114) | TTH (n=76) | p-value | |
---|---|---|---|
DIMS | |||
mean±SD
| 15.5±4.8 | 13.3±3.9 | <0.001a
|
T score >70, n (%)
| 46 (40.4) | 18 (23.7) | 0.017b
|
SBD | |||
mean±SD
| 3.9±1.5 | 3.9±1.7 | >0.999a
|
T score >70, n (%)
| 9 (7.9) | 6 (7.9) | 1.000c
|
DA | |||
mean±SD
| 4.7±1.8 | 4.0±1.4 | <0.001a
|
T score >70, n (%)
| 30 (26.3) | 10 (13.2) | 0.046c
|
SWTD | |||
mean±SD
| 11.8±4.1 | 9.7±3.7 | <0.001a
|
T score >70, n (%)
| 39 (34.2) | 10 (13.2) | 0.002c
|
DOES | |||
mean±SD
| 13.1±4.8 | 10.0±4.1 | <0.001a
|
T score >70, n (%)
| 59 (51.8) | 19 (25.0) | <0.001b
|
SHY | |||
mean±SD
| 3.6±2.4 | 2.7±1.3 | <0.001a
|
T score >70, n (%)
| 17 (14.9) | 2 (2.6) | 0.012c
|
TOTAL | |||
mean±SD
| 52.6±11.9 | 43.5±9.4 | <0.001a
|
T score >70, n (%)
| 59 (51.8) | 17 (22.4) | <0.001b
|
P143 Validity of the ICHD-IIIb criteria in the diagnosis of migraine with aura in children and adolescents
Martina Balestri, Alessandro Capuano, Laura Papetti, Samuela Tarantino, Barbara Battan, Federico Vigevano, M. Valeriani
P144 Headache and personality assessed with the NEO-Five-Factor-Inventory
Louise S Mose 1, 2 , Susanne S Pedersen 3, 4 , Rigmor H Jensen 5 , Bibi V Gram 2
1 Department of Neurology, Hospital South West Jutland, Esbjerg, Denmark; 2 Department of Regional Health Research, University of Southern Denmark/ Hospital South West Jutland, Esbjerg Denmark; 3 Department of Psychology, University of Southern Denmark, Odense, Denmark; 4 Department of Cardiology, Odense University Hospital, Odense, Denmark; 5 Danish Headache Centre, Department of Neurology, Rigshospitalet-Glostrup, University of Copenhagen, Denmark
Correspondence:Louise S Mose (Louise.schlosser@rsyd.dk)
P145 Botulinum toxin A in the Treatment of Chronic Cluster Headache – a pilot study
Christian Lampl, Mirjam Rudolph, Elisabeth Bräutigam
Headache Medical Center, Seilerstätte, Ordensklinikum Linz Barmherzige Schwestern, Austria
P146 Characteristics of 5000 patients in a headache clinic registry
David García-Azorín, Marina Ruiz, María I Pedraza, Laura Blanco, Raquel Moreno, Angel L Guerrero
Headache Unit. Neurology Department. Hospital Clínico Universitario de Valladolid
P147 Life traumas and stressful events in Chronic Migraine and Medication Overuse Headache: What is the relation with the outcome of a detoxification therapy?
Bottiroli Sara 1 , Viana Michele 1 , Sances Grazia 1 , De Icco Roberto 1 , Vito Bitetto 1, 2 , Guaschino Elena 1 , Ghiotto Natascia 1 , Pazzi Stefania 1 , Giuseppe Nappi 1 & Tassorelli Cristina 1,2
1 Headache Science Centre, C. Mondino National Neurological Institute, 27100 Pavia, Italy; 2 Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy
Correspondence:Bottiroli Sara (sara.bottiroli@mondino.it)
P148 Comorbidities in chronic and episodic migraine
Mansoureh Togha 1 , Zahra Yari 1,2 , Reza Rahmanzadeh 1 , Soodeh Razeghi Jahromi 2 , Zeinab Ghorbani 1
1 Headache department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic Of; 2 School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic Of
Correspondence:Mansoureh Togha
P149 Features of chronic primary headaches (CPH) in children and adolescents referred to two third level headache centers
Massimiliano Valeriani 1 , Laura Papetti 1 , Beatrice Bartoli 2 , Cristiano Termine 2 , Irene Salfa 1 , Barbara Battan 1 , Federico Vigevano 1
1 Neuroscience, Bambino Gesù Children Hospital, Rome, Italy; 2 Neuropsychiatric, Insubria University, Varese, Italy
Correspondence:Massimiliano Valeriani (m.valeriani@tiscali.it)
P150 Postural control impairment in patients with migraine with and without aura and chronic migraine
Gabriela Ferreira Carvalho 1 ; Lidiane L Florêncio 1 , Carina Ferreira Pinheiro 1 , Fabiola Dach 2 , Débora Bevilaqua-Grossi 1
1 Department of Biomechanics, Medicine and Locomotor Apparatus Rehabilitation –Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto-SP, Brazil; 2 Department of Neurosciences and Behavioral Sciences – Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto-SP, Brazil
Correspondence:Gabriela Ferreira Carvalho
CG | MoA | MA | CM | |
---|---|---|---|---|
FirmOE | 1.20 (1.05 to 1.34) | 1.52 (1.26 to 1.77) | 2.47 (1.97 to 2.97) | 3.23 (2.21 to 4.24) |
FirmCE | 1.53 (1.31 to 1.74)*
| 2.10 (1.61 to 2.59) | 4.49 (1.97 to 2.97) | 4.53 (2.21 to 4.24) |
FoamOE | 5.09 (4.63 to 5.56)*
| 5.58 (5.03 to 6.14)**
| 8.75 (7.31 to 10.18) | 8.82 (7.66 to 9.97) |
FoamCE | 14.82 (13.72 to 15.92)*
| 17.27 (15.39 to 19.14)**
| 21.87 (19.09 to 24.66) | 22.44 (19.92 to 24.95) |
P151 Perivascular neurotransmitters: Role in primary headaches
Simona D Frederiksen 1 , Kristian A Haanes 1 , Karin Warfvinge 1,2 , Lars Edvinsson 1,2
1 Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet Glostrup, Glostrup, Denmark; 2 Department of Clinical Sciences, Lund University, Lund, Sweden
Correspondence:Simona D Frederiksen (simona.denise.frederiksen@regionh.dk)
P152Headache attributed to aeroplane travelandAereoplane headaches sine aereoplane travel: Headache attributed to imbalance between intrasinusal and external air pressure
Federico Mainardi 1 , Ferdinando Maggioni 2 , Giorgio Zanchin 2
1 Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice, Italy; 2 Headache Centre, Department of Neurosciences, Padua University, Padua, Italy
Correspondence:Federico Mainardi (fmainardi@iol.it)
P153 Thunderclap headache caused by spontaneous pneumocephalus associated with intracranial hypotension
Angela Cervellino 1 , Valeria Coppola 2 , Antonietta Romaniello 1 , Giovanni Gonnella 1 , Nicola Paciello 1, Enrico Ferrante 1
1 Neurology and 2 Neuroradiology Department, AOR San Carlo, Potenza, Italy
Correspondence:Enrico Ferrante (enricoferrante@libero.it)
P154 Women with migraine present hyperactivity of neck extensors muscles during maximal and submaximal tasks
Lidiane L. Florencio1, Gabriela F. Carvalho1, Fabiola Dach2, Anamaria Siriani de Oliveira1, César Fernández-de-las-Peñas3, Débora. Bevilaqua-Grossi1
1Department of Biomechanics, Medicine and Locomotor Apparatus Rehabilitation –Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto-SP, Brazil; 2Department of Neurosciences and Behavioral Sciences – Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto-SP, Brazil; 3Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, Alcorcón, Spain
Correspondence: Lidiane L. Florencio
P155 The role of sexual dysfunction and attachment style in migraine related quality of life
Maria Pia Prudenzano1, Maria Fara De Caro1, Maria Colucci1, Jolanda Losole1, Simona Lamberti1, Maria Elena Roca1, Domenico Laera1, Alessandro Taurino2, Maria Trojano1
1Department of Basic Medical Sciences, Neuroscience and Sense Organs University of Bari; 2Department of Education, Psychology, Communication University of Bari
Correspondence: Maria Pia Prudenzano (centrocefalee.neurologia@uniba.it)
P156 Migraine: a possible risk factor for the development of hypothyroidism in women
Carlo Lisotto 1 , Federico Mainardi 2 , Ferdinando Maggioni 1 , Giorgio Zanchin 1
1 Headache Centre, Department of Neurosciences, University of Padua, Padua, Italy; 2 Headache Centre, Department of Neurology, Hospital of Venice, Venice, Italy
Correspondence:Carlo Lisotto
P157 Contribution of hormonal contraceptives to the risk of ischemic stroke in women with migraine: a meta-analysis of current data
Simona Sacco1, Gabriele S Merki-Feld2, Karen Lehrmann Ægidius3, Johannes Bitzer4, Marianne Canonico5, Tobias Kurth6, Christian Lampl7, Øjvind Lidegaard8, E Anne MacGregor9, Antoinette MaassenVanDenBrink10, Dimos-Dimitrios Mitsikostas11, Rossella Elena Nappi12, George Ntaios13, Per Morten Sandset14, Paolo Martelletti15,16
1Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, Italy; 2Clinic for Reproductive Endocrinology, Department of Gynecology, University Hospital, Zürich, Switzerland; 3Department of Neurology, Bispebjerg Hospital and University of Copenhagen, Denmark; 4Department of Obstetrics and Gynecology, University Hospital of Basel, Basel, Switzerland; 5Université Paris-Saclay, University Paris-Sud, UVSQ, CESP, Inserm UMRS1018, France; 6Institute of Public Health, Charité – Universitätsmedizin Berlin, Germany; 7Headache Medical Center Seilerstaette Linz, Austria; Department of Geriatric Medicine Ordensklinikum Linz, Austria; 8Department of Obstetrics & Gynaecology, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark; 9Centre for Neuroscience & Trauma, BICMS, Barts and the London School of Medicine and Dentistry, London, UK; Barts Sexual Health Centre, St Bartholomew's Hospital, London, UK; 10Erasmus Medical Center Rotterdam, Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Rotterdam, The Netherlands; 11Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece; 12Research Centre for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS S. Matteo Foundation, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Italy; University Consortium for Adaptive Disorders and Head Pain (UCADH), University of Pavia, Italy; 13Department of Medicine, University of Thessaly, Larissa, Greece; 14Department of Haematology, Oslo University Hospital and University of Oslo, Norway; 15Department of Clinical and Molecular Medicine, Sapienza University of Rome, Italy; 16Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy
Correspondence: Simona Sacco (simona.sacco@univaq.it)
P158 Medical (respiratory, sleep, cardiovascular and gastrointestinal) comorbidities of migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study
Richard B. Lipton, MD, 1 Vincent T. Martin, MD, 2 Michael L. Reed, PhD, 3 Kristina M. Fanning, PhD, 3 Aubrey Manack Adams, PhD, 4 Dawn C. Buse, PhD 5
1 The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; 2 University of Cincinnati Headache and Facial Pain Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA; 3 Vedanta Research, Chapel Hill, NC, USA; 4 Global Medical Affairs, Allergan plc, Irvine, CA, USA; 5 Montefiore Headache Center, Bronx, NY, USA
Correspondence:Richard B. Lipton (Richard.Lipton@einstein.yu.edu)
P159 The Effects of probiotic supplementation on chronic migraine(CM) headache: a randomized placebo-controlled double-blind study
Maryam Seyfi-shahpar 1 , Fahimeh Martami 1 , Mansoureh Togha 2 , Zeinab Ghorbani 2,3 , Soodeh Razeghi Jahromi 1,2 , Hossein Ansari 4
1 Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2 Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; 3 School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran; 4 Department of Neurology, University of California San Diego (UCSD), La Jolla, CA, USA
Correspondence:Soodeh Razeghi Jahromi
P160 Capsaicin versus zingember to shed some light on the therapeutic role of CGRP exhaustion versus counter-irritation - Preliminary data
Maria Nicolodi, Vanessa Sandoval, Silvia Mega
Foundation prevention and Therapy Primary Pain, Florence, Italy
Correspondence:Maria Nicolodi
P161 Pediatric Mixed Headache - The relationship between Migraine, Tension-Type Headache and Learning disabilities - in a Clinic-based Sample
Jacob Genizi
Pediatric Neurology Unit, Bnai Zion Medical Center, Israel
SISC POSTER PRESENTATIONS
P162 Clinical features of headache attributed to Idiopathic intracranial hypertension: results from a prospective study
Domenico Cassano 1 , Vincenzo Pizza 2 , Vincenzo Busillo 3
1 Headache Centre, Distretto N. 60, Via S. Giordano, 7 – 84014 Nocera Inf. (SA); 2 Headache Centre, S. Luca Hospital, Vallo della Lucania, ASL Salerno; 3 Headache Centre, Maria SS. Addolorata Hospital, Eboli, ASL Salerno
Correspondence:Domenico Cassano (081-5157425, info@domenicocassano.it)
P163 Safranal, a major constituent ofCrocus sativus, attenuates pain-like responses and neurogenic inflammation via TRPA1 desensitization
Simone Li Puma, Ilaria M. Marone, Francesco De Logu, Elisabetta Coppi, Romina Nassini, Silvia Benemei, Pierangelo Geppetti, Serena Materazzi
Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
Correspondence:Simone Li Puma
P164 The use of Symptomatic Pharmacological Treatment is Associated with the Degree of Sensitization in Patients with Tension Type Headache
Matteo Castaldo 1 , Lars Arendt-Nielsen 1 , Maria Palacios-Ceña 1,2 , Kelun Wang 1 , Paola Torelli 3 , Paolo Pillastrini 4 , Antonella Catena 1 , Cesar Fernández-de-las-Peñas 1,2
1 Department of Health Science and Technology. Aalborg University, Aalborg, Denmark; 2 Departamento de Fisioterapia, Terapia Ocupacional, Rehabilitación y Medicina Física. Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain; 3 Department of Medicine and Surgery, Headache Center, University of Parma, Italy; 4 Department of Biomedical and Neurological Sciences, University of Bologna, Italy
Correspondence:Matteo Castaldo (matteo.castaldo@poliambulatoriofisiocenter.com)
P165 Recurrent painful ophthalmoplegic neuropathy (RPON), can cerebrospinal fluid (CSF) analysis aid the diagnosis, where neuroimaging is still blind? A case report
Ciro De Luca, Filippo Baldacci, Elisa Dini, Martina Cafalli, Sara Gori
Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
P166 Computed perfusion tomography in migrainous aura: a case series and review of literature
Paola Polverino 1 , Antonio Granato 1 , Mariana Ridolfi 1 , Maja Ukmar 2 , Paolo Manganotti 1
1 Department of Medical, Technological and Translational Sciences, Headache Centre, University of Trieste, Italy; 2 Department of Radiology, Cattinara Hospital, University of Trieste, Italy
Correspondence:Paola Polverino (polverinopaola@gmail.com)
Age | Sex | History of Migraine | Presenting symptoms in ED | Headache at the onset of symptoms | NIHSS | Time to PCT after symptoms onset | Thrombolysis | Symptoms duration | |
---|---|---|---|---|---|---|---|---|---|
1
| 22 | M | yes (without aura) | right hemiparesis and blurred vision in the right hemifield | yes | 8 | 60 minutes | no | 2 hours |
2
| 26 | F | yes (without aura) | blurred vision in the right hemifield | no | 2 | 60 minutes | no | 2 hours |
3
| 43 | M | yes (with aura) | left emipharesis | yes | 6 | 90 minutes | yes | 10 hours |
4
| 50 | F | yes (without aura) | left hemiparesis, dyrarthria and left facial palsy | no | 2 | 60 minutes | no | 2 hours |
5
| 81 | F | yes (with aura) | aphasia | no | 4 | 60 minutes | no | 2 hours |
6
| 91 | F | yes (with aura) | aphasia | no | 3 | 90 minutes | no | 10 hours |
P167 Prevalence and clinical characteristics of neuropsychiatric disorders in children with headache
Chiara Raviola, Antonia Versace, Barbara Lauria, Giulia Grasso, Ausilia Enea, Roberta Rossi, Emanuele Castagno, Antonio Francesco Urbino
A.O.U. Città della Salute e della Scienza di Torino, Regina Margherita Children’s Hospital, Department of Pediatric Emergency, Pediatric Headache Centre, Turin, Italy
Correspondence: Antonia Versace
P168 Prophylactic treatment with TanacethumPartenium, 5-Hydrossitriptophan (5-Http) and Magnesium (AURASTOP®) in children with episodic migraine without aura: an observational study
Antonia Versace, Barbara Lauria, Giulia Grasso, Chiara Raviola, Roberta Rossi, Ausilia Enea, Emanuele Castagno, Antonio Francesco Urbino
A.O.U. Città della Salute e della Scienza di Torino, Regina Margherita Children’s Hospital, Department of Pediatric Emergency, Pediatric Headache Centre, Turin, Italy
Correspondence:Antonia Versace
P169 An unusual case of SUNCT responding to Carbamazepine: possible overlap among TACs and Trigeminal Neuralgia
E. Dini, F. Baldacci, C.De Luca, M. Cafalli, S. Gori
Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56100, Pisa, Italy
Correspondence:E. Dini (dini.elisa87@gmail.com)
P170 Cerebral vasoreactivity in migraine patients affected by Ehlers-Danlos syndromes
Giada Giuliani 1 , Massimiliano Toscano 1 , Francesca Puledda 2 , Alessandro Viganò 1 , Marco Ruggiero 1 , Tommaso B Jannini 1 , Claudia Celletti 3 , Filippo Camerota 3 , Edoardo Vicenzini 1 , Vittorio Di Piero 1
1 Department of Neurology and Psychiatry, “Sapienza” University of Rome – Italy; 2 Basic and Clinical Neuroscience, King’s College of London – UK; 3 Physical Medicine and Rehabilitation Division, Umberto I Hospital, Rome, Italy
Correspondence:Giada Giuliani (giuliani.1378642@studenti.uniroma1.it)
EDS (mean ±SD) | Controlli (mean ±SD) | p-value | |
---|---|---|---|
MFV at rest | 73,42 ±16,21 | 60,54 ±11,73 | < 0,01 |
Pi | 0,76 ±0,15 | 0,9 ±0,15 | < 0,01 |
Ri | 0,54 ± 0,09 | 0,6 ±0,05 | 0,02 |
Bh MFV | 94,76 ±21,1 | 79,36 ±13,56 | < 0,01 |
BHI | 1,22 ±0,44 | 1,19 ±0,17 | 0,707 |
P171 How the therapeutic response to BoNT-A in CM-MO is increased through adjustments of treatment protocols and more accurate evaluation and management of patients
Valentina Rebecchi, Lucia Princiotta Cariddi, Megi Meneri, Angelo Maurizio Clerici, Marco Mauri
Department of Neurology and Stroke Unit – ASST-Sette Laghi - University of Insubria, Varese
P172 Pharmacologically- controlled withdrawal from medication overuse in chronic migraine does not improve the therapeutic response to long-term onabotulinumtoxin type-a prophylaxis
Valentina Rebecchi, Lucia Princiotta Cariddi, Angelo Maurizio Clerici, Federico Carimati, Marco Gallazzi, Marco Mauri
Headache Center –Neurology and Stroke Unit, Osp di Circolo, Varese, Università degli Studi dell’Insubria
P173 The antimigraine butterbur ingredient, isopetasin, desensitizes peptidergic nociceptorsviathe TRPA1 channel activationin vivo
De Logu F 1 , Benemei S 1 , Li Puma S 1 , Marone IM 1 , Coppi E 1 , Ugolini F 1 , Liedtke W 2 , Pollastro F 3 , Appendino G 3 , Geppetti P 1 , Materazzi S 1 and Nassini R 1
1 Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy; 2 Departments of Neurology, Anesthesiology and Neurobiology, Clinics for Headache, Head-Pain and Trigeminal Sensory Disorders, Duke University, Durham, NC 27710 USA; 3 Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy
Correspondence:Nassini R
P174 Nervus intermedius neuralgia: a case report with unusual MRI findings
Flora Govone, Annalisa Gai, Alessandro Vacca, Milena Zucca, Paola De Martino, Salvatore Gentile, Maria Teresa Giordana, Innocenzo Rainero, Elisa Rubino
Neurology I - Headache Center, Department of Neuroscience “Rita Levi Montalcini”, University of Torino, Italy
Correspondence:Flora Govone (floragovone@gmail.com)
P175 Impact of visceral pain on migraine symptoms in comorbid patients
Giannapia Affaitati 1 , Raffaele Costantini 2 , Domenico Lapenna 3 , Francesco Cipollone 4 , Maria Adele Giamberardino 1
1 Headache Center, Geriatrics Clinic, Department of Medicine and Science of Aging and Ce.S.I.-Met, Chieti University, Chieti, Italy; 2 Institute of Surgical Pathology, Chieti University, Chieti, Italy; 3 Department of Medicine and Science of Aging, Chieti University, Chieti, Italy; 4 Medical Clinic, Department of Medicine and Science of Aging, Chieti University, Chieti, Italy
Correspondence:Giannapia Affaitati (gp@unich.it)
P176 Disappearance in the spa area in cephalalgic patients in chronic polytherapy. “tabula rasa” project
E. Pucci 1 , S. Cristina2, N. Ghiotto2, F. Antonaci 1 , A. Costa 1 , Massimo Radaelli3
1 Headache Science Center - University Consortium for the Study of Adaptive Disorders and Headache (UCADH), Department of Brain and Behavioral Sciences, University of Pavia, IRCCS “C.Mondino” Pavia; 2 Department of Brain and Behavioral Sciences, University of Pavia, IRCCS “C.Mondino” Pavia. Italy; 3 Saint George School. Boario Terme/Milano
P177 A migraine attack as onset of trigeminal root entry zone ischemic stroke: a case report
VirginiaBozzoni, Elena Pegoraro, Ferdinando Maggioni
Department of Neurosciences, University of Padua, Padua, Italy
Correspondence:VirginiaBozzoni (virginia.bozzoni@gmail.com)
P178 The importance of a multidisciplinary approach in the management of pediatric migraine
Marcuzzi E 1 , Saretta F 1 , Savi L 2
1 Pediatric division, Hospital of Palmanova, AAS2 Bassa Friulana-Isontina; 2 Headache Center, Città della salute, Torino
P179 Investigating metacognitive executive dysfunctions in patients with medication-overuse headache
Milena Zucca, Elisa Rubino, Alessandro Vacca, Flora Govone, Annalisa Gai, Paola De Martino, Silvia Boschi, Maria T. Giordana, Innocenzo Rainero
Neurology I, Department of Neuroscience “Rita Levi Montalcini”, University of Turin
P180 Headache and the female gender
Anna Ambrosini
Headache Clinic - IRCCS Neuromed, Pozzilli (Isernia), Italy
P181 Role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model
Chiara Demartini 1,2 , Rosaria Greco 1 , Anna Maria Zanaboni 1,2 , Germana Tonsi 1,2 , Barbara Richichi 3 , Oscar Francesconi 3 , Cristina Nativi 3,4 , Cristina Tassorelli 1,2
1 Laboratory of Neurophysiology of Integrative Autonomic Systems, Headache Science Center, “C. Mondino” National Neurological Institute, 27100, Pavia, Italy; 2 Department of Brain and Behavioral Sciences University of Pavia, Pavia, Italy; 3 Department of Chemistry ‘Ugo Schiff’, University of Florence, 50019, Sesto Fiorentino, Florence, Italy; 4 FiorGen, University of Florence, 50019 Sesto Fiorentino, Florence, Italy
P182 Chronic and Intermittent administration of systemic nitroglycerin in the rat induces an increase in c-Fos and CGRP gene expression in areas involved in migraine pain
Rosaria Greco 1 , Chiara Demartini 1,2 , Anna Maria Zanaboni 1,2 , Germana Tonsi 1,2 , Attilio Iemolo 3 , Giuseppe Nappi 1 , Giorgio Sandrini 1,2 , Cristina Tassorelli 1,2
1 Laboratory of Neurophysiology of Integrative Autonomic Systems, Headache Science Center, C. Mondino National Neurological Institute, 27100 Pavia, Italy; 2 Department of Brain and Behavioral Sciences, University of Pavia, 27100, Pavia, Italy; 3 Laboratory of Functional Neurochemistry, Center for Research in Neurodegenerative Diseases, Center for Research in Neurodegenerative Diseases, “C. Mondino” National Neurological Institute, 27100, Pavia, Italy
P183 Psychopathological profile of Medication Overuse Headache patients, drug assumption and degree of disability
Simone Migliore, Matteo Paolucci, Livia Quintiliani, Claudia Altamura, Fabrizio Vernieri
Policlinico Universitario Campus Bio-Medico, Roma, Italia
P184 Education of the patient with migraine
Barbara Vitrani 1 , Lidia Savi 2
1 Master’s Degree in Headache Medicine – City of Health and Sciences University Hospital - Turin- Italy; 2 Headache Center- City of Health and Sciences University Hospital - Turin- Italy/Headache Center LBS - Lugano – Switzerland
P185 The Psycopathological comorbidities in children with chronic headaches
E.Tozzi, C.Gammella, A.Onofri, M.Mazzilli
Clinic of Child Neuropsychiatric- Regional center of Headache (Abruzzo), Hospital San Salvatore-University of L’Aquila Italy
Correspondence:E.Tozzi
P186 Headache in the Pediatric Emergency Department: the importance of collaboration with Headache Centre
Roberta Rossi 1 , Antonia Versace 1 , Barbara Lauria 1 , Giulia Grasso 1 , Emanuele Castagno 1 , Fulvio Ricceri 2,3 , Rosaura Pagliero 1 , Antonio Francesco Urbino 1
1 A.O.U. Città della Salute e della Scienza di Torino, Regina Margherita Children’s Hospital, Department of Pediatric Emergency, Pediatric Headache Centre, Turin, Italy; 2 Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy; 3 Unit of Epidemiology, Regional Health Service, ASL TO3, Grugliasco (TO), Italy
≤
18 years referred to the ED of the Regina Margherita Children’s Hospital of Turin, Italy between January 2011 and December 2015, reporting headache as main symptom, were retrospectively reviewed. We screened the medical record databases of our ED and also the one of our PHC for information relative to those children who had been referred there after discharge from the ED.P187 Efficacy of KUZIK® in the prophylaxis of migraine without aura: a retrospective observational study
E.Pucci 1 , F. Solinas 2 , C. Mostardini 3 , M. Loiero 4 , D. Soragna 5 , R. Niego 6 , R. Galante 7
1 Headache Science Center - University Consortium for the Study of Adaptive Disorders and Headache (UCADH), Department of Brain and Behavioral Sciences, University of Pavia, IRCCS “C. Mondino” Pavia; 2 Private neurological outpatient clinic, Sassari; 3 Center for Diagnosis and Treatment of Headache and Facial Neuralgia ,Ostia Hospital, Rome; 4 U.O. of Neurology, G. Pini Hospital, Milan; 5. Neurologist ASST Lariana; 6 Private neurological outpatient clinic, Verona; 7 Gam Farma Srl. Milan
Correspondence:E.Pucci
P188 Dural arteriovenous fistulas: clinical presentation, angiographic features and long-term outcome
Ilenia Corbelli MD 1 , Michele Romoli 1 , Francesca DeMaria 1 , Paolo Eusebi 1 , Gabriela Cardaioli 1 , Mohammed Hamam 2 , Piero Floridi 3 , Paola Sarchielli 1 , Paolo Calabresi 1,4
1 Clinica Neurologica, Dipartimento di Medicina, Ospedale S.M. Misericordia, Università degli Studi di Perugia, Italy; 2 Servizio di Angiografia Interventistica, Ospedale S.M. Misericordia, Italy;3Servizio di Neuroradiologia, Ospedale S.M. Misericordia, Università degli Studi di Perugia, Italy; 4 IRCCS Fondazione “S. Lucia”, Roma, Italy
Correspondence:Ilenia Corbelli (corbelli.ilenia@gmail.com)
P189 Headache and the pregnant patient
Chiara De Pinto 1 , Lidia Savi 2
1 U.O.Anestesia e Rianimazione 4, P.O.S.Anna, Città della Salute e della Scienza di Torino Corso Bramante 89, 10121 Torino, Italy; 2 U.O. Headache Center S.Giovanni Molinette University Hospital -Turin-Italy and Headache Center LBS, Lugano-Switzerland
Correspondence:Chiara De Pinto (cdepinto@cittadellasalute.to.it)
P190 Botulinum toxins for the prevention of migraine in adults: the experience in headache Unit of Cassino
Ottavio Di Marco, Stefania Di Mauro, Fernando Ferrauti
ASL Frosinone
Correspondence:Ottavio Di Marco
P191 Maternal alexithymia and attachment style: which relationship with their children's headache features and psychological profile?
Samuela Tarantino 1 , Laura Papetti 1 , Cristiana De Ranieri 2 , Angela Rocco 2 , Valeria Valeriano 2 , Francesca Boldrini 2 , Barbara Battan 1 , Maria Francesca Paniccia 2 , Federico Vigevano 1 , Simonetta Gentile 2 , Massimiliano Valeriani 1,3
1 Headache Center, Division of Neurology; 2 Unit of Clinical Psychology, Ospedale Pediatrico Bambino Gesù, IRCCS, Piazza Sant’Onofrio 4, Rome, Italy; 3 Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark
Correspondence:Samuela Tarantino (samuela.tarantino@gmail.com)
P192 Vitamin D as a possible new treatment for migraine
Baoran Yang 1,2 , Giorgia Leodori 1,2 , Emma De Maio 1,2 , Guido Granata 1,2 , Massimo Granata 1,2
1 Headache Centre, UOC Clinical Immunology A, Department of Clinical Medicine; 2 Department of Radiology, Policlinico Umberto I, “Sapienza” University of Rome
Correspondence:Massimo Granata (massimo.granata@uniroma1.it)
P193 Clinical presentation and diagnostic evaluation of idiopathic intracranial hypertension in children and adolescents
Barbara Battan, Laura Papetti, Irene Salfa, Federico Vigevano, Massimiliano Valeriani
Headache Center, Child Neurology Unit, Bambino Gesu’ Children’s Hospital, Rome, Italy
Correspondence:Barbara Battan (barbara.battan@opbg.net)
P194 Chronic paroxysmal hemicrania in paediatric age: report of four cases
Laura Papetti, Samuela Tarantino, Barbara Battan, Federico Vigevano, Massimiliano Valeriani
Headache Center, Department of Neuroscience, Bambino Gesù Children Hospital, Rome, Italy
Correspondence:Laura Papetti (laura.papetti@opbg.net)
P195 Amitriptyline plasma level and its possible correlation with cognitive impairment and driving performance in migraine patients; pilot study
Matteo Bellamio 1 , Federico Mainardi 2 , Michele Barp 3 , Alberto Terrin 3 , Giorgio Zanchin 3 , Ferdinando Maggioni 3
1 Headache Centre, Neurological Division, Dell’Angelo Hospital, Venezia-Mestre (VE), 30121 Italy; 2 Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venezia, Italy; 3 Headache Centre, Department of Neurosciences, University of Padua, Padova, Italy
Correspondence: Matteo Bellamio (matteo.bellamio@gmail.com)
P196 Subthalamic Deep Brain Stimulation performed for Parkinson disease treatment: effects on Chronic Migraine
Terrin A, Toldo G, Zanchin G, Mainardi F, Maggioni F
P197 Communication ed information of an Cephalagic patient in contemporary society
Gregorio Iannone 1 , Carlo Piccolini 2 , Sandro Bartoli 3
1 Deputy coordinator S.I.S.C. Macroregione Umbria Abbruzzo Terni Italy; 2 A.O”S.Maria” Neuroscience and neurorehabilitation Department Terni Italy; 3 Dr. sociology Of communication us Perugia head office Terni Italy
P198 Stopping Onabotulinum treatment after the first 2 cycles might not be justified: results of a real-life monocentric prospective study in chronic migraine
Michele Romoli1, Ilenia Corbelli1, Laura Bernetti1, Angela Verzina1, Elona Brahimi1, Stefano Caproni1, Paolo Eusebi2, Cinzia Costa1, Paolo Calabresi1,3, Paola Sarchielli1
1Neurology Clinic, University Hospital of Perugia, Perugia, Italy; 2Regional Health Authority, Public Health Regional Department, Perugia, Italy; 3IRCCS Santa Lucia, Rome, Italy
Correspondence: Michele Romoli (romoli.mic@gmail.com)
P199 Tanacethum Parthenium, 5-hydroxy tryptophan and magnesium (Aurastop®) in the prophylaxis of episodic migraine without aura in a adult population
Alessandra Mandelli, Natascia Beretta, Paola Merlo
U.O. Neurologia- Centro Cefalee Humanitas Gavazzeni, Beragamo
Correspondence:Alessandra Mandelli (alessandra. mandelli@gavazzeni.it)
P200 Migraine aura treatment with the association of Tanacethum Parthenium, 5-Hydroxytryptophan and Magnesium (Aurastop®): an observational study
Paola Merlo 1 , Grazia Sances 2 , Valentina Rebecchi 3 , Fabio Antonaci 2,4,5 , Andrea Giorgetti 6 , Franco Di Palma 7 , Edgar Matta 8 , Carlo Dall’Occhio 9 , Cristina Tassorelli 2,5 , Giorgio Dalla Volta 10 , on behalf of Società Italiana per lo Studio delle Cefalee (SISC–Lombardia) - Italia
1 U.O.Neurologia - Centro Cefalee, Humanitas Gavazzeni, Bergamo; 2 Headache Science Centre, Istituto Neurologico Nazionale Mondino, Pavia; 3 Centro Cefalee UOC Neurologia -Varese- ASST Settelaghi – Univ. Insubria; 4 UC Neurologia Speciale d'Urgenza, Istituto Neurologico Nazionale, Pavia; 5 Dipartimento di Scienze del Sistema Nervoso e del Comportamento Università di Pavia; 6 Centro Cefalee, Dipartimento di Neuroscienze H di Legnano ASST Ovest milanese; 7 Centro Cefalee UOC Neurologia della ASST Lariana-Ospedale S. Anna di Como; 8 Centro Cefalee UOC neurologia ASST Bergamo ovest; 9 UO Neurologia, ASST Pavia. Ospedale Civile, Voghera; 10 Centro Cefalee U.O Neurologia - Istituto Clinico Citta’ di Brescia, Brescia
Correspondence:Paola Merlo (paola.merlo@gavazzeni.it)
P201 Benign intracranial hypertension in children can be due to hypoparathyroidism: a case-report
Giorgia Sforza 1,3 , Annalisa Deodati 2 , Laura Papetti 1 , Barbara Battan 1 , Paolo Curatolo 3 , Federico Vigevano 1 , Massimiliano Valeriani 1
1 Headache Center, Child Neurology Unit, Bambino Gesu’ Children’s Hospital, Rome, Italy; 2 Child Endocrinology Unit, Bambino Gesu’ Children’s Hospital, Rome, Italy; 3 Child Neurology and Psychiatry Unit, Tor Vergata University of Rome, Italy
Correspondence:Giorgia Sforza (sforzagiorgia@gmail.com)
P202 Efficacy in episodic migraine prevention of a combination of Tanacethum Parthenium, 5 - hydroxy tryptophan and magnesium (Aurastop©) A multicentric observational study
Paola Merlo 1 , Ferdinando Maggioni 2 , Giorgio Zanchin 2 , Federico Mainardi 3 , Giorgio Dalla Volta 4
1 Headache Centre of Neurological Division of Gavazzeni Hospital, Bergamo; 2 Headache Centre, Department of Neurosciences, Padua University, Padua; 3 Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice; 4 Headache Center of Neurological Unit of Istituto Clinico Citta’ di Brescia, Brescia
Correspondence:Giorgio Dalla Volta (dalla@numerica.it)
P203 Palmitoylethanolamide: a possible new option for the prophylactic treatment of cluster headache
Carlo Lisotto 1 , Edoardo Mampreso 1 , Federico Mainardi 2 , Ferdinando Maggioni 1 , Giorgio Zanchin 1
1 Headache Centre, Department of Neurosciences, University of Padua, Padua, Italy; 2 Headache Centre, Department of Neurology, Hospital of Venice, Venice, Italy
Correspondence:Carlo Lisotto
P204 Association of Tanacethum Parthenium, 5 - hydroxy tryptophan and magnesium ( Aurastop) versus Mg tablet impact on aura phenomena and its evolution : an observational study
P. Zavarise, M. Manfredi, G. Ngonga, G.Dalla Volta
Headache Center. U.O Neurologia - Istituto Clinico Citta’ di Brescia - Brescia
P205 Mother-child agreement on headache reports in a non-clinical sample
Cristiano Termine 1,2 , Matteo Chiappedi 3 , Chiara Luoni 4 , Micaela De Simone 5 , Sara Crugnola 4 , Beatrice Bartoli 1 , Andrea E. Cavanna 7,8,9 , Umberto Balottin 2,3,5
1 Child Neuropsychiatry Unit, Department ofMedicine and Surgery, University of Insubria, Varese, Italy; 2 University Centre for Adaptive Disorders and Headache (UCADH), Sections of Varese and Pavia, Italy; 3 C. Mondino National Neurological Institute, Pavia, Italy; 4 Child and Adolescence Neuropsychiatry Unit, ASST SetteLaghi, Varese, Italy; 5 Department of Brain and BehavioralSciences, University of Pavia, Italy; 6 Child Neuropsychiatry Unit, CasimiroMondinoNational Neurological Institute, Pavia, Italy; 7 Department of Neuropsychiatry, BSMHFT and University of Birmingham, Birmingham, UK; 8 School of Life and Health Sciences, Aston University, Birmingham, UK; 9 University College London and Institute of Neurology, London, UK
Correspondence:Cristiano Termine (cristiano.termine@uninsubria.it)
P206 Tanacethum Parthenium, 5-hydroxy tryptophan and magnesium in the prophylaxis of migraine without aura
Federico Mainardi 1 , Giorgio Zanchin 2 , Carlo Lisotto 3 , Ferdinando Maggioni 2
1 Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice; 2 Headache Centre, Department of Neurosciences, Padua University, Padua; 3 Headache Centre, San Vito al Tagliamento Hospital
Correspondence:Federico Mainardi (fmainardi@iol.it)
P207 Reversible splenial lesion of the corpus callosum in status migrainosus: a case report
Alberto Terrin 1 , Federico Mainardi 2 , Ferdinando Maggioni 1
1 Headache Centre of the Veneto Region, Department of Neurosciences, University of Padova, Padova, Italy; 2 Headache Centre – Hospital SS. Giovanni and Paolo, Venice, Italy
Correspondence: Alberto Terrin (alberto.terrin89@gmail.com)
P208 Headache and its pharmacologic treatment during pregnancy: preliminary data of a retrospective cohort study (ATENA study)
Chiara Lupi 1* , Elisabetta Gambassi 2* , Tommaso Susini 2 , Pierangelo Geppetti 1 , Silvia Benemei 1
1 Headache Centre, Careggi University Hospital, Department of Health Sciences, University of Florence, Florence, Italy; 2 Maternal and Child Department, Careggi University Hospital, Department of Health Sciences, University of Florence, Florence, Italy
Correspondence:Chiara Lupi
P209 RegistRare: a retro-prospective registry of rare primary headaches in Italian tertiary Headache centres
Chiara Lupi 1 , Roberto De Icco 2 , Luana Evangelista 3 , Valentina Favoni 4 , Antonio Granato 5 , Edoardo Mampreso 6 , Matteo Paolucci 7 , Lanfranco Pellesi 4 , Andrea Negro 9 , Raffaele Ornello 3 , Antonio Russo 10 , Martina Ulivi 7 , Sabina Cevoli 4 , Simona Guerzoni 8 , Silvia Benemei 1
1 Headache Centre, Careggi University Hospital, Department of Health Sciences, University of Florence, Florence, Italy; 2 Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy; 3 Headache Centre, San Salvatore Hospital, ASL Abruzzo 1, Avezzano-Sulmona-L’Aquila, Italy; 4 Institute of Neurological Sciences of Bologna, Bellaria Hospital,Bologna, Italy; 5 Department of Medical, Technological and Translational Sciences, Headache Centre, University of Trieste, Italy; 6 Headache Centre, Medical Department, AULSS 6 Euganea, Padova, Italy; 7 Institute of Neurology, Università Campus Bio-Medico, Rome, Italy; 8 Headache and Drug Abuse Research Centre, Policlinico Hospital,University of Modena e Reggio Emilia, Modena, Italy; 9 Regional Referral Headache Center, Sant'Andrea Hospital, Rome, Italy; 10 Headache Centre, Neurology Department, University of Naples II, Naples, Italy
Correspondence: Silvia Benemei
P210 Ketogenic diet is ineffective in chronic tension-type headache treatment
Cherubino Di Lorenzo 1 , Giulio Sirianni 2 , Gianluca Coppola 3 , Francesco Pierelli 4,5
1 Don Carlo Gnocchi Onlus Foundation, Milan, Italy; 2 Delle Medical Center, Roma, Italy; 3 G.B. Bietti Foundation – IRCCS, Department of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 4 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy; 5 IRCCS – Neuromed, Pozzilli (IS), Italy
Correspondence: Cherubino Di Lorenzo (cherub@inwind.it)
P211 Clinical decision support software in headache management: a new tool for General Practitioners
Cherubino Di Lorenzo 1 , Fabio Adipietro 2 , Mario D’Uva 3 , Grazia Semeraro 4 , Gianluca Coppola 5 , Francesco Pierelli 4,6
1 Don Carlo Gnocchi Onlus Foundation, Milan, Italy; 2 Freelance Engineer; 3 Medicina Primaria, Distretto 1, Azienda Sanitaria Locale, Latina, Italia; 4 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy; 5 G.B. Bietti Foundation – IRCCS, Department of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 6 IRCCS – Neuromed, Pozzilli (IS), Italy
Correspondence: Cherubino Di Lorenzo (cherub@inwind.it)
Questions | Answer |
---|---|
Nausea or Vomiting | - Yes - Not |
Photophobia | - Yes - Not |
Degree of disability | - Mild - Moderate - Severe |
Gets worse with physical activity | - Yes - Not |
Aura | - Always - Sometimes - Never |
Duration | - <4h - 4-72h - >72h |
Localization | - Unilateral, always on the same side - Unilateral, alternating - Other (median, bilateral, variable…) |
Chronic (>15 days/month) | - Yes - Not |
P212
P213 Non pharmacological preventive therapy to chronic migraine in the real world: a Short-Term Psychodynamic Psychotherapy approach
Barbara Petolicchio 1 , Alessandro Viganò 1 , Federica Turchi 1 , Martina Squitieri 1 , Romina Di Giambattista 2 , Marta Altieri 1 ,Edmond Gilliéron 2 , Vittorio Di Piero 1
1 Department of Neurology and Psychiatry, Sapienza University of Rome, 00185 - Rome, Italy; 2 Istituto Europeo di Psicoterapia Psicoanalitica (IREP), 00187 - Rome, Italy
Correspondence:Barbara Petolicchio (barbara.petolicchio@uniroma1.it)
P214 Chronic migraine preventive treatment by prefrontal-occipital transcranial direct current stimulation (TDCS): a pilot study on the effect of psychiatric comorbidities
Giulio Mastria & , Alessandro Viganò & , Alessandra Corrado, Cristina Pirillo, Valentina Mancini, Simone Badini, Barbara Petolicchio, Massimiliano Toscano, Roberto Delle Chiaie, Vittorio Di Piero
1 Neurology and Psychiatry, Sapienza - University of Rome, Rome, Italy
Correspondence:Alessandro Viganò (alessandro.vigano@uniroma1.it)
P215 Prophylaxis of primary headaches with acupuncture, supplements or drug in children and adolescents: the Padua experience
Elena Piretti 1 , Pier Antonio Battistella 1 , Maria Paola Rossaro 1 , Margherita Nosadini 1 , Michela Gatta 2 , Stefano Sartori 1 , Irene Toldo 1
1 Juvenile Headache Centre, Department of Woman's and Child’s Health, University Hospital of Padua, Via Giustiniani 3, 35128 Padua, Italy; 2 Socio-sanitary district, “Struttura Complessa Infanzia Adolescenza Famiglia” (SCIAF), ULSS 6 Euganea Padua, Via Dei Colli 4, 35143 Padua, Italy
Correspondence:Irene Toldo (irene.toldo@unipd.it)
Acupuncture (N=27) | Supplements (N=23) | Pizotifen (N=23) | |
---|---|---|---|
Frequency of the headache (gg/30 gg) pre e post-T (median) | From 9 to 3,5 (p=0.0002)*
| From 12 to 1 (p<0.0001)*
| From 4 to 3 (p=0.02)*
|
Duration of the headache (h) pre e post-T(median) | From 8 to 5,4 (p=0.0002)*
| From 3,4 to 3 (p=0.58) | From 3,5 to 3 (p=0.18) |
Nausea pre e post-T(median) | From 78,9% to 0% (p=0.0005)*
| From 0% to 0% (p=0.49) | From 26,7% to 6,7% (p=0.22) |
Photophobiapre e post-T(median) | From 32,5% to 26,5% (p=0.08) | From 28,6% to 0% (p=0.07) | From 75% to 0% (p=0.03)*
|
Phonophobia pre e post-T (median) | From 40% to 0% (p=0.005)*
| From 37,5% to 0% (p=0.85) | From 100% to 25% (p=0.003)*
|
Symptomatic drug consumption pre e post-T (median) | From 4 to 1 (p=0.003)*
| From 8 to 1 (p=0.0002)*
| From 4,5 to 4 (p=0.15) |
Items PedMidas° |
*4 |
*2 |
*1 |
Items CBCL 6-18° |
*1 |
*1 |
*1 |
Adverse and unpleasant effects (p=0.05) | 6 (24%) | 7 (70%) | 4 (31%) |
Satisfaction (*) | 8,75 | 6 | 7 |
Positive secondary effects | 7 (28%) | 0 (0%) | 0 (0%) |
P216 Life traumas and stressful events in Chronic Migraine and Medication Overuse Headache: What is the relation with the outcome of a detoxification therapy?
Bottiroli Sara 1 , Viana Michele 1 , Sances Grazia 1 , De Icco Roberto 1 , Vito Bitetto 1, 2 , Guaschino Elena 1 , Ghiotto Natascia 1 , Pazzi Stefania 1 , Giuseppe Nappi 1 , Tassorelli Cristina 1,2
1 Headache Science Centre, C. Mondino National Neurological Institute, 27100 Pavia, Italy; 2 Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy
Correspondence:Bottiroli Sara (sara.bottiroli@mondino.it)
P217 Thrombophilic disorders in migraineurs
Cinzia Cavestro 1 , Molinari Filippo 2 , Micca Gianmatteo 3 , Mandrino Silvia 1 , Diana Degan 4 , Francesca Pistoia 4 , Aloi Raffaele 5 , Frigeri MariaCristina 5 , Simona Sacco 4
1 Headache Center, Dep. Of Neurology, “S.Lazzaro” Hosp, ASL CN2 Alba (Italy); 2 Main Laboratory and Hematology and Coagulation Disorders Laboratory, ASL CN2 Alba (Italy); 3 Main Laboratory and Hematology and Coagulation Disorders Laboratory, “Santa Croce” Hosp, Cuneo (Italy); 4 Department of Applied Clinical Sciences and Biotechnology, Section of Neurology, University of L’Aquila, L’Aquila, Italy; 5 Occupational Medicine Service, ASL CN2 Alba (Italy); 6 Administrative Medical Office, “S. Lazzaro” Hosp., ASL CN2 Alba (Italy)
Correspondence:Simona Sacco (simona.sacco@univaq.it)
P218 Clinical pharmacokinetics of oral cannabis FM2 preparations in medication overuse headache (MOH) patients
Lanfranco Pellesi 1 , Simona Guerzoni 1 , Manuela Licata 2 , Luigi A Pini 1
1 Medical Toxicology and Headache Centre, University of Modena and Reggio Emilia, Modena, 41124, Italy; 2 Forensic Toxicology Laboratory, University of Modena and Reggio Emilia, Modena, 41124, Italy
Correspondence:Lanfranco Pellesi (lanfranco.pellesi@gmail.com)
Parameters (mean ± SD) | Cannabis decoction (200 ml) | Cannabis oil (1 ml) |
p-value |
---|---|---|---|
Δ9-THC | |||
Tlag, hours | 0.57 ± 0.19 | 0.71 ± 0.27 | 0.356 |
Tmax, hours | 1.07 ± 0.35 | 1.29 ± 0.39 | 0.200 |
Cmax, ng/ml | 1.58 ± 0.72 | 3.76 ± 1.15 |
< 0.01
|
AUC0-24, ng/ml · min | 3.63 ± 1.84 | 8.39 ± 2.83 |
0.011
|
t1/2, hours | 1.68 ± 1.55 | 1.65 ± 0.75 | 0.964 |
11-OH-THC | |||
Tlag, hours | 0.86 ± 0.63 | 1.21 ± 0.49 | 0.283 |
Tmax, hours | 1.00 ± 0.71 | 1.43 ± 0.45 | 0.143 |
Cmax, ng/ml | 0.49 ± 0.41 | 1.19 ± 0.85 | 0.054 |
AUC0-24, ng/ml · min | 0.85 ± 0.84 | 1.98 ± 1.41 |
0.044
|
t1/2, hours | 0.70 ± 0.51 | 1.90 ± 2.70 | 0.33 |
THC-COOH | |||
Tlag, hours | 1.07 ± 0.35 | 1.21 ± 0.27 | 0.356 |
Tmax, hours | 2.00 ± 0.76 | 2.14 ± 1.03 | 0.752 |
Cmax, ng/ml | 4.74 ± 1.70 | 8.13 ± 4.74 |
0.037
|
AUC0-24, ng/ml · min | 22.61 ± 15.05 | 44.25 ± 42.26 | 0.203 |
t1/2, hours | 3.80 ± 3.99 | 6.29 ± 6.38 | 0.452 |
THC-glucuronate | |||
Tlag, hours | 1.36 ± 0.24 | 1.21 ± 0.27 | 0.356 |
Tmax, hours | 4.43 ± 1.13 | 3.14 ± 0.69 |
0.035
|
Cmax, ng/ml | 30.47 ± 8.23 | 31.92 ± 9.34 | 0.471 |
AUC0-24, ng/ml · min | 453.69 ± 86.48 | 556.66 ± 258.97 | 0.208 |
t1/2, hours | 20.75 ± 5.69 | 20.05 ± 7.23 | 0.843 |
CBD | |||
Tlag, hours | 0.50 ± 0.00 | 0.79 ± 0.39 | 0.103 |
Tmax, hours | 0.57 ± 0.19 | 0.93 ± 0.35 | 0.047 |
Cmax, ng/ml | 5.32 ± 2.80 | 3.49 ± 2.81 | 0.256 |
AUC0-24, ng/ml · min | 5.16 ± 2.46 | 3.35 ± 2.09 | 0.157 |
t1/2, hours | 0.53 ± 0.19 | 0.52 ± 0.31 | 0.923 |
P219 Time-related changes of clinical symptoms induced by Onabotulintoxin A (BONTA) in chronic migraine: data from an innovative smartphone application
Antonio Santoro 1 , Marianna Delussi 2 , Eleonora Vecchio, Olimpia Difruscolo 3 , Laura De Rocco 4 , Maurizio Leone 1 , Marina de Tommaso 2
1 Neurology Division, IRCSS Ospedale Sollievo dalla Sofferenza, San Giovanni Rotondo, Italy; 2 Applied Neurophysiology and Pain Unit, SMBNOS Department, Bari Aldo Moro University (Italy); 3 Division of Neurology, Di Venere Hospital, Bari, Italy; 4 IRIS s.n.c. - Consorzio Stabile Terin- Parco Tecnologico Cittadella Della Ricerca - Mesagne - 72100 Brindisi
Correspondence:Marina de Tommaso (marina.detommaso@uniba.it)
P220 Clinical evaluation in two sub-populations of cluster headache patients with neprilysin (NEP) and pituitary-adenyl cyclase activating polipeptide (PACAP) receptor gene variants
Maria Michela Cainazzo 1 , Elena Bacchelli 2 , Carlo Baraldi 1 , Simona Guerzoni 1 , Lanfranco Pellesi 1 , Michele Zoli 3 , Elena Maestrini 2 , Luigi Alberto Pini 1
1 Headache and Drug Abuse Unit, Policlinico Hospital, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy; 2 Department of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy; 3 Department of Biomedical, Metabolic and Neural Sciences, Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Via G. Campi 242, 41100 Modena, Italy
Correspondence:Maria Michela Cainazzo (cainazzo.michela@policlinico.mo.it); Luigi Alberto Pini (luigialberto.pini@unimore.it)
P221 Medication-overuse headache management: data from SAMOHA study
Angela Verzina 1 , Ilenia Corbelli 1 , Paolo Eusebi 1 , Letizia Maria Cupini 2 , Stefano Caproni 3 , Paola Sarchielli 1 and Paolo Calabresi 1
1 Neurological Clinic, Department of Medicine, University of Perugia, Italy; 2 Headache Center and Cerebrovascular Disease, S. Eugenio Hospital, Roma, Italy; 3 Neurological Clinic, Department of Neuroscience, University of Terni, Italy
Correspondence:Angela Verzina (verzinaangela@hotmail.it)
P222 Orthostatic headache from spontaneous intracranial hypotension (SIH) complicated with convexity subaracnoid haemorragy (SAH) in patient with lung cancer
Francesca Marsili 1 , Antonio Matera 1 , Luca Onofrio Scappatura 1 , Umberto Giulio Sica 1 , Monica Pace 1 , Valeria Coppola 2 , Enrico Ferrante 1
1 Neurology; 2 Neuroradiology Department, AOR San Carlo, Potenza, Italy
Correspondence:Enrico Ferrante (enricoferrante@libero.it)
P223 Awareness of migraine in Neo-Latin countries: a study in 12 headache centers over 7 countries
Michele Viana 1 , Farihah Khaliq 1 , Grazia Sances 1 , María De Lourdes Figuerola 2,3 , Vittorio Di Piero 4 , Pierangelo Geppetti 5 , Rosario Iannacchero 6 , Ferdinando Maggioni 7 , Mauro Eduardo Jurno 8 , Ecaterina Chiriac 9 , Alejandro Marfil 10 , Filippo Brighina 11 , Nelson Barrientos Uribe 12 , Cristina Pérez Lago 13 , Carlos Bordini 14 , Franco Lucchese 4 , Valerio Maffey 4 , Giuseppe Nappi 1 , Giorgio Sandrini 1,15 , Cristina Tassorelli 1,15
1 Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy; 2 Hospital de Clínicas José San Martín; 3 Hospital Alemán, Buenos Aires, Argentina, 4 Sapienza University, Rome, 5 University of Florence, Florence, 6 A.O. “ Pugliese – Ciaccio“, Catanzaro, 7 Padua University, Padua, Italy, 8 FAME/FUNJOB and FHEMIG, Barbacena, Brazil, 9 National Headache Center - Republic of Moldova, Chisinau city, Moldova, Republic of, 10 Hospital Universitario, Monterrey, Mexico, 11 Policlinico Universitario, Palermo, Italy, 12 Hospital DIPRECA, Santiago, Chile, 13 Hospital Maciel, Montevideo, Uruguay, 14 Clínica Neurológica Batatais, Batatais, Brazil, 15 University of Pavia, Pavia, Italy
Correspondence:Michele Viana
Sign | OR (95% CI) | |
---|---|---|
High educational level | <0.001 | 1.97 (1.43-2.78) |
Number of family members with migraine | 0.005 | 1.17 (1.04-1.31) |
Duration of attacks (hours) | 0.001 | 0.98 (0.97-0.99) |
Throbbing pain | 0.005 | 2.02 (1.23-3.31) |
Localization of pain: lateral | 0.043 | 1.36 (1.01-1.83) |
Vomiting | 0.018 | 1.43 (1.06-1.93) |
P224 Guideline adherence reduces neuroimaging utilization in Headache Center
Alessandro Panconesi (alessandro.panconesi@uslcentro.toscana.it)
Headache Center, Department of Neurology, Health Authority 11, Empoli, Italy
Patients (n) | Mean age ± SD (range) | ♀ | ♂ | RMI/CT (n) | Imaged (%) | |
---|---|---|---|---|---|---|
Neurologists | 520 | 41.6 ± 18 (4-91) | 75.2% | 24.8% | 127/10 | 26.3 |
GP | 1078 | 41.0 ± 15 (4-90) | 74.4% | 25.6% | 107/11 | 10.9 |
P225 Availability of effective evidence-based symptomatic treatments for cluster headache in the EU countries: A survey of the European Headache Alliance and European Headache Federation
Paolo Rossi a,b , Elena Ruiz De La Torre a , Dimos Mitsikostas c , Aurore Palmaro d,e,f*
a European Headache Alliance; b Headache Clinic INI Grottaferrata, Italy; c Aeginition Hospital, National & Kapodistrian University of Athens, Athens, Greece; d Medical and Clinical Pharmacology department, Toulouse University Hospital, Toulouse, France; e UMR INSERM 1027, University of Toulouse, Toulouse, France; f CIC 1436, Toulouse University Hospital, Toulouse, France
Correspondence:Paolo Rossi
P226 The evaluation of short-latency afferent inhibition discloses abnormal fluctuations of cholinergic transmission during the migraine cycle
Davide Di Lenola 1 , Gianluca Coppola 2 , Francesca Cortese 2 , Cherubino Di Lorenzo 3 , Francesco Pierelli 3
1 Sapienza University of Rome Polo Pontino, Department of medico-surgical sciences and biotechnologies, Latina, Italy; 2 G.B. Bietti Foundation IRCCS, Department of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 3 Don Gnocchi foundation-IRCCS, Milan, Italy
Correspondence:Davide Di Lenola
P227 The clinical efficacy of short-lasting ketogenic diet in migraine is due to a general normalization of the interictal cortical hyperresponsivity rather than to a direct modulation of the subcortical brainstem activity
Cherubino Di Lorenzo 1 , Gianluca Coppola 2 , Martina Bracaglia 3 , Ilaria Bove 3 , Davide Di Lenola 3 , Mariano Serrao 3 , Vincenzo Parisi 2 , Francesco Pierelli
1 Don Carlo Gnocchi Onlus Foundation, Milan, Italy; 2 G. B. Bietti Foundation-IRCCS, Rome, Italy; 3 “Sapienza” University of Rome Polo Pontino, Latina, Italy; 4 INM Neuromed IRCCS, Pozzilli (IS), Italy
P228 Cerebral grey matter density is reduced in chronic migraine patients: correlations with clinical features
Gianluca Coppola 1 , Barbara Petolicchio 2 , Antonio Di Renzo 1 , Emanuele Tinelli 2 , Cherubino Di Lorenzo 3 , Vincenzo Parisi 1 , Mariano Serrao 4 , Valentina Calistri 2 , Stefano Tardioli 2 , Gaia Cartocci 2 , Francesca Caramia 2 , Vittorio Di Piero 2 , Francesco Pierelli 4,5
1 G.B. Bietti Foundation IRCCS, Research Unit of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 2 “Sapienza” University of Rome, Department of Neurology and Psychiatry, Rome, Italy; 3 Don Carlo Gnocchi Onlus Foundation, Milan, Italy; 4 “Sapienza” University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy; 5 IRCCS-Neuromed, Pozzilli (IS), Italy
Correspondence: Gianluca Coppola
EHF ORAL PRESENTATIONS
O1 Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s)
Koen Paemeleire 1 , Gregor Broessner 2 , Jan Brandes 3 , Jan Klatt 4 , Feng Zhang 5 , Hernan Picard 5 , Daniel D Mikol 5 , Robert A Lenz 5
1 Ghent University Hospital, Ghent, Belgium; 2 Medical University of Innsbruck, Innsbruck, Austria; 3 Nashville Neuroscience Group and Vanderbilt University School of Neurology, Nashville, TN, USA; 4 Novartis, Basel, Switzerland; 5 Amgen Inc., Thousand Oaks, CA, USA
Correspondence: Koen Paemeleire (Koen.Paemeleire@uzgent.be)
O2 GLP-1 Reduces Cerebrospinal Fluid Secretion And Intracranial Pressure: A Novel Treatment For Idiopathic Intracranial Hypertension?
Hannah Botfield 1,2 , Maria Uldall 3 , Connar Westgate 1,2 , James Mitchell 1,4 , Snorre Hagen 3 , Ana Maria Gonzalez 5 , David Hodson 1,6 , Rigmor Jensen 3 , Alexandra Sinclair 1,4
1 Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston; 2 Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom; 3 Danish Headache Center, Clinic of Neurology, Rigshospitalet-Glostrup, University of Copenhagen , Glostrup, Denmark; 4 Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham; 5 Institute of Inflammation and Ageing, University of Birmingham, Edgbaston; 6 Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Edgbaston, United Kingdom
Correspondence: Alexandra Sinclair (a.b.sinclair@bham.ac.uk)
O3 Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: Primary results of the STRIVE trial
Uwe Reuter 1* , Jo Bonner 2 , Gregor Broessner 3 , Yngve Hallstrom 4 , Feng Zhang 5 , Sandhya Sapra 6 , Hernan Picard 7 , Daniel D Mikol 7 , Robert A Lenz 7
1 Dept of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 2 Mercy Research, St Louis, MO, USA; 3 Dept of Neurology, Medical University of Innsbruck, Innsbruck, Austria; 4 Stockholm Neuro Center, Stockholm, Sweden; 5 Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA; 6 Global Health Economics, Amgen Inc., Thousand Oaks, CA, USA; 7 Global Development, Amgen Inc., Thousand Oaks, CA, USA
Correspondence:Uwe Reuter (uwe.reuter@charite.de)
O4 Modelling cortical spreading depression by a computational algorithm of distributed neural excitability: correlation with clinical features in single migraine with aura patients
Marina de Tommaso 1,2 , Julia Maria Kroos 3 , Eleonora Vecchio 1 , Nicola Burdi 4 , Sebastiano Stramaglia 2,5 , Luca Gerardo Giorda 3
1 Applied Neurophysiology and Pain Unit, SMBNOS Department, Bari Aldo Moro University (Italy); 2 TIRES Center, Bari Aldo Moro University (Italy); 3 BCAM -Basque Center for Applied Mathematics-Center, Bilbao, Spain; 4 Neuroradiology Unit, SS.Annunziata General Hospital, Taranto (Italy); 5 Physic Department, Bari Aldo Moro University , Bari (Italy)
Correspondence:Marina de Tommaso (marina.detommaso@uniba.it)
O5 Interventional management in refractory headache disorders; Tertiary Center Based Experiences supported by application videos and a model for interactive practice of attenders
Aynur Özge, Derya Uludüz, Ömer Karadaş, Osman Özgür Yalın, Hayrunnisa Bolay
Correspondence:Aynur Özge (aynurozge@gmail.com)
O6 A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study
Holland C. Detke, Shufang Wang, Vladimir Skljarevski, Jonna Ahl, Brian A. Millen, Sheena K. Aurora, Jyun Yan Yang
Eli Lilly and Company, Indianapolis, IN USA
O7 Improving the differential diagnosis between migraine with aura and transient ischemic attacks
Elena R Lebedeva 1,2 , Natalia M Gurary 3 , Denis V Gilev 4 , Anne F Christensen 5 , Jes Olesen 5
1 Department of Neurology, the Ural State Medical University, Repina 3, Yekaterinburg, 620028, Russia; 2 International Headache Center “Europe-Asia”, Yekaterinburg, 620144, Russia; 3 Medical Union “New Hospital”, Yekaterinburg, Russia; 4 Department of econometrics and statistics, the Graduate school of Economics and Management, the Ural Federal University; 5 Danish Headache Center, Department of Neurology, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
Correspondence:Elena R Lebedeva (cosmos@k66.ru)
O8 Rare primary headaches in Italian tertiary Headache centres: a nationwide retrospective epidemiologic survey (RegistRare study)
Chiara Lupi 1 , Roberto De Icco 2 , Luana Evangelista 3 , Valentina Favoni 4 , Antonio Granato 5 , Edoardo Mampreso 6 , Matteo Paolucci 7 , Lanfranco Pellesi 4 , Andrea Negro 9 , Raffaele Ornello 3 , Antonio Russo 10 , Martina Ulivi 7 , Sabina Cevoli 4 , Simona Guerzoni 8 , Silvia Benemei 1
1 Headache Centre, Careggi University Hospital, Department of Health Sciences, University of Florence, Florence, Italy; 2 Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy; 3 Headache Centre, San Salvatore Hospital, ASL Abruzzo 1, Avezzano-Sulmona-L’Aquila, Italy; 4 Institute of Neurological Sciences of Bologna, Bellaria Hospital, Bologna, Italy; 5 Department of Medical, Technological and Translational Sciences, Headache Centre, University of Trieste, Italy; 6 Headache Centre, Medical Department, AULSS 6 Euganea, Padova, Italy; 7 Institute of Neurology, Università Campus Bio-Medico, Rome, Italy; 8 Headache and Drug Abuse Research Centre, Policlinico Hospital,University of Modena e Reggio Emilia, Modena, Italy; 9 Regional Referral Headache Center, Sant'Andrea Hospital, Rome, Italy; 10 Headache Centre, Neurology Department, University of Naples II, Naples, Italy
Correspondence: Silvia Benemei (silvia.benemei@unifi.it)
O9 Non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: the randomised controlled PRESTO trial
Cristina Tassorelli 1 , Licia Grazzi 2 , Marina de Tommaso 3 , Giulia Pierangeli 4 , Paolo Martelletti 5 , Innocenzo Rainero 6 , Pierangelo Geppetti 7 , Anna Ambrosini 8 , Paola Sarchielli 9 , Eric Liebler 10 , Piero Barbanti 11
1 Headache Science Centre, National Neurological Institute C. Mondino Foundation and University of Pavia, Pavia, Italy; 2 Headache Center, Carlo Besta Neurological Institute and Foundation, Milano, Italy; 3 Neurophysiology and Pain Unit, University of Bari Aldo Moro, Bari, Italy; 4 IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 5 Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy; 6 Department of Neuroscience, University of Turin, Turin, Italy; 7 Headache Centre, University Hospital of Careggi, Florence, Italy; 8 IRCCS Neuromed, Pozzilli (IS), Italy; 9 Neurologic Clinic, Santa Maria della Misericordia Hospital, Perugia, Italy; 10 electroCore, LLC, Basking Ridge, New Jersey, USA; 1 Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy
Correspondence:Cristina Tassorelli (cristina.tassorelli@mondino.it)
O10 Differences between episodic and chronic migraine in white-matter tracts: a diffusion-tensor imaging study
Claudia Marsecano 1 , Alessandra Splendiani 1 , Riccardo Cornia 2 , Federico Bruno 1 , Luana Evangelista 2 , Francesca Pistoia 2 , Simona Sacco 2
1 Radiology section, Department of Applied Clinical Science and Biotechnology, University of L’Aquila, L’Aquila, Italy; 2 Neurology section, Department of Applied Clinical Science and Biotechnology, University of L’Aquila, L’Aquila, Italy
Correspondence:Simona Sacco (simona.sacco@univaq.it)
O11 Headache following head injury: A population-based longitudinal cohort study (HUNT)
Lena Hoem Nordhaug 1 , Knut Hagen 1,2 , Anne Vik 1,3 , Lars Jacob Stovner 1,2 , Turid Follestad 4 , Torunn Pedersen 5 , Gøril Bruvik Gravdahl 2 , Mattias Linde 1,2
1 Department of Neuromedicine and Movement Science (INB), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; 2 Norwegian Advisory Unit on Headaches, St. Olavs University Hospital, Trondheim, Norway; 3 Department of Neurosurgery, St. Olavs University Hospital, Trondheim, Norway; 4 Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; 5 Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
Correspondence:Lena Hoem Nordhaug (lena.h.nordhaug@ntnu.no)
O12 Cerebral grey matter density is abnormally reduced in chronic migraine patients: correlations with clinical features
Gianluca Coppola 1 , Barbara Petolicchio 2 , Antonio Di Renzo 1 , Emanuele Tinelli 2 , Cherubino Di Lorenzo 3 , Vincenzo Parisi 1 , Mariano Serrao 4 , Valentina Calistri 2 , Stefano Tardioli 2 , Gaia Cartocci 2 , Francesca Caramia 2 , Vittorio Di Piero 2 , Francesco Pierelli 4,5
1 G.B. Bietti Foundation IRCCS, Research Unit of Neurophysiology of Vision and Neurophthalmology, Rome, Italy; 2 “Sapienza” University of Rome, Department of Neurology and Psychiatry, Rome, Italy; 3 Don Carlo Gnocchi Onlus Foundation, Milan, Italy; 4 “Sapienza” University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy; 5 IRCCS-Neuromed, Pozzilli (IS), Italy
Correspondence:Gianluca Coppola
O13 The relationship between pain, psychiatric, and endocrine/neurological comorbidities of migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study
Richard B. Lipton 1 , Vincent T. Martin 2 , Michael L. Reed 3 , Kristina M. Fanning 3 , Aubrey Manack Adams 4 , Dawn C. Buse 1
1 The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; 2 University of Cincinnati Headache and Facial Pain Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA; 3 Vedanta Research, Chapel Hill, NC, USA; 4 Global Medical Affairs, Allergan plc, Irvine, CA, USA
Correspondence:Richard B. Lipton (Richard.Lipton@einstein.yu.edu)
O14 Effects of calcitonin gene-related peptide and sildenafil on CNS metabolism: A pharmacological proton magnetic resonance spectroscopy study at 3.0 T
Samaira Younis1, Anders Hougaard1, Casper Emil Christensen1, Mark Bitsch Vestergaard2, Esben Thade Petersen3, Olaf Bjarne Paulson4, Henrik Bo Wiberg Larsson2, Messoud Ashina1
1 Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 2 Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 3 Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and research, Amager and Hvidovre Hospital, Denmark; 4 Neurobiology Research Unit, Department of Neurology, Rigshospitalet, Copenhagen, Denmark and Department of Clinical Medicine, University of Copenhagen, Denmark
Correspondence:Messoud Ashina
O15 Effect of calcitonin gene-related peptide and sildenafil on intracranial dural arteries: A 3T MR- angiography study in healthy volunteers
Casper Emil Christensen 1 , Faisal Mohammad Amin 1 , Samaira Younis 1 , Ulrich Lindberg 2 , Patrick de Koning 3 Esben Thade Petersen 4 , Olaf Bjarne Paulson 5 ; Henrik Bo Wiberg Larsson 2 ; Messoud Ashina 1
1 Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 2 Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 3 Division of Image Processing, Department of Radiology, Leiden University Medical Center, Leiden, Netherlands; 4 Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and research, Amager and Hvidovre Hospital, Denmark; 5 Neurobiology Research Unit, Department of Neurology, Rigshospitalet, Copenhagen, Denmark and Department of Clinical Medicine, University of Copenhagen, Denmark
Correspondence:Messoud Ashina
O16 Volumetric differences between episodic and chronic migraine: a volumetric neuroimaging study
Francesca Pistoia1, Riccardo Cornia1, Claudia Marsecano2, Federico Bruno2, Luana Evangelista1, Alessandra Splendiani2, Simona Sacco1
1 Neurology section, Department of Applied Clinical Science and Biotechnology, University of L’Aquila, L’Aquila, Italy; 2 Radiology section, Department of Applied Clinical Science and Biotechnology, University of L’Aquila, L’Aquila, Italy
Correspondence:Francesca Pistoia (francesca.pistoia@univaq.it)
O17 A population based survey for headaches in Greece
Dimos D. Mitsikostas 1 , Chrisanthy Arvanity 2 , Theodoros Constantinidis 3 , Manolis Dermitzakis 4 , Nikolaos Fakas 5 , Jobst Rudolf 6 , Michail Vikelis 7 , on behalf of the Hellenic Headache Society
1 First Neurology Department, Aeginition Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece; 2 Second Neurology Department, Attikon Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece; 3 Private Headache Clinic, Korinthos, Greece; 4 Department of Neurology, “Geniki Kliniki” Euromedica, Thessaloniki, Greece; 5 401 Army General Hospital of Athens, Neurology Department, Athens, Greece; 6 Neurology Department, Papageorgiou Hospital, Thessaloniki, Greece; 7 Headache Clinic, Mediterraneo Hospital, Glyfada, Greece
O18 Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase
Vladimir Skljarevski 1 , Virginia L. Stauffer 1 , Qi Zhang 1 , Holland C. Detke 1 , Brian A. Millen 1 , Jyun Yan Yang 1 , Katherine J. Selzler 1 , Robert Conley 1,2 , Sheena K. Aurora 1
1 Eli Lilly and Company, Indianapolis, IN, USA; 2 University of Maryland School of Medicine, Baltimore, MD, USA
O19 Real-life use of onabotulinumtoxinA for the symptomatic treatment of chronic migraine: The Repose Study
Fayyaz Ahmed 1 , Charly Gaul 2 , Paolo Martelletti 3 , Juan Carlos Garcia-Monco 4 , Aubrey Manack Adams 5
1 Spire Hesslewood Clinic, Hull York Medical School, Brough, Hull, UK; 2 Department of Headache and Facial Pain, Migraine and Headache Clinic, Koenigstein, Germany; 3 Department of Clinical and Molecular Medicine, Sapienza University, Regional Referral Headache Centre, Rome, Italy; 4 Service of Neurology, Hospital de Galdakao, Vizcaya, Spain; 5 Global Medical Affairs, Allergan plc, Irvine, CA, USA
Correspondence:Fayyaz Ahmed (fayyaz.ahmed@hey.nhs.uk)
O20 Abnormal peripheral and central visual processing in migraine
Filippo Brighina, Elisa Catalano, Viviana Firpo, Giuseppe Cosentino, Salvatore Cillino, Brigida Fierro
Dept of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Italy
O21 Neurosteroids in primary headaches
Andrea Negro 1 , Angela Koverech 1 , Claudia Cicione 1,2 , Marta Maestri 1 , Francesco Passariello 1 , Elisabetta Sabbatini 1 , Cristiano Maria De Marco 1 , Luana Lionetto 2 , Ferdinando Nicoletti 3,4 , Maurizio Simmaco 5 , Paolo Martelletti 1
1 Department of Clinical and Molecular Medicine, Sapienza University of Rome, Italy; 2 Advanced Molecular Diagnostics Unit, IDI Istituto Dermopatico dell'Immacolata - IRCSS, Rome, Italy; 3 IRCCS Neuromed, Pozzilli, Italy; 4 Department of Physiology and Pharmacology, Sapienza University of Rome, Italy; 5 Advanced Molecular Diagnostics Unit, Sant'Andrea Hospital, Sapienza University of Rome, Italy
Correspondence:Andrea Negro (andrea.negro@uniroma1.it)
O22 Lasmiditan (200 mg and 100 mg) compared to placebo for acute treatment of migraine
Bernice Kuca 1 ; Linda Wietecha 2 ; Paul H Berg 2 ; Sheena K Aurora 2
1 CoLucid Pharmaceuticals, Inc., a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, USA; 2 Eli Lilly and Company, Indianapolis, IN, USA
Correspondence:Sheena K Aurora (sheena.aurora@lilly.com)
O23 Activation of peripheral and central trigeminovascular neurons by seizure: Implications to post-ictal headache
Agustin Melo-Carrillo 1,2 , Rami Burstein 1,2
1 Department of Anesthesia, Critical Care & Pain Medicine, Beth Israel Deaconess Medical Center; 2 Harvard Medical School, Boston, Massachusetts, USA; 3 Center for Life Science, 3 Blackfan Circle, 02215. Boston. MA
Correspondence:Agustin Melo-Carrillo (amelo1@bidmc.harvard.edu)
O24 Association between subclinical hypothyroidism and migraine
Innocenzo Rainero 1,2* , Flora Govone 1 , Francesca Garino 3 , Costanza Vicentini 1 , Alessandro Vacca 1 , Annalisa Gai 1 , Salvatore Gentile 2 , Federico Ragazzoni 3 , Lorenzo Pinessi 2 , Maria Teresa Giordana 1,2 , Paolo Limone 2 , Elisa Rubino 1
1 Neurology I – Headache Center, Department of Neuroscience “Rita Levi Montalcini”, University of Torino, 10126 Torino, Italy; 2 Department of Neuroscience and Mental Health, A.O.U. Città della Salute e della Scienza, Torino, 10126 Torino, Italy; 3 Endocrinology, Diabetes and Metabolic Disease Unit, A.O. Ordine Mauriziano di Torino, 10128 Torino, Italy
Correspondence: Innocenzo Rainero (innocenzo.rainero@unito.it)
SISC ORAL PRESENTATIONS
O25 Migrainous infarction in a patient with Sporadic Hemiplegic Migraine and Cystic Fibrosis
Valentina Mancini 1 , Giulio Mastria 1 ,Massimiliano Toscano 1 , Federica Turchi 1 , Barbara Petolicchio, Alessandro Viganò 1 , Vittorio Di Piero 1
1 Neurology and Psychiatry, Sapienza - University of Rome, Rome, Italy. Rome, Rome, Italy
Correspondence:Alessandro Viganò (alessandro.vigano@uniroma1.it)
O26 Features of chronic primary headaches (CPH) in children and adolescents referred to two third level headache centers
Laura Papetti 1 , Irene Salfa 1 , Beatrice Bartoli 2 , Cristiano Termine 2 , Barbara Battan 3 , Massimiliano Valeriani 1
1 Neuroscience, Bambino Gesù Children Hospital, Rome; 2 Neuropsychiatric, Insubria University, Varese; 3 Neuroscience, Bambino Gesù Children Hopsital, Rome, Italy
Correspondence: Massimiliano Valeriani
O27 Clinical features, risk factors and comorbidity of chronic migraine. An Italian nationwide survey among headache centres
Franco Granella
Neurosciences Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy
O28 Prolonged migraine aura: prevalence and comparison with “normal” auras
Michele Viana 1 , Grazia Sances 1 , Mattias Linde 2 , Giuseppe Nappi 1 , Peter J. Goadsby 3 , Cristina Tassorelli 1, 4
1 Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy; 2 Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway; 3 Headache Group – NIHR-Wellcome Trust Clinical Research Facility, King’s College London, London, United Kingdom; 4 Dept. of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
Correspondence:Michele Viana (michele.viana@ymail.com)
O29 Microvascular vasospasm of cerebral cortex in “prolonged” aura migraine
Stefano Viola 1* , Paolo Viola 2 , Maria. P. Buongarzone 1 , Luisa Fiorelli 1 , Mafalda Cipulli 1 , Pasqualino Litterio 1
1 Department of Neurology, Headache Center, via C. De Lellis 66054 Vasto (CH), Italy; 2 Emergency Medical Service, Atessa, Lama dei Peligni (CH), Italy
Correspondence:Paolo Viola
O30 A nutraceutical formulation of Magnesium+Tanacetum parthenum+Griffonia vs Amitriptyline in Migraine prophylaxis
Maria Pia Prudenzano, Alessandro Introna, Maria Tappatà, Simona Lamberti, Maria Elena Roca, Isabella Laura Simone, Maria Trojano
Headache Centre. Department of Basic Medical Sciences, Neuroscience and Sense Organs. University of Bari
Correspondence:Maria Pia Prudenzano (centrocefalee.neurologia@uniba.it)
O31 Comorbidity profiles of migraine sufferers in headache center
Alessandro Panconesi, Maria L Bartolozzi, Leonello Guidi
Headache Center, Department of Neurology, Health Authority 11, Empoli, Italy
Correspondence:Alessandro Panconesi (alessandro.panconesi@uslcentro.toscana.it)
All subjects | ♂ | ♀ | EM | CM | |
---|---|---|---|---|---|
Depression | 5.6 | 3.1 | 6.2 | 5.4 | 6.7 |
Hypertension | 9.3 | 8.1 | 9.6 | 7.5 | 20.8*
|
Diabetes | 1.2 | 1.3 | 1.1 | 1.0 | 2.2 |
Asthma | 3.3 | 3.2 | 3.3 | 3.0 | 5.7 |
Hypothyroidism | 6.4 | 1.3 | 7.8 *
| 6.3 | 6.7 |
Allergy | 19.8 | 21.8 | 19.2 | 19.8 | 19.4 |
O32 Nutraceuticals and herbs in the treatment of pediatric primary headaches
Elena Piretti1, Irene Toldo1, Maria Paola Rossaro1, Stefano Sartori1, Michela Gatta2, Margherita Nosadini1, Pier Antonio Battistella1
1Juvenile Headache Centre, Department of Woman's and Child’s Health, University Hospital of Padua, Italy; 2Socio-sanitarydistrict, “Struttura Complessa Infanzia Adolescenza Famiglia” (SCIAF), ULSS 6 Euganea, Padua, Italy
Correspondence: Antonio Battistella (pierantonio.battistella@unipd.it)
-
Magnesium: significant reduction in attacks, consumption of analgesics and disability in cases with Migraine (M) [5] and Tension-Type Headache (TTH) [6]
-
Riboflavin (vitamin b2): higher efficacy than placebo in the treatment of TTH [7]. In M: effective compared to baseline [8] but not superior to placebo [7, 9]
-
Coenzyme Q10: in CoQ10-deficient patients, CoQ10 supplementation obtained a reduction of attacks’ frequency and disability degree [10]. A trial showed no efficacy versus placebo [11]
-
Alpha lipoic acid: no study available
-
Melatonin: significant reduction in frequency and duration of M or chronic TTH attacks [12]. In another study: reduction of frequency, intensity, duration of M attacks and PedMIDAS score [13]
-
5-hydroxytryptophan: no significant differences vs placebo in M (Santucci M,1986).
-
Petasites hibridus: 50% reduction of attacks in 77% of cases with M in an open-label multicentre study [14]. Long term effects better than placebo in another study [15]
-
Tanacetum parthenium: no study available
-
Ginkgo biloba combined to Coenzyme Q10/Vitamin B2/Magnesium: reduction of the M frequency and the use of symptomatic medication in a open-label study [16]; reduction of the M frequency in another open-label study[17]; reductions of M frequency, duration, intensity, PedMIDAS score, behavioural reactions to M were significantly greater in the Ginkgolide group than in the group received L-tryptophan/5-hydroxytryptophan (from Griffonia simplicifolia)/vitamin PP and B6[18].